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Antibiotic resistance is an increasing concern for global health care, with some estimates
suggesting that 10 million people will die from antibiotic resistant infections in the year 2050.
Fueling this prospect, few antimicrobials are being actively developed and recently commercial
entities have fled from the development of new anti-infectives. New antimicrobials and drug
development strategies are urgently needed to revitalize this critical pipeline. While many
putative antibiotics demonstrate promising in vitro potency, they routinely fail in vivo due to
poor drug-like properties (e.g. oral bioavailability, serum-half life, toxicity) resulting in overly
expensive drug development pipelines. Fortunately, drug-like properties can be modified through
the addition of chemical protecting groups to create “prodrugs”. Lipophilic prodrugging
strategies have been primarily deployed to remedy poor oral absorption but have also been
utilized as a means of specifically delivering active drug to specific cells and tissue types. Here
we demonstrate that lipophilic prodrugging of phosphonate antibiotics through a carboxy ester
modification increases membrane permeability and enhances antimicrobial potency.
Unfortunately, many lipophilic prodrugging strategies are rapidly cleaved in vivo by serum
esterases rendering these potency and transport gains useless during clinical settings. Using three
xxi

species of staphylococci, we identify and biochemically characterize two esterases, GloB and
FrmB responsible for the activation of carboxy ester prodrugs. Additionally, we solve the threedimensional structures of both GloB and FrmB, facilitating additional structure-guided design of
promoieties. Finally, we characterize the substrate specificity of human and mouse sera, enabling
the development of promoieties which are selectively activated by microbial species. These
findings not only allow the development of novel anti-staphylococcals but lay the framework for
identification of microbial-specific prodrug design and design of long-lasting serum prodrugs. As
lipophilic prodrugging expands the number of compounds that are membrane permeable, we
expect that this approach will facilitate an expansion of the number of potential drugs.

xxii

Chapter 1: Introduction
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1.1 Antibiotic resistance threatens modern medicine
1.1.1 The rise of antibiotics
The history of humans is strongly intertwined with microorganisms. Microbes are integral to the
production of fermented foods and beverages such as bread, yogurt, and beer, they contribute to
the production of several modern medical therapies such as insulin and the antibiotic,
tetracycline, and remain with us through our life aiding in the digestion of complex
carbohydrates as members of our “microbiome”. While microbes have contributed many
positives to humans, some contribute a significant disease burden. The microbial parasite,
Plasmodium falciparum, has been estimated as having killed as much as 4-5% of all humans who
have ever lived. In 2019, an estimated 1.4 million humans died due to infection with the bacteria,
Mycobacterium tuberculosis (1). While most parasitic and bacterial infections are now relatively
easy to treat, this has not always been the case.
In the late 19th and early 20th century, chemotherapeutics as we now know them began to
develop. Paul Ehrlich developed the anti-syphilitic compound, arsphenamine, and cemented the
idea that pure chemical compounds could be used to fight disease (2). In 1928 Alexander
Fleming discovered the antibiotic penicillin, when the fungal contaminate, Penicillium rubens,
prevented growth of his desired organism, Staphylococcus aureus (3). As was common at the
time, Fleming was able to culture the fungal contaminant and isolate the growth inhibitory
compound to demonstrate that the compound itself, rather than P. rubens was responsible for
growth inhibition of S. aureus. The most striking observation, however, was that that the isolated
compound was a potent inhibitor of many bacterial cultures and had no notable toxicity against
mammals (3). While many chemicals can kill microbes, penicillin (penicillin G) was the first
compound isolated that did so without also hurting humans.
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Naturally, the identification of penicillin meant that individuals with otherwise life-threatening
infections could be safely cured. Indeed, shortly after it’s discovery, penicillin was utilized
several times to cure bacterial infections (4–6). Unfortunately, as with many chemotherapeutics,
transitioning from performance in laboratory models to humans was difficult. Penicillin G is
rapidly excreted from humans, necessitating multiple doses of penicillin to effectively treat
infections. Further, initial penicillin G production strategies yielded miniscule amounts of
compound limiting the application of penicillin G in the clinic to only a few cases. Large scale
production was eventually achieved in the early 1940s and penicillin became a common
mechanism for curing bacterial infections.

1.1.2 Antibiotic resistance and new antimicrobials
The discovery of penicillin G was heralded as a promising success, yet even before mass
administration was feasible, bacterial resistance to penicillin G existed (7). “Penicillinase”, an
enzyme found both intracellularly and extracellularly depending on the species of bacteria
producing it, was first documented in 1940 and noted to rapidly degrade penicillin (Figure 1).
Penicillin G resistance was, perhaps, to be expected. Penicillin G was isolated as a natural
product of bacteria and its production was likely selected for as a mechanism of reducing
competition for the Penicillium mold. If Penicillium had been producing penicillin G for a long
time, bacteria were also dying from penicillin for a long time. Many experiments in laboratory
settings have demonstrated the ease of resistance to chemical compounds within short time
periods (8, 9). Long-term exposure of microbes to penicillin production, as would be expected
through the co-evolution of microbes with Penicillium, thus would be more than sufficient time
for resistance to arise in certain microbial species.
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As penicillin treatment became common, so too did bacterial resistance to penicillin G. The first
case of clinical resistance to penicillin was documented in 1942 when 4 strains of
Staphylococcus aureus were isolated following penicillin treatment (10). By the late 1960s, over
80% of S. aureus strains were resistant to penicillin (11). Penicillin G resistance was also rapidly
observed among S. pneumoniae, and E. coli (12).
Fortunately, following the discovery of penicillin G was an era of antimicrobial discovery where
new antibiotics were rapidly discovered. Streptomycin was discovered in 1944 (13).
Cephalosporins were discovered the following year and entered clinical use in the 1960s (14).
While natural antibiotic scaffolds were expanding, developments in the field of medicinal
chemistry enabled the scalable production of semi-synthetic antibiotics. Semi-synthetic
antibiotics are produced through a combination of fermentation by an existing antimicrobial
producing strain, and synthetic chemistry approaches to modify specific attributes of a
developing compound. Semi-synthetic antibiotics have proven immensely valuable. In 1959,
Beecham modified the benzyl group of penicillin G to an ortho-dimethoxyphenyl group, creating
the β-lactamase resistant compound, methicillin (Figure 2) (15). While β-lactamases capable of
hydrolyzing methicillin soon became commonplace, the principle that an antibiotic can be
chemically modified to exhibit more favorable properties took hold. A total of four generations
of penicillin modified compounds now exist. Penicillin G was among the first generation of βlactamase sensitive compounds and methicillin and other β-lactamase resistant derivatives came
with the second generation. Subsequent generations focused on extending the antibiotic
spectrum, or number of bacteria that the antibiotic works upon, and altering the uptake,
distribution, and stability of compounds within the human (also known as the pharmacokinetic
and pharmacodynamic properties) (Figure 1). Similar semi-synthetic approaches have occurred
4

for the cephalosporin compounds with great success. In sum, semi-synthetic approaches are an
efficient combination of synthetic chemistry and microbial fermentation that allow for the cheap
production of a variety of antibiotics.
While humans have continued to race against expanding bacterial β-lactamase specificity, it is
worth noting that penicillin resistance occurs via several additional mechanisms which highlight
the flexibility of microbes. It was originally observed that different species of bacteria were
naturally resistant to penicillin independent of any degrading enzymes (7). Later, it was realized
that the action of penicillin G stems from binding to penicillin binding proteins (PBPs) to initiate
bacterial lysis (16). Some of the naturally resistant bacterial species maintain PBPs which do not
readily bind penicillin G, thus conferring natural immunity (Figure 1) (17). Further, some
previously susceptible bacteria have accumulated mutations in PBPs which confer resistance to
penicillin (18).
As penicillins require binding to PBPs to exert their antimicrobial action, altered transit of
penicillins to PBPs is also a resistance mechanism (Figure 1). PBPs of gram-negative bacteria
localize to the periplasm whereas gram-positive bacteria PBPs are localized to the cell surface
(19, 20). In practice, this means that gram-positive PBPs are readily accessible by penicillins,
whereas in gram-negative organisms, penicillin must first transit the outer membrane of the cell.
Porin proteins are responsible for penicillin transit into the gram-negative periplasm, and
mutation of these porin proteins is one mechanism of penicillin resistance (21–26).
Penicillin resistance highlights three mechanisms of antibiotic resistance; compound degradation
(β-lactamases), target modification (PBP alteration), and reduced antibiotic penetration (porin
disruption and deletion) (Figure 1). These resistance mechanisms are commonly observed for
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other antibiotics, though several additional mechanisms are also possible (8, 27–31). Similar to
porin mediated resistance to penicillin, microbes encode several efflux pumps which can reduce
the intracellular concentrations of antibiotic (32–38). For some inhibitors, resistance may be
achieved through altered metabolic regulation. For the competitive inhibitor of isoprenoid
biosynthesis, fosmidomycin, resistance can be achieved by supplying more of the upstream
competitive metabolite (39). Metabolic rerouting around the inhibited step is also possible in
some instances (40). Finally, some antibiotics, known as prodrugs, require activation before their
antimicrobial effects are realized. In these cases, if prodrug activation is performed via the
microbe then deletion or modification of the prodrug activating enzyme(s) is an alternative
resistance strategy (9, 41–43)
Three lessons should be taken from the story of penicillin. First, chemotherapeutics work, and
many lives have been saved with the introduction of antibiotics. Second, microorganisms have
an innate ability to evolve resistance to antibiotics. Finally, through careful and clever chemical
strategies, new antibiotics can be developed which surpass the shortfalls of the previous. When
antimicrobial development is in full force and there is a strong supply of novel antimicrobials
and antimicrobial strategies and the production of novel antibiotics outpaces resistance.
Alarmingly, in recent years there have been fewer antimicrobials entering the development
pipeline and those that have tend to be modifications of existing antibiotics instead of new
strategies (44–47). Simultaneously, there has been an exodus of companies investing in antibiotic
development (44). As a result, several cases have already been documented where no effective
antimicrobial therapy exists (48–51). We are already in a post-antibiotic world and as multi-drug
resistant bacteria continue to spread there is an urgent need to revitalize antibiotic discovery.
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1.1.3 Modern challenges in antibiotic development
The spread of antimicrobial resistance is a pending global health crisis. Recent estimates suggest
that as many as 10 million people will die as a result of antimicrobial resistant infections in 2050
(52, 53). While existing antimicrobials are increasingly facing resistance, in parallel, there is a
mass exodus from commercial antibiotic research and few new antimicrobials are entering the
development pipeline (44). On the surface, this seems paradoxical. There is clearly a large
demand for new antimicrobials, yet supply has not risen to meet this demand. While most public
health inequities disparately impact poorer populations, antimicrobial resistance, like COVID-19,
antimicrobial resistance will impact all individuals. Why then, are there not more antimicrobials
in the development pipeline?
Financial challenges facing antimicrobial development
Perhaps the largest barrier to antimicrobial development is simply the cost. Most estimates place
the cost of developing a new pharmaceutical (identification and optimization of the compound,
development of production capacity, and clinical trials establishing safety and efficacy) at nearly
$1B USD (54). Given that drug patents last approximately 20 years from initial disclosure and
that initial testing typically takes ~10 years to complete, companies have approximately 10 years
to recoup their investment. While this model is feasible for drugs that are frequently prescribed,
antimicrobials are necessarily withheld to prevent unnecessary use and prevent the spread of
antimicrobial resistance. Perhaps the final nail in the antimicrobial development coffin is simply
the uncertainty in drug development. Compounds that appear highly successful in initial
characterization in lab environments have approximately a 1-7% chance of securing approval
from the Food and Drug Administration (FDA) (55). Even compounds, that are the most likely to
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succeed- those that have passed clinical phases 1 and 2 of clinical development- only have
approximately a 50% chance of entering the market. For these reasons, antibiotic development
has stalled or has been converted to simple recombinations of existing antimicrobials as a riskmitigation strategy.
While one could imagine a reinvention of the funding for drug development which encourages
more antimicrobials to be developed, we may better served by asking the question, “why do
novel drugs fail to secure approval so frequently?”. Failure, especially in clinical trials,
exorbitantly increases the cost of new therapeutics. Some drugs in development fail out of
clinical trials as they are unable to recruit and retain sufficient patients. Others fail because the
sponsoring company no longer has sufficient funds to complete the trials. Ultimately, these
failures do not reflect issues with potential drugs. Rather, the two drug-specific reasons for trial
failure are unexpected drug toxicity and/or failure of the drug to perform in humans. Of these
two, drug safety is a less likely cause of drug failure (17% of failures) than poor efficacy (57% of
failures) (55–57). Strategies that address these failures, hopefully in a universal manner, will be
crucial in revitalizing the drug development pipeline.
Poor drug administration
Oftentimes, drugs are poorly efficacious because they do not reach the desired site in high
enough concentrations. This may be because the drug is poorly absorbed via the route of
administration. For example, orally administered drugs must pass through the stomach and be
absorbed via the small or large intestine prior to systemic distribution of the drug. While this
route of administration is facile and transportable, absorption constitutes a large barrier in drug
efficacy. In contrast, drugs that are supplied intravenously (IV) are immediately systemic and do
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not require absorption. While one may make the case that all drugs should be administered IV as
this eliminates barriers to drug deliver; IV delivery is not without drawbacks. IV administration
risks introduction of pathogenic microbes into the bloodstream (58). As a result, IV
administration is non-portable and must be performed via trained healthcare professionals.
Additionally, IV administration can result in tissue damage at the site of injection including
nerve damage, tissue sloughing, and scarring (58).
Premature elimination
In addition to improper absorption, drugs can be ineffective if they are eliminated before they
have had sufficient time to act at their target site. Penicillin G is rapidly removed from the blood
via the kidneys, resulting in a half-life of ~1.4 hours in adults (59). Frequent dosing can be used
to keep systemic drug concentrations high, but this is laborious, requires large amounts of drug,
requires high rates of patient compliance, and missed doses make it more likely for resistance to
arise. The two primary routes of elimination are filtration via the kidney (renal) before
subsequent loss through the urine, and filtration via the liver (biliary) and subsequent secretion
through the bile. Exact rates of elimination vary by individual patient, complicating exact
determination of elimination parameters (60, 61).
Renal and biliary elimination selectively filter different compounds. Renal elimination often
removes small, polar compounds that are not actively reabsorbed by renal tubules (62).
Alternatively, larger molecular weight and lipophilic compounds tend to be excreted biliary (63).
It is important to note, however, that compounds that have been excreted into the bile may be
reabsorbed along the gastrointestinal tract (64–66). As a result, drug like molecules must thread a
balance between size and lipophilicity to avoid secretion.
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Poor drug penetrance
Drugs can fail even if they are optimally administered and have a long half-life if they do not
reach the proper site. Humans naturally have several sites that are difficult to deliver drugs to.
Perhaps most notoriously, the brain is surrounded by a blood-brain barrier which selectively
excludes most compounds. Reflectively, drugs targeting the nervous system have the lowest
likelihood of passing clinical trials (55). The other major tissue difficult to dose is the skeletal
system, primarily due to regions that are avascular (67).
In parallel with specific tissues being difficult to deliver drugs to, the specific infection
environment can make drug delivery problematic. Mycobacterium tuberculosis (Mtb) infections
are characterized by granulomas- thick lesions designed to restrict replication of Mtb.
Unfortunately, granulomas also restrict the delivery of antibiotics (68–70). Similarly, many
bacteria can form biofilms- a series of layers of bacteria cells- during infection settings. Biofilms
help bacteria adhere to a specific niche and prevents clearance via immune cells. Unfortunately,
like granulomas, formation of a biofilm greatly reduces the efficacy of antibiotics, likely due to
poor drug penetrance inside the biofilm.
Poor animal models
The final challenge facing drug development is a lack of good models for human disease. In vitro
systems can be useful in the development of compounds and can rule potential compounds out as
“too toxic”, but they do not capture the complexity of a human. Notably, as highlighted before,
pharmacokinetics are not included in in vitro experiments. Models of disease in mice, rats,
guinea pigs and other small mammalian models are more complex, but still have several
shortcomings. Notably, drug metabolism in rodents does not accurately reflect that of humans.
10

While simian models are likely more reflective of human disease, there are significant ethical
and cost limitations on simian research. Animal models that poorly reflect human disease are not
ultimately predictive of a compound’s success.
With the immense cost associated with drug development and the likelihood of failure, it is
unsurprising that relatively few drugs are developed annually. Risk mitigation strategies, such as
the reformulation or slight modification of existing antibiotics are attractive as information about
toxicity of the original compound are likely to translate. However, reformulations and minor
compound modifications are unlikely to be severe deterrents to the evolution of antimicrobial
resistance. In the next section we will discuss strategies to maximize drug efficacy without
significant modification to the existing drug scaffold. This strategy, known as prodrugging, can
aid in the cost of drug development, may serve to reduce drug toxicity, and can be used to
expand the number of feasible microbial drug targets.

1.2. Prodrugs, novel tools for medicinal chemists
The most simplistic antibiotics are administered and immediately have inhibitory effects without
any further action being needed. Penicillin G binds PBPs to prevent further growth of the target
bacteria. The protein synthesis inhibitor, tetracycline, similarly requires no further processing
before inhibiting protein synthesis. In contrast, prodrugs are compounds that are inactive and
unable to exert any inhibitory action until they have been metabolized. This added complexity is
useful during drug development as medicinal chemists can dissociate target inhibition from other
pharmacokinetic and pharmacodynamic properties. Depending on the goal, different protecting
groups, or promoieties, can be added to the active (parent) drug in effort to modify lipophilicity
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or aqueous solubility. Prodrugging strategies that make use of tissue, cell, or organism specific
activation mechanisms can also be employed to selectively deliver active compound.
Historically, prodrugging approaches have been most often employed to increase the oral
bioavailability of compounds. As was discussed previously, lipophilic compounds are more
likely to be absorbed in the intestinal tract than polar compounds which require specific
transporters. Thus, when a compound is too polar for adequate absorption, polar moieties may be
obfuscated by lipophilic ones. The third-generation cephalosporin, cefditoren, was developed
with strong activity against gram-positive organisms in vitro. Unfortunately, poor oral
bioavailability of cefditoren limited it’s potential clinical use (71, 72). The compound was
resynthesized as a pivaloyloxymethyl (POM) modification on the carboxylate motif and became
orally bioavailable. Similar strategies have been employed for the antibiotics adefovir dipivoxil,
pivampicillin, and pivmecillinam .
While prodrugs, especially POM-prodrugs, were originally applied as a last effort during drug
development, increasingly prodrugs are implemented as a critical early strategy. Prodrugging
approaches, namely lipophilic prodrugging, can be used to both increase cellular penetrance of
otherwise cell impermeable drugs. Depending on the specificity of prodrug activation, prodrug
formulation may also enable the targeted delivery of compounds with the potential to reduce
compound toxicity. These two approaches will be explored in the following sections.

1.2.1 Prodrugs, opportunities to expand the druggable space
While many essential cellular processes utilize charged molecules, few charged molecules are
found in drugs. Phosphates and phosphonates are utilized in the storage of genetic information
(RNA and DNA), and metabolic processes regularly utilize activated di and tri-phosphate
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moieties. While charged residues are critical for competitive inhibition these processes, charged
residues are readily excluded from cellular membranes. As a result, any potential drugs utilizing
phosphonate residues are unlikely to inhibit intracellular targets and thus will not make effective
drugs. However, lipophilic prodrugging of these residues allows phosphonates to be used while
still effectively transiting the compound inside the cell. In the following sections we will discuss
the application of prodrugs allowing the development of nucleotide analogues, isoprenoid
biosynthesis inhibitors, and glycolytic inhibitors.
Nucleotide prodrugs
Perhaps the most frequent application of lipophilic prodrugging is to nucleotide analogues. As
nucleotide/side analogues are polar compounds, they tend to suffer from poor bioavailability, are
readily excluded from cells, and have the potential to be toxic. Despite these limitations, several
nucleotide analogues have been approved or given emergency use authorization to treat viral
infections and cancer (73–75). The development of these compounds has been extensively
reviewed elsewhere, thus we will focus on a few examples of how prodrugging strategies have
improved nucleotide analogue bioavailability, cellular penetrance, and compound safety (75–80).
Oseltamivir carboxylate, the active form of oseltamivir (Figure 3, Tamiflu, anti-influenza)
suffers from low bioavailability with <5% of compound entering circulation (81). As we have
discussed, large polar compounds are unlikely to be absorbed orally. However, modification to
more lipophilic compounds is likely to improve absorption. Since oseltamivir carboxylate had
sufficient activity against whole cell assays, the primary barrier to clinical application was the
lack of oral bioavailability. Prodrugging of the carboxylate moiety with an ethyl ester improved
oral bioavailability to nearly 80% (Figure 3) (82). Once oseltamivir is absorbed, it is rapidly
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hydrolyzed via the serum esterase carboxylesterase 1 to return the active compound (83). Similar
approaches were applied during the development of adefovir dipivoxil (Figure 3, anti-HBV) and
tenofovir disoproxil (anti-HIV/HBV), though both of these compounds employ a POM moeity
(84, 85).
While some nucleotides/sides are sufficiently cell permeable to exert strong inhibitory action,
most are unable to traverse the cell membrane to inhibit intracellular viral replication.
Prodrugging approaches that increase nucleoside transporter mediated cell entrance have been
pursued, but equally attractive is the development of compounds that passively diffuse into cells
(86, 87). Lipophilic prodrugging can increase cell penetrance, to deliver the prodrug inside the
cell where subsequent activation restores the parent compound. This strategy was pursued to
generate the prodrug, Remdesivir (Figure 3), for the treatment of Ebola and SARS-CoV2 (88).
Specifically, the phosphonate moiety of GS-441524 (Figure 3) was identified as likely
responsible for poor cellular penetrance. Protection of the phosphonate with a McGuigan
prodrug dramatically increased compound potency when used in whole cell assays (88, 89).
Unfortunately, when Remdesivir is administered to humans and non-human primates, serum
esterases rapidly remove the McGugian prodrug, resulting in the less permeable compound, GS441524, as the relevant compound in the infection environment (90, 91). This example highlights
how in vitro results can poorly model in vivo realities and exemplifies the need for compound
development to consider both drug administration and activation (92).
HepDirect prodrugs elegantly achieve both tissue targeting while simultaneously improving the
lipophilicity of phosphonates. Using the substrate specificity of a liver specific isoform of P450,
CYP3A4, Erion and colleagues developed a promoiety that is selectively activated within the
liver (93). The HepDirect strategy was applied to the parent compound of adefovir dipivoxil,
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PMEA, and resulted in an almost 12-fold increase in PMEA levels in the liver (Figure 3) (94).
Simultaneously, this approach led to a 2-4 fold decrease of PMEA in the kidney, and virtually no
PMEA in the intestine (94). This prodrug specific prodrug of PMEA is currently in phase 2
clinical trials under the name Pradefovir mesylate. While it remains unclear the extent to which
prodrug activation is selectively in the liver and how much parent compound leaks into other
environments, it is clear that prodrug activation was successfully enriched for liver activation.
This approach is a shining example of the potential reductions in drug toxicity achieved through
targeted drug delivery as well as the possibility that promoieties may remain attached for
biologically relevant periods of time prior to reaching the desired site.

Isoprenoid biosynthesis prodrugs
Isoprenoid biosynthesis is an attractive candidate for several areas of drug development.
Isoprenoid biosynthesis is ubiquitously essential and begins with the synthesis of two five-carbon
building blocks, isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP).
Humans synthesize these building blocks via the mevalonate pathway, whereas some microbes
utilize a divergent, though equally essential, pathway, the 2-C-methyl-D-erythritol 4-phosphate
(MEP) pathway. The divergence in these two synthesis mechanisms makes the MEP pathway an
attractive target for antibiotics. Following IPP and DMAPP synthesis, isoprenoid biosynthesis
reconverges and yields subsequently larger carbon chains. In humans, the later stages of
isoprenoid biosynthesis are attractive targets for the treatment of osteoporosis, with
bisphosphonate inhibitors such as risedronate already in use. Unfortunately, intermediates along
the entire biosynthetic pathway maintain a phosphonate, and any competitive inhibitors
15

developed for these pathways likewise require a charged group like phosphonate to achieve
strong enzyme inhibition. As we have discussed previously, these groups are largely cell
impenetrable and tend to have poor oral bioavailability. Similarly, the charged phosphonate
readily excludes these compounds from cell membranes requiring active transit for their entry.
Lipophilic prodrugging has been applied to both bisphosphonate inhibitors and MEP pathway
inhibitors.
Fosmidomycin is an antibiotic that competitively inhibits an early step in the MEP pathway.
Fosmidomycin has efficacy against Plasmodium falciparum, the protozoan parasite responsible
for most severe malaria cases, as well as Escherichia coli, several zoonotic staphylococci, and
several additional bacteria (8, 95–97). While fosmidomycin is well tolerated at doses up to 8
g/day, it is poorly absorbed via oral administration and rapidly removed from circulation (98). As
with nucleoside analogues, fosmidomycin is readily excluded from cell membranes and requires
active transport to enter the cell (Figure 4) (8, 28, 99). Lipophilic prodrugging approaches,
notably the POM moiety, bypass this requirement (Figure 4) (8, 28). Surprisingly, fosmidomycin
is effective against P. falciparum despite the target enzyme being sequestered behind seven lipid
bilayers (95). How fosmidomycin passes through these membranes remains unclear, but
lipophilic prodrugging significantly increases the antimalarial efficacy of fosmidomycin and
fosmidomycin analogues (100, 101). These potency gains have similarly been observed using
fosmidomycin analogues against Mycobacterium tuberculosis, though have little increased
efficacy against gran-negative bacteria (8, 102).
Similar prodrugging strategies have been deployed for bisphosphonates. Significant potency
gains were achieved by converting the parental compound to a POM-prodrug (103). These in
vitro potency gains are exciting, though in vivo trials have not yet been reported. As POM16

prodrugs are rapidly cleaved by serum esterases, it is unlikely that the same potency gains will be
realized in vivo (100).
Glycolytic prodrugs
Glycolysis is significantly upregulated in cancerous cells and has emerged as a potential anticancer target. In humans, the penultimate step in glycolysis, the conversion of 2phosphoglycerate to phosphoenolpyruvate, is catalyzed by three isoforms of enolase. In most cell
types more than one isoform of enolase is present, however some cancerous cells disrupt a ENO1
while disrupting tumor suppression (104). Consequently, these cells are left with a single isoform
of enolase, ENO2, and exhibit increased sensitivity to selective inhibitors of ENO2. Several
potent and selective inhibitors of ENO2 have been developed, however they utilize phosphonate
moieties to achieve their potency and are thus cell impermeable (104). POM-modification of the
phosphonates affords increased cellular permeability, however serum esterases rapidly hydrolyze
the POM moiety (105). Specific activation of these compounds by glial cells is predicted to both
improve in vivo performance while simultaneously improving the safety profile of the
compounds, however identification and formulation of these promoieties has yet to be achieved.

1.2.2 Prodrug activation and targeting
To present, we have covered how prodrugs can improve pharmacokinetic properties and increase
cellular penetrance of polar compounds such as phosphonates. The latter benefit affords
significant potency gains in vitro, however depending on the promoiety used, they are not
realized in clinical settings due to premature promoiety removal by serum esterases (Figure 4).
Enabling the development of phosphonate antibiotics through the development of serum stable
and microbially labile promoieties opens a significant portion of antimicrobial space to be
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developed. Further, targeting prodrug activation to specific cell types (human or microbial) is
likely to increase the safety profile of any antibiotic as is observed with the HepDirect prodrugs
(94). Here, we will discuss various strategies for prodrug activation and several esterases that
have been noted for their involvement in carboxy ester prodrug activation. Ultimately, for any
prodrug strategy, where the prodrug is activated to achieve the optimal effect is the most
important consideration.
Host esterases- friends or foe?
For compounds that are sufficiently active in whole cell assays but do not achieve sufficient
bioavailability, prodrugging to increase absorption, but not alter cell membrane permeability
may be the best strategy. We have discussed numerous compounds where this strategy was
employed including cefditoren pivoxil, oseltamivir, adefovir dipivoxil, and tenofovir disoproxil.
In this case, rapid drug activation by host enzymes is considered a major benefit as the parent
compound can rapidly take effect. However, in cases where prodrugs are intended to be
delivered to discrete sites intact, host esterases represent a significant barrier. In humans, carboxy
ester prodrug activation is performed by human carboxylesterase (hCES) and most frequently
occurs in the liver or serum (106, 107).
Three isoforms of hCES are expressed in various tissues, though the predominant isoforms in the
liver and to a lesser extent plasma are hCES1 and 2 (108–110). hCES1 and 2 have broad
substrate specificities, however they do have substrate specificity. hCES1 prefers to hydrolyze
substrates with a small alcohol group and a bulky acyl group. In contrast, hCES2 hydrolyzes
compounds with a large alcohol group and a small acyl group (111, 112). While these esterases
seemingly cover the entire substrate range, there is still hope that ester substrates can be designed
18

to avoid or reduce cleavage via these two esterases, as is demonstrated by the HepDirect
prodrugging approach (93, 94). It is also worth noting that esterase substrate specificity and
activity, especially for each tissue type and location within the host, is variable depending on the
species (113–119). As a result, performance of ester prodrugs in pre-clinical models may not
reflect their ultimate performance in the clinic.
Bacterial prodrug activation
We have highlighted the broad application of prodrugs and promoieties for drug development.
The largest barrier to prodrug targeting is identifying promoieties that are specifically activated
by microbial sources. Structure-guided approaches to microbially targeted prodrug activation
have been hindered by a lack of information of microbial esterases and their specificities. In this
thesis, we will present the discovery and characterization of two staphylococcal esterases, FrmB
and GloB, which activate POM prodrugs in combination with at least one additional esterase. In
vitro GloB and FrmB are both capable of partially deprotecting di-POM prodrugs. Neither
enzyme either individually or in combination can fully activate a di-POM prodrug suggesting at
least one among at least one additional enzyme is critical for the complete activation of carboxy
ester prodrugs in vivo (chapter 3 and 4). In addition to identifying GloB and FrmB, we
determined the three-dimensional structure of each enzyme and performed an extensive
structure-activity relationship study using a library of ester substrates. While FrmB and GloB are
both conserved amongst microbial populations, there is a significant amount of sequence
variation in these two loci (chapter 4). Identification of FrmB and GloB is a major step towards
structure guided design of prodrugs (chapter 4 115). How broadly these prodrugs will be
applicable remains an intriguing and open question.
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It is worth noting that both FrmB and GloB were identified because mutations in each prevented
prodrug activation in vivo. While these mutations are well tolerated in rich axenic media, both
GloB and FrmB are involved in cellular detoxification and may be more essential during
infection settings. While future studies should focus on the essentiality and “native function” for
GloB and FrmB, it may also be worthwhile to identify and characterize esterases that are known
to be essential. Recently, 10 functional S. aureus serine hydrolases were identified using an
activity based protein profiling approach (121). It is worth noting that one of the identified
esterases, FphF, is the same enzyme as FrmB which has been previously discussed. Several of
the identified serine hydrolases already have potent and selective inhibitors that have been
developed against them, though these compounds do not have anti-staphylococcal activity
suggesting that either the inhibitor is unable to enter the cell or these esterases are dispensable in
culture media (121). However, disruption of one esterase, FphB, appears to disrupt S. aureus
virulence in the liver and heart, but not the kidney (121). Esterases in other organisms similarly
appear to play a role specifically in infection. For example, deletion of the Francisella tularensis
outer membrane vesicle lipase, FtlA, results in avirulent bacteria (122). Identification of
essential, or virulence essential, esterases and the characterization of them, is an important step
towards the development of microbe specific prodrugs.

Prodrug activation in P. falciparum
Recently, mutations in the P. falciparum carboxylesterase, PfPARE (P. falciparum prodrug
activation and resistance esterase) were found to confer resistance to carboxy ester prodrugs of
pepstatin (43). Further analysis revealed that PfPARE mutant strains are unable to activate the
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pepstatin prodrug and that PfPARE can hydrolyze pepstatin butyl ester in vitro. PfPARE
mutations also confer resistance to prodrug esters of the lindenane sesquiterpenoid,
Chlorajaponilide C, and prodrug esters of benzoxaboroles (42, 123). Based on enzyme assays on
PfPARE and patterns of cross resistance, PfPARE appears to preferentially hydrolyze
unbranched and minimally branched C6 substrates (42, 43, 123).
Identification of PfPARE is a critical step towards the development of P. falciparum targeted
prodrugs. However, as with GloB and FrmB in S. aureus, the rapid evolution of prodrug
resistance through PfPARE disruption and the apparent non-essentiality of PfPARE raise
concerns about the long-term efficacy of this as a targeting strategy. In addition to identifying
essential esterases, one strategy for P. falciparum targeted prodrugs is the development of
erythrocyte targeted prodrugs. P. falciparum is unique in that it continually resides within
erythrocytes for most of its lifecycle. Nutrient channels have been identified which promote
nutrient exchange between the erythrocyte cytosol and the parasite cytosol, and these may
additional transit drug-like molecules between the two cytosols (124). Erythrocyte targeted
prodrug activation has the benefit that esterase mutations are not a feasible resistance mechanism
for the parasite. Indeed, some prodrugs appear to already be activated selectively by erythrocyte
esterases as opposed to parasite esterases (125). Whether this strategy is ultimately feasible will
depend on the substrate specificities of serum and liver esterases as opposed to erythrocyte
esterases.

1.3 Challenges and opportunities for prodrugs
The utility of prodrugs is undeniable and has begun to be realized in drug development. Between
2008 and 2018, 30 new FDA approved prodrugs entered the market (126). This expansion of
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prodrug production has continued. In quarter 3 of 2020 alone, four new prodrugs (31% of
approved Q3 drugs) entered the market (127). As prodrugs continue to attract attention for their
potential, new developments in prodrug targeting will enable an expanded druggable space for
antimicrobials while simultaneously de-risking antibiotic development. However, several
challenges and open questions should be addressed prior to widespread prodrug development.
Ideally, lipophilic prodrugging strategies can be developed such that any phosphonate compound
becomes orally bioavailable, membrane permeable, and is specifically cleaved by the
microorganism(s) of interest. This will enable any metabolic process inside the cell to be targeted
when this was previously unachievable. Simultaneously, the specific targeting of prodrugs to
microbial populations will reduce potential toxicity in human cells as the compound will be
ineffective until activated. Unfortunately, promoieties that achieve this have not yet been
identified. New research should focus on identifying prodrug activators in pathogenic microbes
and subsequently determining the substrates cleavable by those activators. Additionally, we have
highlighted that animal models do not accurately human esterase activity. New animal models
need to be developed for effective pre-clinical prodrug assessment. Perhaps the best route
forward is the development of large, high-throughput substrate libraries to enable massive
screening of esterase activity. This has already started, and should continue (128).
One aspect of prodrug biology that needs to be considered during drug development is the
toxicity of promoiety biproducts upon parental compound release. POM-prodrugs are expected
to release pivalate and formaldehyde upon activation, and long-term treatment of POM prodrugs
has lead to depletion of carnitine (129). It remains unclear how microbe-specific prodrug
delivery will impact promoiety toxicity, especially if activation is incredibly specific for the
microbe(s) that are targeted.
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Confusingly, potency increases as a result of lipophilic prodrugging are not universal. In
zoonotic staphylococci, POM-modification of fosmidomycin analogues improves potency by
500-1000 fold (8). Lipophilic prodrugging of bisphosphonates confers a 25-fold potency increase
against human cells (103). Conversely, lipophilic prodrugs of fosmidomycin have no activity
against many gram negatives, despite the parent compound being efficacious (8). Whether these
differences are a result of poor activation in vivo by gram-negative organisms, activation in the
incorrect cellular compartment, or a failure to transit the hydrophilic periplasmic space remains
unknown. Understanding the limitations surrounding gram-negative prodrug activation will
impact the scope of lipophilic prodrugging approaches.
Finally, we have thoroughly discussed the benefits of lipophilic prodrugging regarding oral
bioavailability. Less is known about how lipophilic prodrugs will distribute systemically. It is
well established that lipophilic compounds are more likely to bind serum proteins and are less
likely to undergo renal elimination. Whether lipophilic prodrugs will have a release rate from
serum proteins sufficient to deliver active compound to microbial targets remains an open
question.
Lipophilic prodrugging strategies have been recognized and employed as modifiers of oral
bioavailability for many years. Lipophilic prodrugging may also increase cell membrane
penetration and reduce toxicity concerns around developing compounds. Targeted prodrug
delivery is feasible for some compounds, however lipophilic promoieties that specifically target
compounds to microbial cells have not been identified. Identification of microbial prodrug
activators represent an attractive first step towards the development of microbe specific
prodrugs.
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1.4 Figures

Figure 1 Penicillin resistance mechanisms. Top left- in wild-type gram negative bacteria sensitive to penicillin, extracellular penicillin is
transited by porin proteins to reach periplasmic or cytoplasmic penicillin binding proteins (PBPs). Top right- expression of β-lactamase enzymes
(βLs) confers protection via penicillin hydrolysis. Bottom left- Disruption of the transit mechanism confers penicillin resistance. Bottom rightmutation of penicillin binding protein confers resistance to penicillins.
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Figure 2 Structures of Penicillin and Penicillin derivatives. Highlighting identifies variation from Penicillin G. Orange highlighting indicates
the molecule is resistant to β-lactamases (second generation penicillin), green compounds are more likely to be uptaken by cells (third generation
penicillins), and the purple highlighting illustrates expanded antimicrobial susceptibility (third generation penicillin).
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Figure 3 Nucleotide prodrug structures. Parent compounds are displayed on the left and prodrug variants to the right. Promoieties highlighted
in orange.
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Figure 4 MEPicide and MEPicide prodrug action. Prodrugging bypasses GlpT mediated transit. Promoeities are removed via an intracellular
esterase prior to DXR inhibition. Serum esterases rapidly hydrolyze POM-promoieties.
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Chapter 2: Potent, specific MEPicides for
treatment of zoonotic staphylococci
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2.1 Abstract
Coagulase-positive staphylococci, which frequently colonize the mucosal surfaces of animals,
also cause a spectrum of opportunistic infections including skin and soft tissue infections, urinary
tract infections, pneumonia, and bacteremia. However, recent advances in bacterial identification
have revealed that these common veterinary pathogens are in fact, zoonoses that cause serious
infections in human patients. The global spread of multidrug-resistant zoonotic staphylococci, in
particular the emergence of methicillin-resistant organisms, is now a serious threat to both
animal and human welfare. Accordingly, new therapeutic targets that can be exploited to combat
staphylococcal infections are urgently needed. Enzymes of the methylerythritol phosphate
pathway (MEP) of isoprenoid biosynthesis represent potential targets for treating zoonotic
staphylococci. Here we demonstrate that fosmidomycin (FSM) inhibits the first step of the
isoprenoid biosynthetic pathway catalyzed by deoxyxylulose phosphate reductoisomerase (DXR)
in staphylococci. In addition, we have both enzymatically and structurally determined the
mechanism by which FSM elicits its effect. Using a forward genetic screen, the glycerol-3phosphate transporter GlpT that facilitates FSM uptake was identified in two zoonotic
staphylococci, Staphylococcus schleiferi and Staphylococcus pseudintermedius. A series of
lipophilic ester prodrugs (termed MEPicides) structurally related to FSM were synthesized, and
data indicate that the presence of the prodrug moiety not only substantially increased potency of
the inhibitors against staphylococci, but also bypassed the need for GlpT-mediated cellular
transport. Collectively, our data indicate that the prodrug MEPicides selectively and robustly
inhibit DXR in zoonotic staphylococci, and further, DXR represents a promising, druggable
target for future development
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2.2 Introduction
Coagulase-positive staphylococci, such as S. pseudintermedius and S. schleiferi subsp.
coagulans, are leading causes of skin, soft tissue, and invasive infections in companion animals
such as dogs and cats. In addition, these organisms cause zoonotic infections in humans that are
clinically indistinguishable from infections with S. aureus including pneumonia, skin and soft
tissue infections, hardware infections, and bacteremia(1–5). Newer clinical microbiological
techniques, such as mass spectrometry, now readily distinguish S. aureus from zoonotic
coagulase-positive staphylococci, which were previously often misidentified(3,6,7). Thus, there
is a growing recognition of the importance of zoonotic staphylococci in human disease. Because
mecA-mediated methicillin resistance is on the rise in both veterinary and human clinical
isolates, new antibacterial strategies to specifically target zoonotic staphylococci are highly
desirable(8–10).

Two distinct and independent pathways for isoprenoid biosynthesis have evolved, the
mevalonate pathway and a mevalonate-independent route that proceeds through methylerythritol
phosphate, called the MEP pathway(11). Unusual among bacteria, the least common ancestor of
all Staphylococcus spp. appears to have possessed both pathways. Primate-associated
staphylococcal lineages, including S. aureus, possess the mevalonate pathway, and evidence
suggests that mevalonate pathway activity is required for peptidoglycan synthesis, growth, and
virulence(12–14). In contrast, nonprimate-associated staphylococcal species, including S.
pseudintermedius and S. schleiferi, utilize the MEP pathway for isoprenoid biosynthesis(15).
Importantly, humans and other mammals lack homologs of MEP pathway enzymes, and MEP
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pathway activity is required for cellular growth in all organisms in which it has been
experimentally determined(16–21). Thus, new chemical inhibitors of MEP pathway enzymes
hold promise as effective antimicrobials that may provide a high margin of safety.

The first dedicated enzyme of the MEP pathway, deoxyxylulose phosphate reductoisomerase
(DXR; E.C. 1.1.1.267), is rate-limiting for MEP pathway activity. DXR is known to be
susceptible to small molecule inhibition. For example, the phosphonic acid antibiotic
fosmidomycin (FSM) is a slow, tight-binding, competitive inhibitor of DXR(22). FSM is safe
and well-tolerated in humans and animals(23–25). Unfortunately, FSM has poor oral
bioavailability and a short serum half-life, which has hampered clinical efficacy. Moreover, the
charged nature of FSM and its phosphonate analogs has challenged their clinical development as
the compounds are excluded from cells unless actively transported. As a result, many
microorganisms, such as Mycobacterium tuberculosis and Toxoplasma gondii, are inherently
resistant to FSM (due to poor cellular uptake) even though FSM potently inhibits their DXR
orthologs in vitro(16,18,26). In Gram-negative organisms, FSM import is dependent on a
glycerol-3-phosphate/Pi antiporter (GlpT), and FSM resistance can be achieved by reduced
expression or activity of GlpT(27,28).

In this work, we use the highly specific inhibitor FSM to chemically validate the MEP pathway
enzyme DXR as an essential, druggable antibacterial target for zoonotic staphylococcal
infections. Furthermore, we establish the structural and enzymatic mechanism of staphylococcal
DXR inhibition by FSM. Using a chemical genomics approach, we define the genetic basis of
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FSM resistance in zoonotic staphylococci and define the FSM transporter GlpT in these strains.
Finally, we reveal that structurally related lipophilic ester prodrugs (called MEPicides) yield
substantially increased potency and circumvent the need for GlpT-dependent import. Thus,
lipophilic prodrugs provide a promising new approach to combat zoonotic staphylococcal
infections.

2.3 Methods
2.3.1 DXR Inhibitors.
FSM (Millipore Sigma) and FR-900098 (Millipore Sigma) were resuspended in sterile water.
Compounds 1-4 were synthesized and resuspended in DMSO as previously described(41,42,53).

2.3.2 Growth inhibition assays of Staphylococcus species.
Overnight cultures were diluted 1:200 in LB media and grown at 37°C until the mid-logarithmic
phase (OD600 = 0.5 – 0.8). Cultures were diluted in a 96-well plate to 1 x 105 in 150 µL LB
media and treated with inhibitors at concentrations ranging from 2 nM to 100 μM. Bacteria were
grown at 37°C for 20 h with cyclic shaking at 700 rpm in a FLUOstar Omega microplate reader
(BMG Labtech). Growth was assessed over 20 h by measuring the OD600 at 20 min increments.
The half-maximal inhibitory concentration (IC50) values were determined during logarithmic
growth using GraphPad Prism software. All experiments were performed at least in triplicate and
data reported represent the mean ± SEM.

2.3.3 Minimum bactericidal (MBC) assay.
Overnight cultures were diluted 1:200 in LB media and grown at 37°C until reaching midlogarithmic phase of growth. Compounds were added to cultures at their respective IC50 and at
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10 x IC50, and the bacteria were incubated at 37°C for 24 h while shaking. Cultures were serially
diluted in Dulbecco’s Phosphate Buffered Saline (PBS; Gibco) and plated on LB agar. Colonies
were enumerated after overnight growth at 37°C. Values reflect the mean and standard
deviations of at least three independent experiments.

2.3.4 Sample preparation for mass spectrometry analysis.
Overnight cultures of Staphylococcus spp. were diluted 1:200 in LB media and grown at 37°C
until reaching mid-logarithmic phase. Cultures were then treated for 2 h with FSM at 10x their
IC50 while shaking at 37°C. For normalization, the OD600 was determined after 2 h of treatment
with the DXR inhibitors. Cells were pelleted by centrifugation for 5 min at 3000 x g at 4°C. The
supernatants were removed and cells were washed twice with PBS (Gibco). The supernatants
were removed and the pellets stored at -80°C until analysis. MEP intermediates were extracted
from the samples using glass beads (212-300 u) and 600 µL chilled H2O: chloroform: methanol
(3:5:12 v/v) spiked with PIPES (piperazine-N,N′-bis(2-ethanesulfonic acid) as internal standard.
The cells were disrupted with the TissueLyser II instrument (Qiagen) using a microcentrifuge
tube adaptor set pre-chilled for 2 min at 20 Hz. The samples were then centrifuged at 16,000 x g
at 4ºC for 10 min, the supernatants collected, and pellet extraction repeated once more. The
supernatants were pooled and 300 µL chloroform and 450 µL of chilled water were added to the
supernatants. The tubes were vortexed and centrifuged. The upper layer was transferred to a 2
mL tube PVDF filter (ThermoFisher, F2520-5) and centrifuged for 5 min at 4,000 x g at 4ºC.
The samples were transferred to new tubes and dried using a speed-vac. The pellets were redissolved in 100 μL of 50% acetonitrile.
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2.3.5 LC-MS/MS analysis.
For LC separation, Luna-NH2 column (3 µm, 150 x 2 mm, Phenomenex) was used flowing at
0.4 mL/min. The gradient of the mobile phases A (20 mM ammonium acetate, pH 9.8, 5%
acetonitrile) and B (100% acetonitrile) was as follows: 60% B for 1 min, to 6% B in 3 min, hold
at 6% B for 5 min, then back to 60% B for 0.5 min. The LC system was interfaced with a Sciex
QTRAP 6500+ mass spectrometer equipped with a TurboIonSpray (TIS) electrospray ion source.
Analyst software (version 1.6.3) was used to control sample acquisition and data analysis. The
QTRAP 6500+ mass spectrometer was tuned and calibrated according to the manufacturer’s
recommendations. The metabolites were detected using MRM transitions that were previously
optimized using standards. The instrument was set-up to acquire in negative mode. For
quantification, an external standard curve was prepared using a series of standard samples
containing different concentrations of metabolites and a fixed concentration of the internal
standard. The limit of detection for 1-deoxy-D-xylulose 5-phosphate (DOXP), 4diphosphocytidyl-2-C-methylerythritol (CDP-ME), and 2-C-methyl-D-erythritol 2,4cyclopyrophosphate (MEcPP) was 0.0064 μM for a 10 μL injection volume. Data reflect the
mean and SD of at least three independent experiments. T-tests were used to test for significance
between untreated (UNT) and drug-treated bacteria (Prism).

2.3.6 Recombinant expression and purification of DXR.
Wild-type dxr from S. schleiferi was amplified from genomic DNA using the forward primer 5’CTCACCACCACCACCACCAT ATGAAAAATATAGCAATTTTAGGCGC-3’ and the
reverse primer 3’-ATCCTATCTTACT CACCTACACCTCATATGATTTTGTTTTATAAT-5’
The PCR product was cloned into vector BG1861 by ligation-independent cloning to introduce a
N-terminal 6xHis tag, and transformed into Stellar™ chemically competent cells (Clontech
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Laboratories)(68). The sequence was confirmed by Sanger sequencing and the plasmid was
transformed into E. coli BL21(DE3) pLysS (Life Technologies). Gene expression was induced
for 2 h with 1 mM isopropyl-β-D-thiogalactoside (IPTG) and cells were harvested by
centrifugation at 4274 x g for 10 min at 4°C. The cell pellet was lysed by sonication in lysis
buffer containing 25 mM Tris HCl (pH 7.5), 100 mM NaCl, 20 mM imidazole, 10% glycerol, 1
mM MgCl2, 1 mM dithiothreitol (DTT), 1 mg/mL lysozyme, 75 U benzonase and 1 Complete
Mini EDTA-free protease inhibitor tablet (Roche Applied Science). The hexahistidine-tagged
DXR protein was affinity purified from soluble lysate via nickel agarose beads (Gold
Biotechnology). Bound protein was eluted in 300 mM imidazole, 25 mM Tris HCl (pH 7.5), 1
mM MgCl2 and 100 mM NaCl. Purified protein was dialyzed in buffer containing 10% glycerol
without imidazole prior to analysis. The enzyme was frozen in liquid nitrogen and stored
permanently at -80°C.

2.3.7 DXR enzyme activity and inhibitory constant determination.
Oxidation of NADPH to NADP+ as a result of substrate turnover was monitored at 340 nm in a
POLARstar Omega microplate reader (BMG Labtech)(69). The standard reaction had a final
concentration of 62.5 nM purified DXR protein, 0.5 mM NADPH, 100 mM NaCl, 25 mM Tris
pH 7.5, 10% glycerol, 1 mM MgCl2 and 0.09 mg/mL BSA in 50 µL volume per assay. Reactions
were initiated by the addition of DOXP after 15 min incubation of the reaction mixture without
DOXP at 37°C. Absorption at 340 nm was measured continuously for up to 45 min. For Km
[DOXP] determination, DOXP concentrations between 0 and 2 mM were tested at 0.5 mM
NADPH. The linear range of enzyme activity was determined by varying the DXR concentration
at 1 mM DOXP and 1 mM NADPH. IC50 assays were performed using the standard reaction
conditions with the respective amount of DXR inhibitor added to obtain the given final
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concentrations. Data points from at least three independent replicates were analyzed by nonlinear
regression using GraphPad Prism software. Slopes of changing absorbance values were
converted to (µM DOXP)(mg enzyme)-1 s -1 using a NADPH standard curve (data not shown).
For the determination of the inhibitory constant Ki [FSM] of DXR, enzyme activity over a range
of DOXP substrate concentrations between 0 and 2 mM was measured for FSM between 0 mM
to 4 mM. Data points from at least three independent replicates were analyzed as described
above.

2.3.8 Protein crystallography.
Crystals of S. schleiferi DXR were grown at 4°C using the vapor diffusion method in hanging
drops of a 1:1 mixture of protein (10 mg mL-1) and crystallization buffer (2 M ammonium
sulfate, 100 mM sodium citrate/citric acid, pH 5.5). Crystals of the S. schleiferi DXR•FSM
complex were obtained in 100 mM HEPES/MOPS (pH 7.5), 20 mM D-glucose, 20 mM Dmannose, 20 mM D-galactose, 20 mM L-fucose, 20 mM D-xylose, 20 mM N-acetyl-Dglucosamine, 20% glycerol, 10% PEG 4000, and 2 mM FSM. Prior to data collection, crystals
were stabilized in cryoprotectant (mother liquor supplemented with 30% glycerol) before flash
freezing in liquid nitrogen for data collection at 100 K. All diffraction images were collected at
beamline 19-ID of the Argonne National Laboratory Advanced Photon Source at Argonne
National Laboratory. HKL3000 was used to index, integrate, and scale the data sets(70). For
phasing of the apoenzyme structure, molecular replacement was performed in PHASER using
the x-ray crystal structure of E. coli DXR (PDB: 1T1S) as a search model(31,71). Two
monomers were found in the asymmetric unit, with each forming a physiological dimer by
crystallographic symmetry. For iterative rounds of model building and refinement, COOTand
PHENIX were used, respectively(72,73). The resulting model was used to solve the structure of
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the FSM complex by molecular replacement with PHASER. Two molecules were found in the
asymmetric unit with crystallographic symmetry completing each dimer. Data collection and
refinement statistics are summarized in Table S2. Atomic coordinates and structure factors of S.
schleiferi DXR (PDB:6MH4) and the S. schleiferi DXR•FSM complex (PDB:6MH5) were
deposited in the RCSB Protein Data Bank.

2.3.9 Generation of FSM-resistant mutants in S. schleiferi and S.
pseudintermedius.
Clinical isolates of S. schleiferi (S53022327s) and S. pseudintermedius (H20421242p) were
cloned and adapted to laboratory media via four rounds of sequential colony isolation and growth
on LB agar plates. The isolated FSM-sensitive parental clones were incubated overnight on LB
agar containing FSM (32 µM). Surviving single colonies were re-struck onto LB agar for clonal
isolation. FSM resistance of isolated clones was confirmed by overnight growth on LB agar
containing FSM (32 µM). The FSM-sensitive parental clones were used as a control to confirm
growth and antibiotic-resistance.

2.3.10 Quantification of MEPicide resistance.
Minimum Inhibitory Concentration (MIC) assays were conducted by microtiter broth dilution in
clear 96-well plates(74). MEPicides were serially diluted in duplicate at concentrations ranging
from 1.5 mM – 19.5 nM in 75 µL of LB broth. Bacteria cultured without drug were used as a
positive control for growth. The plates were inoculated with 75 µL bacteria diluted to 1 x 105
CFU/mL in LB. Plates were incubated for 18-20 h while shaking at 200 RPM at 37°C. The plates
were then visually inspected, and the MIC value was defined as the lowest concentration of
MEPicide that prevented visual growth.
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2.3.11 Whole genome sequencing and variant discovery.
Genomic DNA was isolated from overnight cultures of S. pseudintermedius and S. schleiferi
using a standard phenol-chloroform extraction and ethanol precipitation protocol. Sequencing
libraries were prepared and sequenced by the Washington University Genome Technology
Access Center (GTAC). 1 µg of DNA was sonicated to an average size of 175 bp. Fragments
were blunt ended and had an A base added to the 3´ end. Sequence adapters were ligated to the
ends and the sequence tags were added via amplification. Resulting libraries were sequenced on
an Illumina HiSeq 2500 to generate 101 bp paired end reads. DNA quantity and quality were
assessed by GTAC using Agilent Tapestation.
For WGS, sequences from GenBank were retrieved from the following organisms: S.
pseudintermedius ED99 (accession number CP002478) and S. schleiferi 1360-13 (CP009470)
assemblies were downloaded from NCBI (ftp://ftp.ncbi.nlm.nih.gov). Paired-end reads were
aligned to each of the available genomes using Novoalign v3.03. (Novocraft Technologies) and
deposited in NCBI (accession number PRJNA488092). Duplicates were removed and variants
were called using SAMtools(75). SNPs were filtered against parent variants and by mean depth
value and quality score (minDP =5, minQ = 37)(76). Genetic variants were annotated using
SnpEff v4.3 (Table S4)(77). For all samples, at least 90% of the genome was sequenced at 20x
coverage. All whole genome sequencing data is available in the NCBI BioProject database and
Sequence Read Archive. Point mutations found in the GlpT domain were mapped onto the
predicted transmembrane topology of GlpT using Protter(78).
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2.3.12 Sanger Sequencing of S. schleiferi and S. pseudintermedius glpT.
Reference sequences for glpT in S. schleiferi (WP_016426432.1) and S. pseudintermedius
(WP_014613322.1) were found with the Basic Local Alignment Search Tool (BLAST, v.
2/2/22). The regions of interest were amplified from S. pseudintermedius and S. schleiferi using
gene-specific primers (Table S1). Amplicons were sequenced by the Washington University
Protein and Nucleic Acid Laboratory using BigDye Terminator v3.1 Cycle Sequencing reagents
(Life Technologies). Representative traces for all strains are available through the NCBI Trace
Archive.

2.4 Results
2.4.1 Anti-staphylococcal activity of canonical MEP pathway inhibitors.
Because previous evidence had suggested that zoonotic staphylococci might be sensitive to MEP
pathway inhibition, we quantified the dose-dependent antibacterial effects of FSM and FR900098, a structurally similar DXR inhibitor (Table 1)(15). FSM was 5-10-fold more potent
against both S. schleiferi (IC50 = 0.78  0.13 M) and S. pseudintermedius (IC50 = 0.31  0.04
M), respectively (Table 1), despite modest chemical differences between the two inhibitors.
Data indicate that both compounds elicit their effect via a bacteriostatic mechanism-of-action, as
neither caused a substantial drop in viable cells (Fig S1). Because S. aureus does not utilize the
MEP pathway for isoprenoid biosynthesis, neither FSM nor FR-900098 inhibit S. aureus growth
(Table 1). Together, these data indicate that both S. schleiferi and S. pseudintermedius have a
functional MEP pathway that is required for bacterial growth.
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2.4.2 Fosmidomycin inhibits isoprenoid metabolism in zoonotic staphylococci.
To establish the presence of MEP pathway intermediates and to determine the cellular
mechanism-of-action of FSM, we performed targeted metabolic profiling of MEP pathway
intermediates in S. schleiferi and S. pseudintermedius, with and without drug treatment. We
confirmed that both species contain MEP pathway intermediates, including the DXR substrate,
deoxyxylulose 5-phosphate (DOXP), and the downstream metabolite, methylerythritol
cyclodiphosphate (MEcPP) (Fig 1). Upon FSM treatment, intracellular levels of DOXP increase
dramatically (23.8-fold; p < 0.05 and 34.8-fold; p < 0.05 for S. schleiferi and S.
pseudintermedius, respectively), consistent with DXR inhibition. Similarly, intracellular levels of
MEcPP are substantially reduced following FSM treatment (4.5-fold; p < 0.01 and 2.4-fold; p <
0.05 for S. schleiferi and S. pseudintermedius, respectively), consistent with FSM-mediated
reduction in MEP pathway metabolism. Together, these data confirm the presence of active MEP
pathway metabolism in zoonotic staphylococci and establish that FSM inhibits growth through
MEP pathway inhibition.

2.4.3 Fosmidomycin is a competitive inhibitor of S. schleiferi DXR.
To establish the enzymatic mechanism-of-action of DXR inhibitors against staphylococci, we
cloned and purified S. schleiferi DXR (Fig S2; Table S1). Enzymatic characterization of DXR
confirmed a Michaelis constant (Km) [DOXP] (0.52 ± 0.08 mM), similar to that of other DXR
orthologs (Fig 2A)(29,30). Both FSM and FR-900098 inhibit S. schleiferi DXR in a dosedependent manner (Table 1). Further, we confirm that DXR inhibition by FSM is competitive
with respect to the DOXP substrate, with a Ki [DOXP] of 0.29 ± 0.022 µM (Fig 2B).
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2.4.4 Structural basis of fosmidomycin inhibition.
To establish the structural basis of FSM action, we solved the three-dimensional structures of S.
schleiferi DXR as an apoenzyme and a FSM complex to 2.15 Å and 2.89 Å resolution,
respectively (Table S2; Fig 3). S. schleiferi DXR is a physiologic dimer with each monomer
related by crystallographic symmetry (Fig 3A). A DALI search identified multiple DXR from
Escherichia coli, Plasmodium falciparum, M. tuberculosis, and other microbes (Z-scores: 49-51;
r.m.s.d. ~1.6 Å2 for 370-400 Cα-atoms; 39-40% amino acid sequence identity)(31–36). The
monomer consists of three regions (Fig 3A): an N-terminal α/β-domain with a central 7-stranded
β-sheet (β1-β7) and 7 α-helices that serves as the nucleotide binding site; a middle region of the
protein that includes a second β-sheet (β8- β11) and 4 α-helices (α8 and α12- α14); and a Cterminal α-helical domain (α9- α11 and α15- α18) that locks FSM into the active site(37).
Clear electron density for FSM was observed in the active site (Fig 3B) and revealed multiple
protein-ligand interactions (Fig 3C). Interactions with Ser170, Ser206, Asn211, and Lys212
positions the FSM phosphonate toward the catalytic histidine (His241) and the NADP(H)
binding site. The hydroxamic acid of the ligand contacts Asp144, Glu146, and Glu215.
Additional van der Waals contacts are provided by Trp196, which resides in the α10- α11 loop.
Comparison of the S. schleiferi DXR apoenzyme and FSM complex structures reveals how the
C-terminal capping region (α9- α11 and α16-18) shift position to allow for the α10- α11 loop to
position Trp196 adjacent to the inhibitor (Fig 3D). Movement of this flexible loop is a key
feature for FSM inhibition of DXR from a variety of microorganisms(38). The residues that
interact with FSM in the S. schleiferi DXR are conserved in the crystal structures of DXR from
E. coli, P. falciparum, and M. tuberculosis with some variation in the sequence of the α10- α11
loop, although the tryptophan that contacts FSM is conserved in all these enzymes(34,36,37).
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2.4.5 Resistance selection reveals a candidate FSM transporter, GlpT.
To establish the molecular basis of compound uptake, we performed independent, parallel,
forward genetic screens for FSM resistance in both S. schleiferi and S. pseudintermedius (Fig
4A). Candidate FSM resistant (FSMR) strains were colony purified and resistance was quantified
by MIC determination (Fig 4B and Table S3). For both S. schleiferi and S. pseudintermedius,
FSMR strains possessed FSM MICs >100-fold higher than the wild-type parental lines. We
employed whole genome sequencing to characterize the single-nucleotide polymorphisms
(SNPs) that were present in the resistant strains (Table S4). In both species, FSM selective
pressure enriched for new nonsynonymous changes in a single homologous locus, RN70_03745
(10/11 S. schleiferi strains) and SPSE_0697 (10/12 S. pseudintermedius strains) (Figs. S3A and
S3B). These loci are close homologs (>90% sequence identity and 95.4% sequence similarity),
which belong to the glycerol-3-phosphate transporter (GlpT) subfamily (Interpro: IPR005267) of
the major facilitator superfamily (MFS) family of proteins (Interpro: IPR011701). These data
suggest a model in which GlpT mediates FSM import, such that loss of GlpT function confers
FSM resistance.

2.4.6 Fosmidomycin-resistance alleles of the candidate transporter, GlpT.
We predicted that the FSM-resistance alleles likely reduce GlpT function. In S. schleiferi, nine
distinct alleles were found with GlpT changes: two with nonsense mutations and seven others
with amino acid variants that are predicted to be highly deleterious (Polyphen-2 score >0.9;
Table S3)(39). Similarly, in S. pseudintermedius, a total of seven distinct alleles were identified
with GlpT sequence changes. Of these, one contained a nonsense mutation and six other GlpT
variants contained amino acid substitutions that are strongly predicted to reduce function
(Polyphen-2 score >0.9; Table S3). FSM-resistant variants map along the length of the nearly 50
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Kd GlpT transporter, in both S. schleiferi and S. pseudintermedius (Figs S3A and S3B).
Altogether, the finding of multiple independent loss-of-function alleles, including nonsense
mutations, in two different selections in distinct organisms, strongly suggests that reduced GlpT
function is responsible for FSM resistance in these strains.

2.4.7 Lipophilic ester prodrugs with improved anti-staphylococcal potency.
Due to their charged nature, phosphonic acid antibiotics have poor cellular penetration and
bioavailability, and serum half-lives are relatively brief(23,25,40). In the ongoing effort to
develop new treatments for malaria and tuberculosis by improving upon the drug-like properties
of phosphonates, numerous lipophilic ester prodrugs that target DXR have been generated(41–
53) Our phosphonate parent compounds (1 and 3) are similar in anti-staphylococcal potency to
FSM and FR-900098 (Table 1); however, lipophilic modification of either compound
dramatically improves potency (in most cases by 100-fold) against both S. schleiferi and S.
pseudintermedius (compare compound 1 to its prodrug, compound 2, and compound 3 to its
prodrug, compound 4) (Table 1). As expected, prodrugs 2 and 4 poorly inhibit purified
recombinant S. schleiferi DXR in vitro, since cleavage of the prodrug moiety is required for
activity (Table 1). Our data suggest that lipophilic ester modifications improves uptake of the
DXR inhibitors, and that active phosphonates are released intracellularly for target inhibition
(model, Fig 6).

2.4.8 Lipophilic prodrugs bypass need for GlpT-mediated transport.
We anticipated that our lipophilic ester prodrugs do not require active cellular transport. To
evaluate whether GlpT is required for prodrug uptake, we characterized the MEPicide sensitivity
of four different FSMR glpT mutant S. schleiferi strains. As expected, we find that FSMR glpT
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strains are cross-resistant to the phosphonate parent drug (compound 3), suggesting a common
mechanism of transport (Fig 5). In contrast, FSMR glpT strains remain sensitive to the MEPicide
prodrugs compounds 2 and 4, supporting a model in which GlpT mediates phosphonate
transport, with the ester modifications substantially improving cellular uptake (Fig 6)(21).
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2.5 Discussion
S. schleiferi and the Staphylococcus intermedius group (SIG) (including S. pseudintermedius, S.
intermedius, and S. delphini) cause pyodermic infections in companion animals, such as dogs
and cats(8). Treatment of these infections is complicated by rising rates of antimicrobial
resistance, particularly methicillin-resistance(54). A growing recognition that SIG species also
cause zoonotic human infections, indistinguishable from infections with S. aureus, has led to new
urgency in the search for additional therapeutics against these organisms. The non-mevalonate
pathway of isoprenoid biosynthesis through MEP has been previously explored for development
of targeted therapeutics for malaria and tuberculosis. In this current work, we establish the MEP
pathway enzyme DXR as an attractive new therapeutic target for treatment of infections due to
zoonotic staphylococci.
The MEP pathway has a number of major advantages as an antimicrobial target for veterinarian
applications. Since mammals utilize the mevalonate pathway for isoprenoid biosynthesis, they
lack homologs of the MEP pathway enzymes. As a result, MEP pathway inhibition is expected to
have a high therapeutic index, and indeed, such inhibitors have been well-tolerated in preclinical
and Phase I and II human studies(23–25,55,56). In addition, use of antibiotics in animal health
and agriculture has been implicated as a major driver of antimicrobial resistance in human
pathogens(57–60). Of particular relevance to treatment of canine and feline infections, the close
physical contact between owners and household pets facilitates not only the cross-colonization of
organisms, but also direct transfer of drug-resistance traits(61–63). Because human-associated
staphylococci, including S. aureus, S. warnerii, and S. epidermidis, use the mevalonate pathway
for isoprenoid biosynthesis, they are not susceptible to MEP pathway inhibitors (Table 1).
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Importantly, while Gram-negative organisms such as E. coli and Klebsiella pneumoniae are
modestly susceptible to MEP pathway inhibition, our lipophilic prodrug compound 2 does not
inhibit growth of these organisms (Table S5). Our MEPicide compounds therefore have a highly
specific and valuable antimicrobial spectrum, which may help break the cycle of resistance
transfer from antibiotic-treated animals to the microbiota of humans.
In the current study, we establish the cellular, enzymatic, and structural mechanisms-of-action of
FSM against zoonotic staphylococci. We confirm that FSM is a competitive inhibitor of
staphylococcal DXR, interrupts cellular isoprenoid biosynthesis, and inhibits growth of zoonotic
staphylococci. Of note, the staphylococcal DXR enzyme appears somewhat distinct from
previously characterized orthologs, particularly in the α10- α11 loop sequence, which could be
explored with additional SAR studies. Together, our work provides insights into differences in
staphylococcal DXR that may be key to driving future structure-based inhibitor design efforts.
A well-appreciated liability of antibacterial phosphonates, including fosfomycin and FSM, has
been the ready acquisition of resistance through loss of transport (27,64–66). Our work
establishes GlpT as the likely phosphonate transporter in zoonotic staphylococci (Fig. 6).
Identification of multiple, independent loss-of-function alleles from independent screens in two
separate species is compelling evidence for a role of this locus in FSM-resistance in
staphylococci. In addition, the homology between staphylococcal GlpT orthologs and Gramnegative phosphonate transporters suggests that the staphylococcal proteins are functionally
similar. The finding that lipophilic prodrug MEPicides, which do not require active transport, are
still active against the glpT mutant strains indicates that the molecular basis of phosphonate
resistance is through loss of GlpT-mediated transport (Fig 6). The prodrug MEPicides
circumvent GlpT, which our study has shown is easily mutated in staphylococci. Whether
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staphylococci also readily develop resistance to the prodrug MEPicides is currently unclear, and
is an important question for future studies.
It is important to note that while data indicate that the glpT mutants are resistant to phosphonate
parent compound 3, the magnitude of resistance is substantially less than that of FSM. These
data suggest that compound 3 may preferentially use an alternative transporter, thereby
bypassing the dependence on GlpT. Surprisingly, staphylococcal glpT mutants are hypersensitive
to MEPicide prodrugs, suggesting that after penetration and cleavage by cellular esterases, the
compounds may accumulate intracellularly in the absence of GlpT (Fig 5). Future studies should
examine the cellular transport of the MEPicide compounds, and further, explore whether synergy
exists between the parent and prodrug varieties of this class of inhibitors.
The MEPicide prodrugs, including compounds 2 and 4, represent promising leads for ongoing
preclinical testing and development of new therapeutics for zoonotic staphylococcal infections.
The prodrugs harness the microbial specificity and thus safety of MEP pathway inhibition, while
avoiding the dependency on active GlpT-mediated transport. In addition, we find that ester
modification has a dramatic effect on anti-staphylococcal potency in vitro, suggesting that
phosphonate transport limits the anti-bacterial efficacy of FSM and related compounds.
Lipophilic ester modifications have previously been employed to improve pharmacokinetic
properties and bioavailability of anti-staphylococcal agents (e.g., cefditoren pivoxil)(67). Since
MEPicide ester modification at the site of infection is necessary to facilitate bacterial cell entry
of inhibitors, future studies will aim to understand what chemical features drive intestinal and
serum cleavage of the MEPicide prodrugs.
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2.6 Figures

Figure 1 FSM inhibits the MEP pathway in Staphylococcus spp. MEP pathway metabolites were compared between untreated (UNT) S.
schleiferi (A) and S. pseudintermedius (B) and bacteria treated with FSM at 10x the respective IC50 values. After 2 h treatment, bacterial
cells were harvested and the cell pellets analyzed by LC-MS/MS. Displayed are the means ± SD of the metabolite levels from three
independent experiments. P-values were determined using a Student’s t-test.
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Figure 2 Inhibition of staphylococcal DXR by FSM is competitive with DOXP. (A) S. schleiferi DXR velocity in µmol NADPH/min
with respect to the DOXP concentration in mM. Displayed are the means ± SD from three independent experiments. (B) Lineweaver−Burk
double reciprocal plots of S. schleiferi DXR activity over a range of DOXP substrate concentrations, for illustrative purposes only.
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Figure 3 Crystal structure of S. schleiferi DXR. (A) Overall structure of the S. schleiferi DXR•FSM complex. The dimer is shown as a
ribbon diagram with αhelices and β-strands of one monomer colored gold and blue, respectively. The position of FSM (space-filling model)
in one monomer is indicated. (B) Electron density for FSM is shown as a 2Fo-Fc omit map (1 σ). (C) Stereoview of FSM binding in the
active site. Dotted lines indicate protein-ligand interactions. (D) Comparison of S. schleiferi DXR apoenzyme and FSM complex structures.
Structural changes in the active site region between the apoenzyme (rose) and FSM complex (gold) are shown. The major change in the
position of the α10-α11 loop is emphasized by the position of Trp196 in each structure.
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Figure 4 Successful evolution of FSM resistance. (A) Wild-type and FSM-resistant isolates from S. schleiferi (top) or S. pseudintermedius
(bottom) were struck on LB agar plates with (right) and without (left) 32 µM FSM. (B) Distribution of the MIC values for WT (gray) and
FSM-resistant mutants (black) from S. schleiferi (circles) and S. pseudintermedius (triangles). Displayed are the mean values for each strain
from three independent experiments.
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Figure 5 glpT mutant staphylococci are sensitive to MEPicide prodrugs. Wild-type (WT) and FSM-resistant, glpT mutant S. schleiferi
isolates (strains 3408, 4494, 7376, and 8400) were treated with MEPicides and the MIC values determined during overnight growth.
Displayed are the mean values of the fold change (resistant isolate/WT) ± SEM from at least three independent experiments. *MIC values
observed for glpT strain 7376 were identical in three independent experiments performed in technical duplicate.
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Figure 6 Model. In wild-type zoonotic staphylococci, GlpT transports the MEP pathway inhibitor FSM intracellularly where it inhibits its
target, DXR. In staphylococci with glpT mutations, FSM is excluded from cells, resulting in FSM resistance. In contrast, lipophilic prodrug
MEPicides do not require active transport and remain effective.
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Figure S1 DXR inhibitors are bacteriostatic. Growth in CFU/mL of S. schleiferi and S. pseudintermedius after 24 h treatment is plotted
against the respective treatment. Cultures were treated at 1 x IC50 concentration and/or 10x IC50 concentration of the inhibitors. Shown are
the mean values + SD from at least three independent experiments.
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Figure S2 SDS-PAGE of purified S. schleiferi DXR. Molecular mass standard (M) and approximately 1 µg of purified recombinant S.
schleiferi DXR.
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Figure S3 Membrane topology of GlpT. (A) Wild-type amino acid sequences and predicted transmembrane topology of S. schleiferi GlpT.
Residues Gly-99, Trp-148, Trp-161, Ala-267, Gly-298, Ala-309, and Gln-379 are indicated in the sequence. Red indicates a stop mutation at
the site, while blue indicates a missense mutation. (B) Wild-type amino acid sequences and predicted transmembrane topology of S.
pseudintermedius GlpT. Residues Asp-88, Gly-99, Gly-135, Trp-301, Gly-400, and Gly-404 are indicated in the sequence. Red indicates a
stop mutation at the site, while blue indicates a missense mutation. Schematic diagrams were prepared with the program Protter(5).
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2.7 Tables
Table 1: Inhibitory effect of MEPicides against the S. schleiferi DXR enzyme and in vitro activity against
Staphylococcus spp.
Compound

Structure

S. schleiferi
DXR enzyme

S. schleiferi

S. pseudintermedius

S. aureus

IC50 [𝝁M]

IC50 [𝝁M]

IC50 [𝝁M]

IC50 [𝝁M]

FSM

0.67 ± 0.06

0.78 ± 0.13

0.31 ± 0.04

> 100

FR-900098

1.00 ± 0.18

41.06 ± 6.65

34.14 ± 6.54

> 100

1

3.31 ± 1.02

55.50 ± 2.41

54.45 ± 1.14

> 100

2

> 100

0.10 ± 0.01

0.26 ± 0.03

> 100

3

0.41 ± 0.11

4.17 ± 0.47

4.31 ± 0.51

> 100

4

12.56 ± 1.98

0.03 ± 0.00

0.21 ± 0.04

> 90

Data represent the mean ± SEM from at least three independent experiments. POM =
(CH3)3CCOOCH2
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Table S2: Primers used in this study.
Number

Primer Name

Species

Gene

Sequence (5'-3')

IH3

SS_DXR_LIC_FWD

S. schleiferi

dxr

CTCACCACCACCACCACCATATGAAAAATATAGCAATTTTAGGCGC

IH4

SS_DXR_LIC_REV

S. schleiferi

dxr

ATCCTATCTTACT CACCTACACCTCATATGATTTTGTTTTATAAT

ITS4

Sp_GlpT_dwn125_rev

S. pseudintermedius

glpT

GATACCCCTCCACTTTCCAC

ITS5

Sp_GlpT_in576_fwd

S. pseudintermedius

glpT

AGGCTTTGAAGGGGCATTTA

ITS6

Sp_GlpT_up86_fwd

S. pseudintermedius

glpT

TGTAGAAATGCGATTGACAAACT

ITS15

Ss_GlpT_up258_fwd

S. schleiferi

glpT

TTGGCTGCTGATAGTGGTTA

ITS16

Ss_GlpT_in171_fwd

S. schleiferi

glpT

AATGGGGTTTACAAAAGCAG

ITS17

Ss_GlpT_in1211_rev

S. schleiferi

glpT

CCGCCTAAATAGCCAAATAA

ITS18

Ss_GlpT_dwn387_rev

S. schleiferi

glpT

CAGCTTGATTCAACAGATCG
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Table S3: Summary of crystallographic data collection and refinement statistics.
Crystal

apoenzyme

FSM complex

P3112

C2

a = b = 71.37 Å, c = 318.8 Å;

a = 132.7 Å, b = 53.98 Å, c = 116.8 Å;

g = 107.7°

b = 91.6°

0.98 Å

0.98 Å

40.3 - 2.15 Å

46.1 - 2.89 Å

(highest shell)

(2.23 - 2.15 Å)

(2.99 - 2.89 Å)

Reflections (total / unique)

96, 253 / 50,961

33,914 / 18,289

Completeness (highest shell)

99.2% (96.2%)

97.4% (91.1%)

33.9 (2.3)

14.7 (1.8)

10.1% (66.7%)

11.6% (53.2%)

0.197 / 0.230

0.208 / 0.265

5,830

5,898

No. water molecules

81

-

No. ligand atoms

35

22

R.M.S.D. bond lengths

0.016 Å

0.010 Å

R.M.S.D. bond angles

1.07 °

Space group
Cell dimensions
Data collection
Wavelength
Resolution range

I/s (highest shell)
Rsym (highest shell)
Model and refinement
Rcryst / Rfree
No. protein atoms

Avg. B-factor - protein, ligand,
water

64.6, 86.2, 55.5 Å

Ramachandran plot - favored,
allowed, outlier

97.5, 2.3, 0.3 %
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1.26 °
2

65.1, 70.3, - Å2
95.7, 2.3, 2.0 %
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Chapter 3: Antimicrobial prodrug activation
by the staphylococcal glyoxalase GloB
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3.1 Abstract
With the rising prevalence of multidrug-resistance, there is an urgent need to develop novel
antibiotics. Many putative antibiotics demonstrate promising in vitro potency but fail in vivo due
to poor drug-like qualities (e.g. serum half-life, oral absorption, solubility, toxicity). These druglike properties can be modified through the addition of chemical protecting groups, creating
“prodrugs” that are activated prior to target inhibition. Lipophilic prodrugging techniques,
including the attachment of a pivaloyloxymethyl group, have garnered attention for their ability
to increase cellular permeability by masking charged residues and the relative ease of the
chemical prodrugging process. Unfortunately, pivaloyloxymethyl prodrugs are rapidly activated
by human sera, rendering any membrane permeability qualities absent during clinical treatment.
Identification of the bacterial prodrug activation pathway(s) will allow for the development of
host-stable and microbe-targeted prodrug therapies. Here, we use two zoonotic staphylococcal
species, S. schleiferi and S. pseudintermedius, to establish the mechanism of carboxy ester
prodrug activation. Using a forward genetic screen, we identify a conserved locus in both species
encoding the enzyme hydroxyacylglutathione hydrolase (GloB), whose loss-of-function confers
resistance to carboxy ester prodrugs. We enzymatically characterize GloB and demonstrate that
it is a functional glyoxalase II enzyme, which has the capacity to activate carboxy ester prodrugs.
As GloB homologs are both widespread and diverse in sequence, our findings suggest that GloB
may be a useful mechanism for developing species- or genus-level prodrug targeting strategies.

3.2 Introduction
In 2019, the United States recorded 2.8 million antibiotic-resistant infections, resulting in over
35,000 deaths (1). The recent surge in antibiotic use in the setting of the COVID-19 pandemic
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portends an acceleration of the antibiotic resistance threat (2, 3). Staphylococcus aureus is a
formidable human pathogen that causes a wide variety of invasive and life-threatening
infections. Closely related staphylococcal species, S. pseudintermedius and S. schleiferi, cause
similar skin, soft tissue, and invasive infections in companion animals and are increasingly
appreciated as serious pathogens of humans (4–7). Rising rates of methicillin resistance are
reported in all three species, with methicillin-resistant S. aureus (MRSA) labeled a “serious
threat” by the Centers for Disease Control and Prevention (CDC) (1, 8–10). Novel antimicrobial
strategies that circumvent existing drug resistance mechanisms are urgently needed.

Bacterial metabolism is a promising area for antimicrobial development (11, 12). Many
metabolic processes are essential for bacterial growth and pathogenesis. However, targeting
metabolic processes can be inherently challenging, as a substantial portion of metabolism
involves the catalytic transformation of highly charged substrates (e.g. phosphate transfer
reactions). Substrate-competitive inhibitors of metabolic enzymes frequently deploy phosphonate
functional groups as isosteric phosphate mimics (13). These negatively charged phosphonate
antimetabolite inhibitors are prone to unacceptable drug-like characteristics and often diffuse
poorly across membranes (14–19).

Prodrugging, or the modification of an inhibitor through addition of labile chemical adducts, is a
common medicinal chemistry strategy to improve drug-like properties of an inhibitor under
development (19–21). As promoieties are released prior to inhibitor-target engagement,
prodrugging can temporarily cloak problematic pharmacokinetic properties such as poor
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absorption or solubility. For example, the third-generation cephalosporin, cefditoren, is poorly
absorbed in the small intestine unless its carboxylate is masked with a lipophilic
pivaloyloxymethyl (POM) promoiety, in the form of cefditoren pivoxil (22). Similarly,
nucleoside analogues are generally cell-impermeable, but their cognate prodrugs have much
improved cellular penetration and antiviral efficacy, as seen in remdesivir (SARS-CoV2),
tenofovir disoproxil (HIV), and sofosbuvir (hepatitis C virus, HCV) (23–26). We have recently
employed lipophilic prodrugging strategies to increase the efficacy of broad-spectrum
antimicrobial phosphonate antibiotics. Notably, POM ester modification of a phosphonate
isoprenoid biosynthesis inhibitor (ERJ) increases antistaphyloccal activity by 200- and 500-fold
for S. schleiferi and S. pseudintermedius, respectively (Figure 1A,B) (27). Similar dramatic
potency gains are observed for the same class of compounds against Mycobacterium
tuberculosis, Yersinia pestis, Franciscella novicida, and the malaria parasite, Plasmodium
falciparum (16, 28–31).

While POM-prodrugs demonstrate remarkable potency in vitro, POM-promoieties are known to
be rapidly hydrolyzed by serum carboxylesterases (32, 33). If cell-impermeable phosphonate
antibiotics are to be effective at the site of infection, the promoiety must be resistant to premature
bioactivation during absorption and distribution in the circulation. This specificity in prodrug
activation has been successfully achieved for liver-targeted prodrugs, using the “HepDirect”
prodrug approach, but has not yet been deployed for antibiotic delivery. HepDirect prodrugs are
cleaved via a hepatocyte-specific cytochrome P450 enzyme, CYP3A4, and are resistant to
cleavage by other human esterases (34). Selective bioactivation of prodrugs within microbes
would not only increase the circulating half-life, but may also improve the therapeutic selectivity
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of therapeutics that target microbial enzymes with human homologs. Understanding the
molecular basis of host and microbe prodrug activation will facilitate design of microbially
targeted prodrugs.

In this study, we use two zoonotic staphylococcal species, S. schleiferi and S. pseudintermedius,
to uncover the enzymatic mechanism of prodrug activation in staphylococci. We identify and
characterize the first bacterial carboxy ester prodrug activating enzyme, GloB, a type II
glyoxalase. Using detailed biochemical analyses, we demonstrate that GloB recognizes the
carboxy ester portion of the prodrug and is responsible for prodrug activation. Since GloB
homologues are broadly maintained, yet have substantial sequence variation, we propose that this
group of enzymes may be a strategy towards microbe-specific prodrug targeting.

3.3 Methods
3.3.1 Inhibitors.
Fosmidomycin (Millipore Sigma) and FR-900098 (Millipore Sigma) were resuspended in sterile
water. POM-ERJ and POM-HEX were synthesized and stored in DMSO as described (29, 32).
Cefditoren pivoxil (Millipore Sigma), cefditoren sodium (Clearsynth), and mupirocin (Millipore
Sigma) were resuspended in DMSO. The synthesis of
[({[(E)‐benzoyloxy]methoxy}[(1E)‐3‐(N‐hydroxyacetamido)prop‐1‐en‐1yl]phosphoryl)oxy]methyl benzoate (BOM-ERJ) followed that of POM-ERJ, except
chloromethyl benzoate was substituted for chloromethyl pivalate (35). 1H NMR (400 MHz,
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Chloroform-d) δ 9.35 (s, 1H), 7.96 (dd, J = 8.1, 1.4 Hz, 4H), 7.61-7.45 (m, 2H), 7.37 (t, J = 7.8
Hz, 4H), 6.86-6.69 (m, 1H), 6.04-5.91 (m, 1H), 5.91-5.80 (m, 4H), 4.29 (s, 2H), 2.09 (s, 3H). 13C
NMR (101 MHz, Chloroform-d) δ 165.04, 149.18, 134.20, 130.31-130.14, 128.87-128.54,
118.38, 116.46, 82.34, 50.64. High resolution mass-spectrometry (fast atom bombardment)
calculated for C21H23NO9P [M+H]+, 464.1105; found, 464.1097. LC-MS (electrospray
ionization) m/z [M+H]+ 464.1, [M+Na]+ 486.1. Purity was greater than 95% as determined by
LC-MS.

3.3.2 Generation of POM-ERJ-resistant mutants in S. schleiferi and S.
pseudintermedius.
Clinical isolates of S. schleiferi (S53022327s) and S. pseudintermedius (H20421242p) were
cloned and adapted to laboratory media through three rounds of sequential colony isolation and
growth on Luria Broth (LB) agar plates. The isolated POM-ERJ-sensitive parental clones were
incubated overnight on LB agar containing POM-ERJ at 3.56 µM and 7.12 µM for S. schleiferi
and 11.2 µM and 22.4 µM for S. pseudintermedius. Surviving single colonies were re-struck onto
LB agar for clonal isolation. POM-ERJ resistance of isolated clones was confirmed by overnight
growth on LB agar containing POM-ERJ (3.56-22.4 µM). The POM-ERJ-sensitive parental
clones were used as a control to confirm growth and antibiotic resistance.
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3.3.3 Quantification of resistance.
Minimum Inhibitory Concentration (MIC) assays were performed using microtiter broth dilution
in clear 96-well plates (83). Compounds were serially diluted in duplicate for a total of 10 serial
dilutions. Top well concentrations were: POM-ERJ 280 µM , BOM-ERJ 53.95 µM, KMH-102
53.95 µM, cefditoren pivoxil 201.38 µM, cefditoren sodium 56.65 µM, POM-HEX 100 µM,
mupirocin 2.50 µM, FR-900098 1 mM, fosmidomycin 100 µM. Bacteria cultured without drug
were used as a positive control for growth, and LB without bacteria was used as a negative
control for contamination. Plates were inoculated with 75 µL bacteria diluted to 1 x 105 CFU/mL
in LB. After inoculation, plates were incubated for 16-24 h while shaking at 200 RPM at 37°C.
Plates were visually inspected, and the lowest concentration of antibiotic suppressing visual
growth was recorded as the MIC. All experiments were performed at least in triplicate and data
reported represent the mean ± SD.

3.3.4 Transmission Electron Microscopy.
For ultrastructural analysis, bacteria were cultured in 5 mL LB while shaking at 37°C until
OD600 = 0.25-1.0. A 1 mL sample of exponential phase bacteria was pelleted at 6,000 rcf and
resuspended in 1 mL fix (2% paraformaldehyde/2.5% glutaraldehyde (Polysciences Inc.,
Warrington, PA) in 100 mM sodium cacodylate buffer, pH 7.2) for 1 h while rocking at RT. The
fixed suspension of bacteria was washed in sodium cacodylate buffer and postfixed in 1%
osmium tetroxide (Polysciences Inc.) for 1 h. Samples were then rinsed extensively in dH2O
prior to en bloc staining with 1% aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for 1 h.
Following several rinses in dH2O, samples were dehydrated in a graded series of ethanol and
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embedded in Eponate 12 resin (Ted Pella Inc.). Sections of 95 nm were cut with a Leica Ultracut
UC7 ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), and stained with uranyl
acetate and lead citrate. Samples were viewed at 30,000X on a JEOL 1200EX transmission
electron microscope (JEOL USA, Peabody, MA) equipped with an AMT 8 megapixel digital
camera (Advanced Microscopy Techniques, Woburn, MA). Cell wall thickness was measured
(ImageJ 1.38g customized for AMT images) for 100 bacteria in three independent samples (total
n = 300).

3.3.5 Whole genome sequencing and variant discovery.
Using a standard phenol-chloroform extraction and ethanol precipitation protocol, genomic DNA
was isolated from overnight cultures of S. pseudintermedius and S. schleiferi. Sequencing
libraries were prepared and sequenced by the Washington University Genome Technology
Access Center (GTAC). 1 µg of DNA was sonicated to an average size of 175 bp. Fragments
were blunt ended and had an A base added to the 3´ end. Sequence adapters were ligated to the
ends and the sequence tags were added via amplification. Resulting libraries were sequenced on
an Illumina HiSeq 2500 to generate 101 bp paired end reads. DNA quantity and quality were
assessed by GTAC using Agilent Tapestation.
For the analysis, sequences from GenBank were retrieved from the following organisms: S.
pseudintermedius ED99 (accession number CP002478) and S. schleiferi 1360-13 (CP009470)
assemblies were downloaded from NCBI (ftp://ftp.ncbi.nlm.nih.gov). Paired-end reads were
aligned to each of the available genomes using Novoalign v3.03. (Novocraft Technologies).
Duplicates were removed and variants were called using SAMtools (37). SNPs were filtered
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against parent variants and by both mean depth value and quality score (minDP =5, minQ = 30)
(38). Genetic variants were annotated using SnpEff v4.3 (39). For all samples, at least 90% of the
genome was sequenced at 20x coverage. Whole genome sequencing data is available in the
NCBI BioProject database and Sequence Read Archive under the BioProject ID 648133.

3.3.6 Sanger sequencing of S. schleiferi and S. pseudintermedius variants.
The SNPs, the reference sequences, and gene specific primers can be found in Table S4 for both
S. schleiferi and S. pseudintermedius. Amplicons were sequenced by GENEWIZ.

3.3.7 Staphylococcal GloB homology modeling.
SWISS-MODEL (https://swissmodel.expasy.org/) was used to generate homology models.
Modeling parameters were left at default. Both SsGloB and SpGloB models were built using the
solved Metallo-β-lactamase superfamily protein, 2ZWR.1.A, which is 39.2% identical in
sequence.

3.3.8 Recombinant expression and purification of GloB.
WT GloB from S. schleiferi was amplified using the forward and reverse primers in Table S4.
The PCR product was then cloned into the BG1861 vector by ligation-independent cloning to
introduce a N-terminal 6xHis tag and transformed into Stellar™ chemically competent cells
(Clontech Laboratories) for plasmid propagation (40). Proper insertion was verified using
restriction digest and Sanger sequencing. For S. schleiferi protein expression, the plasmid was
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transformed into E. coli Arctic Express (Agilent). Cells were grown to OD600 = 0.4-0.7, chilled to
8°C, and GloB expression was induced with 0.5 mM isopropyl-β-D-thiogalactoside (IPTG)
overnight. For S. aureus protein expression, the plasmid was transformed into E. coli BL21
(DE3) pLysS cells (Promega). Cells were grown to OD600 = 0.4-0.7 and GloB expression was
induced with 0.5 mM IPTG for 2 h. Cells were harvested by centrifugation at 4274 x g for 5 min
at 4°C. The cell pellet was lysed by sonication in 50 mL lysis buffer containing 25 mM Tris HCl
(pH 7.5), 20 mM imidazole, 1 mM MgCl2, 1 mM dithiothreitol (DTT), 1 mg/mL lysozyme, 75 U
benzonase and 1 Complete Mini EDTA-free protease inhibitor tablet (Roche Applied Science).
Insoluble proteins were removed by centrifugation twice at 20,000 x g for 20 min each. The
hexahistidine-tagged SsGloB protein was affinity purified from soluble lysate via nickel agarose
beads (Gold Biotechnology). Bound protein was washed with 50 mL of lysis buffer and eluted in
300 mM imidazole, 25 mM Tris HCl (pH 7.5), 1 mM MgCl2, 10% glycerol, and 250 mM NaCl.
Affinity purified protein was further purified over a HiLoad 16/60 Superdex 200 gel filtration
column (GE Healthsciences) using an AKTAExplorer 100 FPLC (GE Healthsciences). FPLC
buffer contained 25 mM Tris HCl (pH 7.5), 250 mM NaCl, 1 mM MgCl2 and 10% glycerol.
Fractions containing >90% pure enzyme (evaluated by SDS-PAGE) were concentrated by
centrifugation using Amicon Ultra-15 centrifugal filter units (EMD Millipore) and flash frozen in
liquid nitrogen before permanent storage at -80°C. Protein identity was verified using mass
spectrometry at the University of Nebraska.

85

3.3.9 GloB mutant generation.
WT GloB for S. schleiferi was synthesized by GeneWiz, Inc (Beijing, China) with a CAT->AAT
mutation in the 54th codon (H54N) and cloned into the BG1861 vector to introduce an Nterminal 6xHis tag. Proper insertion was verified by Sanger sequencing.

3.3.10 β-lactamase activity assay.
S. schleiferi GloB was tested for β-lactamase activity using the chromogenic cephalosporin
substrate Nitrocefin (Sigma Aldrich 484400) as in (41) but with minor changes. 50 μL reactions
containing 25 mM Tris HCl (pH 7.5), 250 mM NaCl, 1 mM MgCl2, 10% glycerol, and 200 μM
Nitrocefin were preincubated for 15 min at 37oC, and reactions were initiated upon addition of
GloB. Cleavage of Nitrocefin was allowed to proceed at 37°C and tracked kinetically at 486 nm.
Assays were carried out over a range of GloB concentrations starting at 2 g of protein (1.6 M).

3.3.11 Glyoxalase II activity assay.
S. schleiferi GloB was tested for type II Glyoxalase activity as previously with minor changes
(42). 50 μL reactions containing 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM divalent salt, 10%
glycerol, 200 μM 5,5′-Dithiobis(2-nitrobenzoic acid) (DTNB, Sigma D8130), and 1 mM Dlactoylglutathione (Sigma L7140) were monitored in a 96-well plate for an increase in
absorbance at 412 nm. Reactions were pre-incubated at 37°C and initiated with the addition of
GloB. The conversion of DTNB to the yellow colored substrate, TNB, by glutathione produced
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by GloB, was measured through time at 37°C and 412 nm. Assays were carried out over a range
of GloB concentrations to ensure that the reaction rates are linear over the period of the assay. To
determine metal dependence of GloB, assays were performed using assay buffer with a final
concentration of 1 mM divalent salts. Divalent salts were provided as follows: zinc chloride,
manganese chloride, magnesium chloride, cobalt chloride, and calcium chloride.

3.3.12 Sample preparation for GloB vs. POM-ERJ mass spectrometry
analysis.
Reactions containing 25 mM Tris HCl (pH 7.5), 250 mM NaCl, 10% glycerol, 1 mM MnCl2, and
1 mM POM-ERJ were pre-warmed to 37°C before addition of WT GloB, catalytically inactive
GloB (H54N), boiled GloB, or an equal amount of protein storage buffer to a final concentration
of 1 μM. Reactions were placed at 37°C and sampled at 0, 15, 30, 60, 90, and 120 min. A 50 µL
sample was withdrawn from each reaction at the times indicated, and the sample reaction was
quenched by the addition of 200 µL acetonitrile containing 100 ng/μL enalapril as an internal
standard. The samples were immediately frozen on dry ice and stored at -80°C until analysis.

The quenched reaction mixtures were centrifuged at 3200 rpm for 5 min, and 2 μL of the
supernatant was diluted to 500 µL with water containing 100 ng/mL enalapril as an internal
standard. Samples were analyzed by LC-MS/MS using an Applied Biosystems-Sciex API 4000.
Analyte/internal standard peak area ratios were used to determine concentration and evaluate
stability. Standards were evaluated over the range of 1 ng/mL to 1000 ng/mL. The MRM
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transitions for enalapril and POM-ERJ were m/z: 376.9 > 91.2 and 424.0 > 364.0, respectively.
A Phenomenex Luna Omega polar C18 column (2.1 × 50 mm, 5 μm) was used for
chromatographic separation. Mobile phases were 0.1% formic acid in water and acetonitrile with
a flow rate of 0.5 mL/min. The starting phase was 1% acetonitrile increased to 100% acetonitrile
over 0.9 min. Peak areas were integrated using Analyst Software (AB Sciex, Foster City, CA).

3.3.13 In vivo cleavage of POM-ERJ.
S. schleiferi cultures of WT and POM-ERJR strains were grown to an OD600 = 0.5-0.8 and then
treated with 1 μM of POM-ERJ. The cultures were grown shaking at 37°C and 200 rpm and 50
μL were sampled at 0, 1, 2, and 3 h. The reactions were quenched by pelleting the cells at 4274 x
g at 4°C and resuspending in 200 μL of acetonitrile with 100 ng/μL enalapril as an internal
standard. The reactions were repeated in triplicate for each timepoint and strain. The LC-MS
analysis was performed as described above.

3.3.14 NMR characterization of GloB POM-prodrug products.
Five hundred micromolar POM-ERJ and POM-HEX were incubated with 50 μl buffer (50 mM
tris pH 7.5, 50 mM NaCl, 1mM MgCl2) and 20 μl SaGloB or 40 μl SsGloB with stock
concentrations of 200 μM and 100 μM respectively at 37 °C for 90 minutes. Samples were
prepared for NMR studies by resuspending them in water and 10% (50 μl) D2O (Deuterium
Oxide 99.9 atom % D, contains 0.75 wt %3-(trimethylsilyl)propionic -2,2,3,3-d4 acid, sodium
salt, Sigma–Aldrich). NMR spectra are acquired on a Bruker Avance III HD 500 MHz
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spectrometer equipped with a cryoprobe. Two-dimensional (2D) 1H-31P heteronuclear single
quantum correlation (HSQC) measurements were obtained using hsqcetgp pulse program (with
duration of 15 minutes and scan parameters of 4 scans, td=1024 and 128, gpz2 %=32.40, 31P
SW= 40 ppm, O2p=20 ppm, cnst2=22.95) and analyzed using 3.1 TopSpin. The 1D projection of
columns excluding the water signal was obtained from the 2D 1H-31P HSQC spectrum by
obtaining spectra of positive projection of columns 1 to 600 and 650 to 1024 and adding them.

3.3.15 Phylogenetic tree construction.
The sequences of S. schleiferi GloB and RpoB homologs were retrieved from NCBI using BlastP
against each specified organism. Organisms were selected to represent a wide array of
commensal and pathogenic bacteria (43). Additional sequences were added from Mus musculus,
Homo sapiens, and other previously characterized GloB orthologs for additional comparison.
Sequence alignment was performed using MUSCLE, and visualized using iTOL (44, 45).

3.4 Results
3.4.1 Selection of prodrug-resistant staphylococci.
In our previous study, we identified phosphonate antibiotics with activity against zoonotic
staphylococci (S. schleiferi and S. pseudintermedius) (27). Lipophilic carboxy ester prodrug
modification of these phosphonates dramatically increases antistaphylococcal potency,
presumably through increased cellular penetration (Figure 1A, B). However, prodrug
modifications block direct engagement of inhibitors with their enzyme target (27). For this
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reason, we hypothesized that one or more staphylococcal esterases were required for intracellular
prodrug activation (Figure 1A). To identify candidate prodrug activating enzymes, we designed a
genetic screen/counter-screen strategy to enrich for staphylococcal strains that fail to activate
lipophilic ester prodrugs.

In our strategy, we took advantage of inhibitor pairs with the same target engagement, with and
without prodrug modification. We employed the phosphonate antibiotic ERJ, which selectively
inhibits the intracellular enzyme deoxyxylulose phosphate reductoisomerase (DXR), and POMERJ, the bis-pivaloyloxymethyl prodrug form of ERJ, which inhibits intracellular DXR even
though it has been shown to lack direct activity against purified recombinant DXR in vitro (27).
We sought to enrich for staphylococcal strains that were resistant to prodrugged inhibitors (e.g.
POM-ERJ) but remained sensitive to the parent phosphonate ERJ itself (27). For this reason, we
first isolated staphylococcal colonies that arose from solid media containing POM-ERJ. Next, we
screened these POM-ERJ-resistant isolates for cross-resistance to our parent compound, ERJ.
POM-ERJ-resistant strains that remained sensitive to ERJ were subjected to whole genome
sequencing to identify candidate genetic mutations giving rise to the resistance phenotype
(Figure 1C). To identify conserved resistance mechanisms, we performed this screen/counterscreen independently in two staphylococcal species, S. schleiferi and S. pseudintermedius. We
isolated and characterized a total of 18 POM-ERJ-resistant staphylococcal strains, with MIC90
values ~10-50 fold higher than that of the respective wild-type (WT) parental lines (Figure
1D). In axenic growth in rich media, no changes in growth rate are observed between WT and
three POM-ERJ-resistant isolates (Figure S1).
90

3.4.2 POM-ERJ resistance does not alter cell wall size in staphylococci.
In previous work, we and others have found that cellular entry of the phosphonate antibiotic ERJ
and ERJ analogs requires the phosphonate transporter GlpT (16, 27, 35, 36). In contrast, entry of
POM-ERJ is transporter-independent (16, 27). POM-ERJ resistance could therefore arise through
cell wall modifications that directly disrupt cell penetration of prodrugs. Such cell wall
alterations might therefore lead to cross-resistance to other antimicrobials, such as daptomycin or
vancomycin. To establish the selectivity of POM-ERJ-resistance, we determined the
antimicrobial sensitivity of a subset of our prodrug-resistant strains against a panel of 18 clinical
antibiotics with diverse mechanisms-of-action. We find that POM-ERJ-resistant strains are not
cross-resistant to other inhibitors, including daptomycin and vancomycin (Table S1), suggesting
a prodrug-specific mechanism of resistance. Additionally, we quantified the cell wall size in
POM-ERJ-resistant staphylococci by transmission electron microscopy, because an established
daptomycin and vancomycin resistance strategy for S. aureus is the generation of thickened cell
walls that reduce inhibitor entry (48, 49). We find no changes in cell wall thickness in prodrugresistant isolates compared to their prodrug-sensitive WT parental lines (Fig 2).

3.4.3 POM-ERJ-resistant staphylococci are cross-resistant to other carboxy
ester prodrug antibiotics.
If POM-ERJ resistance is due to loss of a prodrug activating enzyme(s), we hypothesized that
POM-ERJ-resistant staphylococci would likewise be cross-resistant to other carboxy ester
prodrug antibiotics. To evaluate this possibility, we selected several additional pairs of inhibitors
(carboxy ester prodrugs and their cognate parent (non-prodrugged) compounds), with distinct
cellular targets (e.g. penicillin binding protein, deoxyxylulose reductoisomerase (DXR), and
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enolase) (Figure 3) (22, 32). For three of our POM-ERJ-resistant S. schleiferi isolates, we
determined the minimum inhibitory concentration (MIC) for each compound, compared to the
WT parental strain (Figure 4).

We find that POM-ERJ-resistant staphylococci remain equally sensitive to non-prodrugged
compounds (such as ERJ analogues) and the third-generation cephalosporin cefditoren. In
contrast, POM-ERJ-resistant staphylococci exhibit significantly increased MICs to multiple
classes of lipophilic ester prodrugs, exhibiting cross-resistance to both cefditoren pivoxil (cell
wall inhibitor) and POM-HEX (inhibitor of enolase) (Figure 4, Table S2). Thus, POM-ERJresistant staphylococci are cross-resistant to other POM-prodrug inhibitors, regardless of the
intracellular target. Our data suggest that POM-prodrugs follow a common and conserved
activation mechanism that has been disrupted in our POM-ERJ-resistant isolates.

To explore how changes in the chemical structure of the prodrug group impacts prodrug
resistance, we also evaluated whether our POM-ERJ-resistant isolates were cross-resistant to
antimicrobial prodrugs that possess another common carboxy ester prodrug moiety,
benzoyloxymethyl (BOM) (Figure 3). Indeed, we find our POM-ERJ-resistant isolates are also
cross-resistant to BOM-ERJ (Figure 4).

Carboxy ester prodrugs are more lipophilic than their parental molecules. To evaluate whether
prodrug resistance in our strains is driven by the lipophobicity of the molecule rather than its
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ester bond, we selected an additional highly lipophilic antibiotic, mupirocin, which inhibits
protein biosynthesis (Figure 3). POM-ERJ-resistant staphylococci were not cross-resistant to
mupirocin, further supporting that prodrug resistance in these strains is specific to the carboxy
ester bond of the prodrug (Figure 4).

3.4.4 POM-ERJ resistant staphylococci are enriched in mutations in the GloB
gene.
To characterize the genetic changes associated with carboxy ester prodrug resistance, we
performed whole genome sequencing of prodrug resistant isolates of both S. schleiferi and S.
pseudintermedius. The whole genomes of each isolate were compared to the respective parental
genome and candidate genetic changes were verified by Sanger sequencing. We prioritized
nonsynonymous genetic changes that were represented in more than one strain. A complete list
of identified mutations is found in Table S3.

In both independent genetic screens, we found that prodrug resistant staphylococci were enriched
in mutations in an evolutionarily conserved locus. We identified multiple isolates (3/16 S.
schleiferi, 14/18 S. pseudintermedius) with sequence modifications in the locus annotated as
hydroxyacylglutathione hydrolase, gloB (LH95_06060 in S. schleiferi, SPSE_1252 in S.
pseudintermedius, Table S3). Most genetic changes in gloB were nonsynonymous single
nucleotide polymorphisms, though two nonsense alleles that would truncate approximately 50%
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of the protein were also identified (Figure 5, Table S3). In several strains, the only genetic
variation that distinguished WT and resistant genomes was within the gloB locus.

Of the 17 identified GloB mutations, 12 unique alleles were identified in prodrug-resistant
staphylococci. Using PROVEAN, an algorithm which quantifies the predicted impact of amino
acid substitutions on protein function, each of these 12 alleles is predicted to have deleterious
effects on protein function (below the threshold score of -2.5) (Figure 5) (50). S. schleiferi and S.
pseudintermedius are non-model organisms that possess endogenous CRISPR-Cas9 systems and
transformation of these organisms has not yet been described (51). Attempts to ectopically
complement gloB mutant strains with WT GloB (>90 independent transformation attempts using
established methods for S. aureus, S. epidermidis, and B. subtilis) were unsuccessful in
recovering transformed colonies, despite preparing plasmid from the S. aureus restriction
deficient cloning intermediate, RN4220, and the cytosine methyltransferase negative E. coli
mutant, DC10B (52–58). However, the independent selection of 12 unique loss-of-function
alleles in two different species strongly suggests that loss of GloB function is responsible for
prodrug resistance in S. schleiferi and S. pseudintermedius.

3.4.5 Structural basis of GloB loss-of-function.
As prodrug-resistance mutations in GloB map along its entire linear sequence, we next examined
the structural basis for GloB loss-of-function. We generated homology models of both SsGloB
and SpGloB using SWISS-MODEL (59). The resulting staphylococcal model is based on the
sequence-similar metallo-β-lactamase superfamily member from Thermus thermophilus (PDB
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2ZWR) (60). This hit had a global model quality estimate (GNQE) of 0.71 and 0.70 for S.
schleiferi and S. pseudintermedius GloB homologs, respectively, suggesting the built models are
reliable and accurate. In both protein models, we find that POM-ERJ-resistance mutations are
primarily located towards the interior of the protein, occupying the same cavity as the well
conserved glyoxalase II metal binding motif (THxHxDH) (61). This modeling thus indicates that
these prodrug-resistance alleles impair the GloB active site (Figure 5).

3.4.6 GloB is a functioning type II glyoxalase, not a β-lactamase.
GloB is predicted to be a type II glyoxalase and a member of the large metallo-β-lactamase
protein superfamily (INTERPRO IPR001279). Members of this superfamily hydrolyze thioester,
sulfuric ester, and phosphodiester bonds, such as the ester linkage present in POM-ERJ (42, 61–
63). Type II glyoxalases catalyze the second step in the glyoxalase pathway that is responsible
for the conversion of methylglyoxal (a toxic byproduct endogenously produced during
metabolism) to lactic acid. Specifically, GloB catalyzes the conversion of D-lactoylglutathione to
D-lactate.
To determine whether SsGloB encodes a functional type II glyoxalase, we evaluated whether
SsGloB hydrolyzes S-lactoylglutathione using an assay in which hydrolysis of Slactoylglutathione is linked to a change in absorbance (Figure 6A). We purified recombinant WT
SsGloB protein and its catalytically inactive variant, SsGloBH54N, in which the histidine of the
canonical metal binding motif (THxHxDH) has been altered to an asparagine (Figure S2) (61–
63). We find that SsGloB, but not SsGloBH54N, hydrolyzes S-lactoylglutathione with a specific
activity of 0.493 μmol*min-1mg-1 (Figure S3, Figure 6B,C). This activity is similar to other
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characterized microbial type II glyoxalases (Saccharomyces cerevisiae, 1.34 μmol*min-1mg-1;
Trypanosoma brucei, ~8 μmol*min-1mg-1), but is much lower than that of previously
characterized type II glyoxalases from plants and mammals (20-2000 μmol*min-1mg-1) (64–72).
We determined the metal dependence of SsGloB and find that SsGloB is a functional type II
glyoxalase in manganese, cobalt, calcium, and zinc, with a modest preference noted towards
magnesium (Figure S4).

As some members of the metallo-β-lactamase protein superfamily mediate hydrolysis of βlactam antibiotics, we considered whether GloB also had β-lactamase activity. Because gloB
mutant strains are not cross-resistant to the β-lactam-containing antibiotics (except for the
prodrugged cephalosporin, cefditoren pivoxil) (Figure 4, Table S2), we predicted that GloB was
not a functional metallo-β-lactamase. As expected, we find that SsGloB does not hydrolyze the
β-lactamase ring of nitrocefin (a canonical β-lactamase substrate), in contrast to the active B.
cereus β-lactamase (Figure S3).

3.4.7 Staphylococcal GloB hydrolyzes POM-ERJ in vitro and in vivo.
Loss-of-function mutation in GloB is associated with resistance not only to POM-ERJ, but also
to other ester prodrugs. Because GloB does not mediate resistance to ERJ or other phosphonates,
our data suggested that GloB might directly catalyze the conversion of POM-ERJ to ERJ. To
determine whether GloB de-esterifies POM-ERJ, we developed a liquid chromatography-mass
spectrometry (LC-MS)-based assay to quantify POM-ERJ concentrations. Incubation of purified
recombinant SsGloB protein, but not its inactive variant (SsGloBH54N), with POM-ERJ results in
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rapid loss of POM-ERJ, consistent with SsGloB-mediated cleavage (Figure 7A). To determine
whether prodrug activation activity is conserved among staphylococcal GloB homologs, we also
purified recombinant GloB from the human pathogen S. aureus (Figure S2). We find that
SaGloB also directly hydrolyzes POM-ERJ (Figure 7A).

To determine whether GloB mediates intracellular prodrug activation, we evaluated the
intracellular concentrations of POM-ERJ in drug-treated WT and gloB mutant staphylococci. We
prepared staphylococcal cultures treated with POM-ERJ and quenched the reaction at several
timepoints to monitor the course of intracellular prodrug depletion. As expected, we find that
POM-ERJ is rapidly depleted in WT S. schleiferi, consistent with enzymatic activation. In
contrast, POM-ERJ concentrations do not decrease over time in gloB mutant strains, in which the
sole genetic change in each strain compared to WT is in the gloB locus (Figure 7B). This
suggests that the initial step in carboxy ester prodrug activation in staphylococci lacks functional
redundancy and is exclusively dependent on GloB.

3.4.8 POM-ERJ is a GloB substrate
We next characterized the reaction products resulting from POM-ERJ incubation with GloB.
Using a highly sensitive 31P-1H HSQC NMR protocol, we find that WT S. schleiferi and WT S.
aureus GloB remove at least one carboxy ester from POM-ERJ but are unable to fully deprotect
the compound in appreciable quantities (Figure S5A). We hypothesize that the intermediate
product may be the singly de-POMylated version of POM-ERJ (Hemi-POM-ERJ). To evaluate
whether other POM-containing inhibitors were also direct substrates, we repeated this
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experiment using POM-HEX (Figure S5B). We find that GloB is likewise capable of partially
activating POM-HEX, but is unable to act upon Hemi-POM-HEX, suggesting at least one
additional enzyme may be required for prodrug activation in vivo.

3.4.9 Staphylococcal GloB enzymes represent a distinct clade of bacterial
glyoxalases.
Because staphylococcal GloB mediates de-esterification of ester prodrugs, we sought to evaluate
the feasibility of using these enzymes to design prodrugs specifically targeted for activation in
staphylococci. We constructed a phylogenetic tree of GloB homologs across diverse microbial
genomes, as well as in humans and mice (Figure S6A), specifically including sequences of
previously characterized GloB homologs. We find that considerable sequence variation exists
within GloB homologs, with no clear clustering by phylogeny except for those GloB homologs
originating in plants and mammals. This contrasts with a phylogenetic tree generated using the
DNA-directed RNA polymerase subunit beta (rpoB), which generally follows the traditional tree
of life (Figure S6B).

While sequence differences between staphylococcal GloB and human GloB suggest that there
may be substrate utilization differences between humans and staphylococci, ultimately
differences within the active site are likely to drive substrate specificity. Using pymol, we
aligned our homology model of SsGloB with the glutathione-bound GloB from humans (PDB
ID: 1qh5) (73, 74). The two structures align well with a root-mean-square deviation (RMSD) of
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1.528Å, and are well conserved in the overall structure as well as the characteristic Zn binding
motif, THxHxDH (Figure S7A,B). Notably, however, HsGloB has a significant C-terminal
extension which is not present in SsGloB. This C-terminal extension forms an α-helix which
borders the active site and contains two residues, K252 and R249, which appear to be involved in
coordinating the co-crystallized glutathione substrate (Figure S7C). The absence of this Cterminal extension in our SsGloB homology model suggests that HsGloB and SsGloB have
distinct active site chemistry that may be exploited to drive prodrug activation selectively by
SsGloB vs HsGloB.
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3.5 Discussion
Antimicrobial resistance is a substantial challenge for treatment of both human and animal
staphylococcal infections. Widespread methicillin resistance contributes both to poor clinical
outcomes and increased treatment costs, and resistance is emerging to agents of last resort such
as vancomycin and linezolid (1). Current antimicrobial therapies target a fraction of essential
cellular processes, and metabolism remains a promising area for therapeutic development (11,
12). Many metabolic genes are essential for growth, especially in the nutrient limited setting of
infection (75–78). Additionally, chemical ligands are readily designed with high potency by
mimicking natural substrates used by metabolic enzymes. Finally, because active site mutations
that disrupt binding of competitive inhibitors are likely to deleteriously affect enzyme function,
the barrier to resistance can be high (79, 80). Although many metabolic processes are conserved
between humans and microbes, selective targeting of microbes is achievable as is demonstrated
by the success of folate antagonists (trimethoprim/sulfamethoxazole) and bedaquiline (a F0F1
ATP synthase inhibitor of Mycobacterium tuberculosis) (81–83).

Unfortunately, many metabolic inhibitors require cell-impermeable phosphonic acids for
efficient target inhibition. Prodrugging strategies to increase cellular penetration have been
developed for a variety of therapeutics, most notably the anti-cancer and anti-viral nucleosides
(19). These prodrug strategies must be sufficient labile that the compound is activated within the
target cell, yet stable enough to resist premature prodrug activation by the sera. Prodrugs which
are selectively activated within target cells have the added benefit of reducing off-target toxicity
effects. To achieve cell-targeted prodrug activation, knowledge of the activation mechanisms in
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sera, as well the target cell, are essential. While prodrug targeting has been achieved for liver
therapies, this strategy has yet to be employed for bacterial antibiotics that employ ester prodrug
moieties (34).

In this work, we have identified a new mechanism for the de-esterification and activation of
lipophilic ester prodrugs though a conserved staphylococcal esterase in the metallo-β-lactamase
superfamily. Loss-of-function of GloB confers resistance to lipophilic carboxy ester prodrugs in
two zoonotic pathogens, S. schleiferi and S. pseudintermedius (Figure 1D, Table S3). Purified
recombinant GloB from S. schleiferi and the related human pathogen S. aureus directly catalyzes
pro-drug de-esterification in vitro (Figure 7A). Because gloB mutant staphylococci are crossresistant to other POM-containing prodrugs that differ in “warhead” and intracellular targets
(Figure 4), we propose that substrate-specificity of GloB appears driven by recognition of the
lipophilic promoiety, rather than the target inhibitory portion of each compound.

Bacterial prodrug ester activation through GloB hijacks a conserved bacterial protective
mechanism in bacteria, as hydroxyacylglutathione hydrolase represents the second enzyme of the
two-step glyoxalase pathway. During normal metabolism, the glycolytic intermediates
glyceraldehyde-3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP) undergo
nonenzymatic decomposition to methylglyoxal, a toxic metabolite. GloB is required for
glutathione mediated methylglyoxal detoxification, as methylglyoxal is highly reactive and
irreversibly glycates proteins and nucleic acids (84–86). A secondary pathway for methylgloxal
detoxification utilizing the glutathione independent enzyme, glyoxalase III, was recently
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described in S. aureus and orthologs are found in S. schleiferi and S. pseudintermedius (77). The
redundancy of the glutathione-dependent and -independent glyoxalase pathways remains unclear.
In S. aureus, methylglyoxal accumulation potentiates antibiotic susceptibility (87). In addition,
methylglyoxal is itself directly antibacterial and postulated to be the primary antistaphylococcal
ingredient in Manduka honey (used on chronic wounds) (87–90). Our studies suggest that strains
of S. schleiferi and S. pseudintermedius lacking GloB have preserved axenic growth in rich
media, which raises concern for the ease of resistance development when GloB-targeted
prodrugs are used as anti-infectives. However, the known toxicity of methylglyoxal in a host
infection setting suggests that reduced methylglyoxal detoxification as the result of GloB loss-offunction would not be well tolerated in vivo.

Identification of GloB as a prodrug activating enzyme in staphylococci is a major step forward
for highly selective microbial targeting of compounds. Though GloB homologs are widespread
in microbes and are present in humans, significant sequence variation exists in GloB sequences,
which results in a variety of GloB substrate preferences (Figure S6). For example, human GloB
has an additional α-helix along the active site that introduces two additional residues, K252 and
R249 to the substrate binding pocket (Figure S7) (74). These residues, and this α-helix, are
notably absent in microbial GloBs, suggesting that there are underlying substrate differences
between human and microbial GloB enzymes. Furthermore, there is substantial sequence
variation in GloB orthologs across all microbes, suggesting that GloB substrate specificities may
discern between individual clades of bacteria. We expect that development of prodrugs specific
to GloB would result in a narrow-spectrum antibiotic, which would reduce off-target effects on
the microbiome and decrease the broad pressure to evolve resistance.
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3.6 Figures

Figure 1 POM-prodrug activation and resistance generation. (A) Predicted POM-ERJ activation pathway. POM-promoiety highlighted
in pink. (B) Dose-dependent growth inhibition of zoonotic staphylococci, S. schleiferi (left) and S. pseudintermedius (right), by ERJ (blue)
and POM-ERJ (pink). Displayed values are the means ± SD of three independent experiments performed in technical duplicate. (C)
Screening strategy to identify prodrug activating enzymes. (D) Distribution of MIC values for WT (pink) and POM-ERJ resistant mutants
from S. schleiferi (left) and S. pseudintermedius (right). Displayed values are the means values for each strain from three independent
experiments performed in technical duplicate.
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Figure 2 POM-ERJ resistant Staphylococci exhibit normal cell wall sizes. (A-D) Representative transmission electron micrographs of
WT (A) or three independent POM-ERJ resistant S. schleiferi strains (B-D). Scale bars = 500 nm. (E) Distribution of cell wall thickness in
WT and POM-ERJ resistant S. schleiferi as measured in a total of 300 cells from three independent experiments of 100 cells each. Midline
indicates mean of all measurements.
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Figure 3 Structures of antistaphylococcal inhibitors used in this study. Structures are grouped by mechanism of action. For prodrugged
compounds, promoieties are highlighted in pink.
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Figure 4 Cross-resistance to lipophilic ester prodrugs in POM-ERJ-resistant S. schleiferi. WT and POM-ERJ resistant S. schleiferi
were treated with the compounds displayed in Figure 3. Compounds are grouped by mechanism of action and color coded to indicate
whether a given compound is a carboxy ester prodrug. Displayed are the mean values of the fold change (resistant isolate/WT) of three
independent experiments performed in technical duplicate. * indicates compounds whose MIC values were too high to measure. Numerical
data additionally provided in Table S2.
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Figure 5 POM-ERJ resistant staphylococci are enriched for mutations in the locus encoding hydroxyacylglutathione hydrolase
(GloB). (A) Locations and identities of GloB mutations discovered by whole-genome sequencing and independently verified by Sanger
sequencing. Line coloring represents predicted impact of a given mutation on GloB function, scores below -2.5 are predicted to be
deleterious. (B, C) Homology models of S. schleiferi (B) and S. pseudintermedius (C) GloB generated using SWISS-MODEL. Residues
found to be mutated in POM-ERJ resistant staphylococci explicitly shown in blue.
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Figure 6 Enzymatic function of GloB. (A) Enzymatic catalysis of S-lactoylglutathione by GloB. DTNB conversion to TNB results in
increased absorbance at 412 nm. (B) Reaction progress curve for SsGloB (blue) and catalytically inactive SsGloB H54N (pink), using Slactoylglutathione as a substrate. (C) SsGloB and SsGloB H54N specific activity for S-lactoylglutathione. Displayed are the means ± SD
from three independent experiments performed in technical duplicate.
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Figure 7 GloB functions activates POM-prodrugs in vitro and in vivo. (A) Recombinant SsGloB, catalytically inactive SsGloB H54N,
GloB from S. aureus (SaGloB), or buffer were incubated with POM-ERJ and prodrug concentrations were measured by LC-MS. (B) Wildtype and POM-ERJ-resistant gloB mutant S. schleiferi isolates were treated with POM-ERJ and intracellular drug concentrations were
measured by LC-MS. Displayed are the mean values ± SD from three independent experiments. Error bars may not be visible due to
precision in measurement.
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Figure S1 Growth rates of WT and POM-ERJ resistant S. schleiferi. (A) Average optical density (600 nm) of WT and POM-ERJ
resistant S. schleiferi in LB media. Average is of three biological replicates in technical duplicate. (B) Doubling times for WT and POM-ERJ
resistant S. schleiferi in LB media. Experiment performed in technical duplicate and biological triplicate. Error bars denote SEM. Means are
not statistically different [Kruskal-Wallis test (p = 0.179)].
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Figure S2 SDS-PAGE/Coomassie of purified recombinant SsGloB, SsGloBH54N, and SaGloB.
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Figure S3 GloB does not have β-lactamase activity. (A) Nitrocefin activation mechanism. Cleavage of the β-lactam ring results in
increased absorbance at 486 nm. (B) Progress curve for nitrocefin cleavage by SsGloB, SsGloBH54N, and commercially available β-lactamase
from B. cereus. (C). Specific activity for SsGloB, SsGloBH54N, and B. cereus β-lactamase against nitrocefin.
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Figure S4 Assay validation for SsGloB S-lactoylglutathione cleavage and detection via DTNB. (A) S-lactoylglutathione cleavage rate as
a function of increasing SsGloB. (B) SsGloB metal dependence for cleavage of S-lactoylglutathione. SsGloB was incubated with 1 mM of
each divalent salt prior to S-lactoylglutathione reaction initiation.

113

Figure S5 NMR characterization of POM-ERJ and POM-HEX prodrug activation by SsGloB and SaGloB. Two-dimensional (2D)
1

H-31P HSQC NMR spectra of products following incubation of SaGloB, SsGloB, catalytically inactive (boiled) GloB, or buffer alone with

POM-ERJ (A) or POM-HEX (B). Also included are the 1H-31P HSQC NMR spectra of ERJ and HEX. Displayed are representative traces of
three independent experiments.
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Figure S6 Phylogenetic trees of GloB (A) and RpoB (B) sequences. Pink highlighting overlain on staphylococcal species.
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Figure S7 Structural conservation of GloB. Alignment between HsGloB (orange, PDB ID: 1qh5) and SsGloB (blue) homology model. (A)
Overall protein alignment, RMSD = 1.528Å. (B) Metal binding pocket (left), sequence alignment of residues contacting the bound Zn (HsGloB)
and their analogous residues colored according to amino acid chemical properties (right). (C) Substrate binding pocket (left), sequence alignment
of residues contacting the bound glutathione colored according to amino acid chemical properties (GSH, right).
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3.7 Tables
Table S1: Zones of inhibition for POM-ERJ resistant zoonotic staphylococci against common frontline therapeutics. Presented are the zones of inhibition and whether the isolate is sensitive to the
therapeutic (S), resistant (R), or intermediate (*) according to Clinical and Laboratory Standards Institute (CLSI) standard breakpoints.

WT S.
pseudintermedius

Sp80xa
Zone
(in
mm)
S/R?
40 *
24 R
37 S
38 S
34 S
37 S

Sp80xb

Mechanism of Action
Cell wall synthesis inhibitor
Cell wall synthesis inhibitor
Cell wall synthesis inhibitor
Protein Synthesis Inhibitor
Protein Synthesis Inhibitor
RNA synthesis inhibitor

Zone (in
mm)
40
21
36
38
32
37

TMP-SMX
Clindamycin
Erythromycin
Vancomycin
Delafloxacin
Chloromphenicol
Synercid
Ciprofloxacin
Gentamicin
Nitrofurantoin
Oxacillin

DHFR inhibitor
(thymidine/DNA synthesis)
Protein Synthesis Inhibitor
Protein Synthesis Inhibitor
Cell wall synthesis inhibitor
DNA gyrase inhibitor
Protein Synthesis Inhibitor
Protein Synthesis Inhibitor
DNA gyrase inhibitor
PRotein Synthesis Inhibitor
RNA and DNA disruption
Cell wall synthesis inhibitor

33
29
32
20
51
25
30
37
33
25
22

S
S
S
*
*
S
S
S
S
S
S

34
30
33
20
53
25
32
40
35
28
22

S
S
S
*
*
S
S
S
S
S
S

35
30
36
20
52
25
32
39
34
28
21

S
S
S
*
*
S
S
S
S
S
S

35
30
35
22
54
26
31
39
35
31
23

S
S
S
*
*
S
S
S
S
S
S

34
30
32
20
52
25
32
39
34
26
22

S
S
S
*
*
S
S
S
S
S
S

Daptomycin (e-test)

Cell membrane disruptor, cell
depolarizer

0.032

S

0.032

S

0.032

S

0.064

S

0.047

S
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S/R?
*
R
S
S
S
S

Zone
(in mm)
40
26
38
39
36
41

Sp80xd

Antimicrobial
Cefoxitin
Penicillin
Ceftaroline
Linezolid
Doxycycline
Rifampin

S/R?
*
R
*
S
S
S

Zone
(in mm)
40
24
37
37
34
38

Sp80xc
S/R?
*
R
S
S
S
S

Zone
(in mm)
41
22
36
38
34
37

S/R?
*
R
S
S
S
S

Sp80xe
Antimicrobial
Cefoxitin
Penicillin
Ceftaroline
Linezolid
Doxycycline
Rifampin
TMP-SMX
Clindamycin
Erythromycin
Vancomycin
Delafloxacin
Chloromphenicol
Synercid
Ciprofloxacin
Gentamicin
Nitrofurantoin
Oxacillin

Daptomycin (e-test)

Zone
(in mm)
41
24
37
37
34
37

S/R?
*
R
S
S
S
S

Sp80xf
Zone
(in mm)
40
24
38
37
35
37

S/R?
*
R
S
S
S
S

Sp80xg
Zone
(in mm)
41
24
36
38
34
37

Sp80xh

S/R?
*
R
S
S
S
S

Zone
(in mm)
40
23
36
38
33
38

S/R?
*
R
S
S
S
S

SpMJ40.1
Zone
(in mm)
40
23
37
38
38
38

S/R?
*
R
S
S
S
S

SpMJ40.2
Zone
(in mm)
40
21
36
36
33
38

S/R?
*
R
S
S
S
S

Sp40xa
Zone
(in mm)
37
17
33
34
31
34

S/R?
*
R
S
S
S
S

35
30
33
20
52
25
32
40
35
27
22

S
S
S
*
*
S
S
S
S
S
S

34
30
33
21
53
25
32
39
34
27
21

S
S
S
*
*
S
S
S
S
S
S

35
30
32
20
52
25
32
39
35
27
22

S
S
S
*
*
S
S
S
S
S
S

34
29
32
20
53
25
32
39
33
27
22

S
S
S
*
*
S
S
S
S
S
S

34
29
33
20
52
26
33
39
34
26
22

S
S
S
*
*
S
S
S
S
S
S

34
29
33
20
52
25
31
38
32
26
22

S
S
S
*
*
S
S
S
S
S
S

32
26
29
18
42
24
30
36
30
24
22

S
S
S
*
*
S
S
S
S
S
S

0.047

S

0.032

S

0.032

S

0.032

S

0.032

S

0.047

S

0.047

S
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Sp40xb
Antimicrobial

Zone
(in mm)

S/R?

Sp40xc
Zone
(in mm)

S/R?

Sp40xd
Zone
(in mm)

Sp40xf

S/R?

Zone
(in mm)

S/R?

Sp40xh
Zone
(in mm)

S/R?

Sp40xe
Zone
(in mm)

S/R?

Sp40xf
Zone
(in mm)

S/R?

Cefoxitin

39

*

36

*

38

*

38

*

38

*

40

*

38

*

Penicillin

22

R

18

R

21

R

22

R

21

R

21

R

20

R

Ceftaroline

36

S

34

S

34

S

34

S

34

S

35

S

35

S

Linezolid

36

S

35

S

33

S

35

S

34

S

36

S

35

S

Doxycycline

34

S

31

S

31

S

34

S

32

S

36

S

38

S

Rifampin

35

S

34

S

34

S

35

S

36

S

36

S

35

S

TMP-SMX

35

S

32

S

33

S

34

S

33

S

34

S

34

S

Clindamycin

29

S

26

S

27

S

28

S

28

S

28

S

28

S

Erythromycin

31

S

29

S

30

S

29

S

30

S

31

S

31

S

Vancomycin

20

*

18

*

19

*

19

*

20

*

20

*

20

*

Delafloxacin

50

*

48

*

49

*

49

*

49

*

50

*

50

*

Chloromphenicol

25

S

25

S

24

S

25

S

25

S

26

S

26

S

Synercid

31

S

30

S

30

S

30

S

30

S

31

S

30

S

Ciprofloxacin

38

S

37

S

36

S

36

S

36

S

36

S

37

S

Gentamicin

30

S

29

S

29

S

31

S

30

S

31

S

29

S

Nitrofurantoin

27

S

25

S

26

S

27

S

25

S

28

S

27

S

Oxacillin

23

S

21

S

22

S

27

S

22

S

22

S

22

S

0.023

S

0.047

S

0.032

S

0.047

S

0.016

S

0.023

S

0.023

S

Daptomycin (e-test)
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Antimicrobial
Cefoxitin
Penicillin
Ceftaroline
Linezolid
Doxycycline
Rifampin
TMP-SMX
Clindamycin
Erythromycin
Vancomycin
Delafloxacin
Chloromphenicol
Synercid
Ciprofloxacin
Gentamicin
Nitrofurantoin
Oxacillin

Daptomycin (e-test)

WT S. schleiferi
Zone
(in
mm)
S/R?
36 *
50 S
42 *
33 S
33 S
37 S
29
29
30
19
42
25
30
32
33
25
25

S
S
S
*
*
S
S
S
S
S
S

0.047 S

Ss40xa
Zone
(in
mm)
S/R?
39 *
48 S
42 *
32 S
32 S
36 S
27
29
28
19
40
26
30
31
30
25
26

S
S
S
*
*
S
S
S
S
S
S

0.047 S

Ss40xd
Zone
(in
mm)
S/R?
35 *
58 S
42 *
32 S
31 S
36 S
27
27
29
19
41
25
31
31
29
24
25

S
S
S
*
*
S
S
S
S
S
S

0.032 S
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Ss40xg
Zone
(in
mm)
S/R?
36 *
46 S
40 *
36 S
38 S
38 S
28
29
30
20
41
24
29
30
30
24
26

S
S
S
*
*
S
S
S
S
S
S

0.032 S

Ss40xe
Zone
(in
mm)
S/R?
36 *
48 S
40 *
32 S
31 S
35 S
28
26
27
18
40
23
28
30
28
23
25

S
S
S
*
*
S
S
S
S
S
S

0.047 S

Antimicrobial
Cefoxitin
Penicillin
Ceftaroline
Linezolid
Doxycycline
Rifampin
TMP-SMX
Clindamycin
Erythromycin
Vancomycin
Delafloxacin
Chloromphenicol
Synercid
Ciprofloxacin
Gentamicin
Nitrofurantoin
Oxacillin

Daptomycin (e-test)

Ss80xa
Zone
(in
mm)
S/R?
36 *
50 S
42 *
35 S
33 S
37 S
27
29
32
19
42
25
30
32
30
24
25

S
S
S
*
*
S
S
S
S
S
S

0.047 S

Ss80xe
Zone
(in
mm)
S/R?
34 *
48 S
42 *
34 S
31 S
35 S
29
28
30
18
41
24
30
31
29
24
26

S
S
S
*
*
S
S
S
S
S
S

0.032 S

Ss80xf
Zone
(in
mm)
S/R?
34 *
48 S
42 *
35 S
33 S
38 S
29
31
35
21
43
28
32
32
31
26
26

S
S
S
*
*
S
S
S
S
S
S

0.047 S
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Ss80xg
Zone
(in
mm)
S/R?
35 *
48 S
42 *
40 S
35 S
37 S
30
31
35
20
43
27
33
34
33
27
27

S
S
S
*
*
S
S
S
S
S
S

0.047 S

Table S2 Minimum inhibitory concentrations (MIC) for values for selected antistaphylococcals against POM-ERJ resistant staphylococci, R1-R3. Displayed are the mean ± SD of three
independent biological experiments performed in technical duplicate. In some cases, SD is listed as N/A as MIC values are discrete measurements and each replicate provided the same measurement,
hence there is no variability.

Compound

Wild-Type
MIC
(μM)
SD

R1

R2

MIC (μM)

SD

MIC
(μM)

R3
SD

MIC (μM)

SD

FSM
FR-900098
BOM-ERJ
POM-ERJ

6.3
500
7.9
0.50

N/A
N/A
4.6
N/A

5.2
500
27
180

1.6
N/A
N/A
N/A

5.2
500
27
37

1.6
N/A
N/A
13

5.2
500
27
180

1.6
N/A
N/A
N/A

Cefditoren Sodium
Cefditoren Pivoxil

0.74
0.76

0.54
N/A

0.55
12

0.27
N/A

0.59
6.0

0.23
N/A

0.59
10

0.23
3.1

HEX
POM-HEX

3.1

N/A

100

N/A

50

N/A

100

N/A

Mupirocin

0.010

0.0041

0.010

0.0041

0.010

0.0041

0.0092

0.0032
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Table S3. Single Nucleotide Polymorphisms identified via whole-genome sequencing.

WT
Allele

SNP

45418

G

A

S. pseudintermedius

1282386

A

sp40xa

S. pseudintermedius

2227530

sp40xa

S. pseudintermedius

sp40xb

Strain

Species

sp40xa

S. pseudintermedius

sp40xa

Base

Read
Depth

Gene

Annotation

5

SPSE_0038

P-type Copper Transporter

T

219

SPSE_1252

Hydroxyacylglutathione hydrolase

C

A

562

SPSE_2164

Putative glutamyl-endopeptidase

2228995

C

A

519

SPSE_2165

Putative glutamyl-endopeptidase

S. pseudintermedius

45418

G

A

5

SPSE_0038

P-type Copper Transporter

sp40xb

S. pseudintermedius

1282347

C

A

230

SPSE_1252

Hydroxyacylglutathione hydrolase

sp40xc

S. pseudintermedius

45418

G

A

5

SPSE_0038

P-type Copper Transporter

sp40xc

S. pseudintermedius

1110010

A

T

75

SPSE_1082

Transposase

sp40xc

S. pseudintermedius

2227530

C

A

722

SPSE_2164

Putative glutamyl-endopeptidase

sp40xd

S. pseudintermedius

1282655

C

T

358

SPSE_1252

Hydroxyacylglutathione hydrolase

sp40xe

S. pseudintermedius

1282745

G

T

406

SPSE_1252

Hydroxyacylglutathione hydrolase

sp40xe

S. pseudintermedius

1651160

C

A

493

SPSE_1610

Putative oxidoreductase

sp40xf

S. pseudintermedius

1282565

C

T

283

SPSE_1252

Hydroxyacylglutathione hydrolase

sp40xf

S. pseudintermedius

2228995

C

A

618

SPSE_2165

Putative glutamyl-endopeptidase

sp40xg

S. pseudintermedius

2228995

C

A

526

SPSE_2165

Putative glutamyl-endopeptidase

sp40xh

S. pseudintermedius

1282347

C

A

279

SPSE_1252

Hydroxyacylglutathione hydrolase

sp40xh

S. pseudintermedius

1651160

C

A

492

SPSE_1610

Putative oxidoreductase

sp40xh

S. pseudintermedius

2227530

C

A

611

SPSE_2164

Putative glutamyl-endopeptidase

sp80xa

S. pseudintermedius

1282655

C

T

328

SPSE_1252

Hydroxyacylglutathione hydrolase

sp80xb

S. pseudintermedius

2227530

C

A

679

SPSE_2164

Putative glutamyl-endopeptidase

sp80xc

S. pseudintermedius

1282655

C

T

372

SPSE_1252

Hydroxyacylglutathione hydrolase
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WT
Allele

SNP

2228995

C

A

S. pseudintermedius

668455

T

sp80xe

S. pseudintermedius

1282874

sp80xe

S. pseudintermedius

sp80xf

Strain

Species

sp80xd

S. pseudintermedius

sp80xe

Base

Read
Depth

Gene

Annotation

586

SPSE_2165

Putative glutamyl-endopeptidase

G

5

SPSE_0610

RNA-directed DNA polymerase

G

A

292

SPSE_1252

Hydroxyacylglutathione hydrolase

1651160

C

A

415

SPSE_1610

Putative oxidoreductase

S. pseudintermedius

668455

T

G

6

SPSE_0610

RNA-directed DNA polymerase

sp80xf

S. pseudintermedius

1282386

A

T

327

SPSE_1252

Hydroxyacylglutathione hydrolase

sp80xf

S. pseudintermedius

2227530

C

A

545

SPSE_2164

Putative glutamyl-endopeptidase

sp80xg

S. pseudintermedius

1282347

C

A

280

SPSE_1252

Hydroxyacylglutathione hydrolase

sp80xg

S. pseudintermedius

2227530

C

A

613

SPSE_2164

Putative glutamyl-endopeptidase

sp80xh

S. pseudintermedius

1282385

G

T

35

SPSE_1252

Hydroxyacylglutathione hydrolase

sp80xh

S. pseudintermedius

2228043

A

C

174

SPSE_2164

Putative glutamyl-endopeptidase

sp80xh

S. pseudintermedius

2227746

C

A

226

SPSE_2164

Putative glutamyl-endopeptidase

sp80xh

S. pseudintermedius

2227738

G

A

242

SPSE_2164

Putative glutamyl-endopeptidase

sp80xh

S. pseudintermedius

2227731

C

A

251

SPSE_2164

Putative glutamyl-endopeptidase

sp80xh

S. pseudintermedius

2227735

G

C

255

SPSE_2164

Putative glutamyl-endopeptidase

sp80xh

S. pseudintermedius

2227530

C

A

579

SPSE_2164

Putative glutamyl-endopeptidase

sp80xh

S. pseudintermedius

2228995

C

A

589

SPSE_2165

Putative glutamyl-endopeptidase

spmj401

S. pseudintermedius

1282794

G

T

225

SPSE_1252

Hydroxyacylglutathione hydrolase

spmj401

S. pseudintermedius

2228995

C

A

520

SPSE_2165

Putative glutamyl-endopeptidase

spmj402

S. pseudintermedius

1282329

G

T

240

SPSE_1252

Hydroxyacylglutathione hydrolase

spmj402

S. pseudintermedius

2227530

C

A

597

SPSE_2164

Putative glutamyl-endopeptidase

ss40xa

S. schleiferi

925052

G

A

526

gatA

Galactitol PTS system EIIA component
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WT
Allele

SNP

Read
Depth

Gene

Annotation

925052

G

A

465

gatA

Galactitol PTS system EIIA component

S. schleiferi

178904

G

T

543

LH95_00765

124153

G

T

564

murQ

Putative Tributyrin Esterase
N-acetylmuramic acid 6-phosphate
etherase

ss40xf

S. schleiferi

ss40xg

S. schleiferi

971929

G

A

18

LH95_04455

tRNA Val

ss40xg

S. schleiferi

971915

A

T

43

LH95_04455

tRNA Val

ss40xg

S. schleiferi

971919

G

T

43

LH95_04455

tRNA Val

ss40xg

S. schleiferi

971911

C

A

45

LH95_04455

tRNA Val

ss40xg

S. schleiferi

971900

G

T

155

LH95_04455

ss40xg

S. schleiferi

2095855

T

C

541

LH95_09910

tRNA Val
Potassium-transporting ATPase
potassium-binding subunit

ss80xa

S. schleiferi

1282737

C

A

347

LH95_06060

Hydroxyacylglutathione hydrolase

ss80xe

S. schleiferi

1282513

G

A

424

LH95_06060

Hydroxyacylglutathione hydrolase

ss80xe

S. schleiferi

1291886

G

A

386

LH95_06115

Lipoyl(octanoyl) transferase

ss80xf

S. schleiferi

1282335

C

T

289

LH95_06060

Hydroxyacylglutathione hydrolase

ss80xg

S. schleiferi

1291886

G

A

294

LH95_06115

Lipoyl(octanoyl) transferase

ss80xh

S. schleiferi

1319671

G

T

406

LH95_06255

Ribonuclease Z

ss80xh

S. schleiferi

1478053

C

G

458

LH95_07010

Unknown function

Strain

Species

ss40xd

S. schleiferi

ss40xe

Base
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Table S4. Primers used during this study.

Primer Sequence

Gene

Species

Purpose

ATATCGCTGCATTAGATGATG

SPSE_1252(gloB)

S. pseudintermedius

Sequencing

AGGCACATCATATCGTGTTAG

SPSE_1252(gloB)

S. pseudintermedius

Sequencing

TGCTGCATTCCTTCATCAAGTG

SPSE_1252(gloB)

S. pseudintermedius

Sequencing

CCGTTCAATAAAGGGCTCGATC

SPSE_1252(gloB)

S. pseudintermedius

Sequencing

TGATGAATTTGCAGTAGTGGGC

SPSE_1252(gloB)

S. pseudintermedius

Sequencing

TTAACCTTGACCGTCTAAAAACG

SPSE_1252(gloB)

S. pseudintermedius

Sequencing

CTGGGCAAAAGCAGTATTGACAGGC

SPSE_2164

S. pseudintermedius

Sequencing

GTTAGCGGTTTCACAGATGCC

SPSE_2164

S. pseudintermedius

Sequencing

AGTTCGGGTTATTCATCCTAACACC

SPSE_2164

S. pseudintermedius

Sequencing

CGTCAACTGTCGCATTAACTGC

SPSE_2164

S. pseudintermedius

Sequencing

TAATTTGCGTTTTTGTTAACCC

SPSE_2164

S. pseudintermedius

Sequencing

GTTAGCGGTTTCACAGATGCC

SPSE_2164

S. pseudintermedius

Sequencing

ATGAAAATTTCCTACCTGACTTTAG

LH95_06060(gloB)

S. schleiferi

Sequencing

ATTTTTTTTGATTCTGAAGATGGG

LH95_06060(gloB)

S. schleiferi

Sequencing

ATGCACAGCCTACTGCGATCGAAG

LH95_06060(gloB)

S. schleiferi

Sequencing

TTACTCATGCACATTTTGATC

LH95_06060(gloB)

S. schleiferi

Sequencing

AATGCCCAGGTGTATGCAATGC

LH95_06060(gloB)

S. schleiferi

Sequencing

TTAGCCATGAAGATAAGGATTC

LH95_06060(gloB)

S. schleiferi

Sequencing

GGAGTGAGTATTTTGGCACG

LH95_00765

S. schleiferi

Sequencing

AGGATCAAAAGGTGTCCCCACAAC

LH95_00765

S. schleiferi

Sequencing

GCGGTGATTATGCCCAATGCAGACC

LH95_00765

S. schleiferi

Sequencing

TTATACCATCTCACGCGTATGATGG

LH95_00765

S. schleiferi

Sequencing

CTCACCACCACCACCACCATATGAAAATTTCCTACCTGACTTTAG

LH95_06060(gloB)

S. schleiferi

LIC Cloning

ATCCTATCTTACTCACTTAGCCATGAAGATAAGGATTC

LH95_06060(gloB)

S. schleiferi

LIC Cloning

CTCACCACCACCACCACCATATGAATATTTCTAATCTTACTTTAG

SPSE_1252(gloB)

S. pseudintermedius

LIC Cloning

ATCCTATCTTACTCACTTAACCTTGACCGTCTAAAAACG

SPSE_1252(gloB)

S. pseudintermedius

LIC Cloning
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4.1 Abstract
Carboxy ester prodrugs have been widely employed as a means of increasing oral absorption and
potency of phosphonate antibiotics. These prodrugs can be used to mask problematic drug
residues that prevent cellular uptake as well as target delivery of compounds to specific tissue
types. Unfortunately, many carboxy ester promoieties are rapidly hydrolyzed by serum esterases
limiting their potential benefits in clinical applications. While carboxy ester-based prodrug
targeting is feasible, it has been limited in microbes due to a paucity of information about the
selectivity of microbial esterases. Here we identify the bacterial esterases, GloB and FrmB,
which are required for carboxy ester prodrug activation in Staphylococcus aureus. Additionally,
we determine the substrate specificities for FrmB and GloB, and demonstrate the structural basis
of these preferences. Finally, we establish the carboxy ester substrate specificities of human and
mouse sera, identifying several promoieties likely to be serum esterase resistant while still being
microbially labile.
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4.2 Introduction
Antimicrobial resistance presents a major challenge to modern healthcare (1, 2). In 2019, 2.8
million antibiotic resistant infections occurred in the United States and resulted in 35,000 deaths
(3). Some estimates have suggested that antimicrobial resistant infections will cause as many as
10 million deaths annually in 2050 (4). Staphylococcus aureus is an efficient human pathogen
capable of displaying methicillin-resistance and has been labeled a “serious threat” by the
Centers for Disease Control and Prevention (3, 5, 6). New antimicrobials, especially those with
novel mechanisms of action, are urgently needed, however most developing antiinfectives are
reformulations of existing antibiotic scaffolds (7, 8).
While many metabolic processes are essential for microbial growth and pathogenesis, few
existing antimicrobials exploit this target making bacterial metabolism a promising avenue for
new antibiotic discovery (9–11). Metabolic drug design can be facile, using natural substrates as
a template for competitive inhibitors. As metabolism often involves the transformation of highly
charged metabolites, most metabolic inhibitors deploy phosphonate functional groups to achieve
target binding (12). Unfortunately, these negatively charged phosphonate groups are readily
excluded from cell membranes and often exhibit poor drug-like properties (13–21). New
strategies enabling effective deployment of antimetabolites will serve to expand the druggable
space for antimicrobials.
One means of improving phosphonate cellular permeability is to chemically mask the negative
charge with lipophilic groups. This action, termed prodrugging, can be designed as a reversible
process such that the original phosphonate antibiotic is returned following removal of the
masking group, termed promoiety (Figure 1A) (19–21). We have previously demonstrated that
addition of the lipophilic prodrugging motif, pivaloyloxymethyl (POM), to the isoprenoid
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biosynthesis inhibitor, fosmidomycin, bypasses active cellular entry mechanisms while
simultaneously increasing compound potency against the zoonotic staphylococci, S. schleiferi
and S. pseudintermedius (14). Similar potency increases have been observed for this class of
compounds against several additional microorganisms (16, 22–25). Regrettably, POMpromoieties are rapidly hydrolyzed by serum carboxylesterases limiting the efficacy of POMprodrugs as a means of improving phosphonate cellular entry (15, 26).

To enable effective cellular delivery of phosphonate antibiotics, new lipophilic prodrugging
strategies that are resistant to serum carboxylesterases yet cleavable by microbial esterases are
needed. This feat has been achieved for prodrugs targeting delivery to human liver cells, but no
strategies have been described yet enabling drug delivery specifically to microbes (27, 28).
Notably, liver-targeted prodrug delivery was achieved by understanding the substrate specificity
of the liver specific isoform of P450, CYP3A4 (27, 28). Accordingly, understanding how
microbes activate prodrugs, and the specificities of their activating enzymes, will facilitate the
development of microbe-specific prodrugs.

We recently described the staphylococcal enzyme, GloB, which is responsible for partially
activating carboxy ester prodrugs in the zoonotic staphylococci S. schleiferi and S.
pseudintermedius (29). Notably, GloB is unable fully activate prodrugs in vitro, suggesting that
at least one additional enzyme is necessary for complete prodrug activation. Here, we describe
how two staphylococcal esterases, GloB and FrmB, each act on carboxy ester prodrugs and
contribute to carboxy ester prodrug activation in S. aureus. We demonstrate that both esterases
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have defined substrate specificities which diverge from the substrate specificities of human and
mouse sera. Additionally, we demonstrate that ester modifications have critical roles during the
in vivo activation of prodrugs, and finally we present the three-dimensional structures of GloB
and FrmB to enable structure-guided design of FrmB and GloB targeted prodrug activation.
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4.3 Methods
4.3.1 Materials. POM-HEX, Hemi-HEX, and HEX were synthesized and resuspended in
DMSO as described previously. Fluorescent ester compounds were generously provided by the
laboratory of Geoffrey Hoops (30). Pooled, delipidated, defibronated, and lyophilized human and
mouse serum was obtained from Rockland Inc.
4.3.2 Quantification of resistance. Half maximal inhibitory concentration (IC50)
determination was performed using microtiter broth dilution in clear 96-well plates (31). Briefly,
POM-HEX was added to 75 µL LB media at a final concentration of 20 – 50 µM POM-HEX and
0.5% DMSO, with POM-HEX concentrations varying according to resistant strain.
Subsequently, POM-HEX was serially diluted in LB media containing 0.5% DMSO for a total of
10 dilutions. Two wells were left without drug, one used to define 100% growth, and the other
used to control for media contamination and to define 0% growth. 75 µL of mid-log phase S.
aureus diluted to 1 x 105 colony forming units/mL were subsequently added to the plate.
Following inoculation, plates were incubated at 37 ºC with shaking, and OD600 measurements
were taken every 20 minutes for a total of 16 hours. Half maximal inhibitory concentrations were
determined by fitting the OD600 of each condition following 10 hours of growth to a nonlinear
regression using GraphPad Prism software. Experiments were performed in triplicate with
technical duplicates.

4.3.3 Generation of POM-HEX resistant strains was performed by plating log-phase S.
aureus Newman on LB agar containing 3.33 μM POM-HEX and incubating at 37 °C overnight.
Surviving single colonies were grown overnight in LB media and frozen in 10% glycerol for
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long term storage. All assays were performed from fresh overnight inoculations from glycerol
stocks.

4.3.4 Whole Genome Sequencing. Genomic DNA integrity was determined using Agilent
4200 Tapestation. Library preparation was performed with 0.25-0.5ug of DNA. DNA was
fragmented using a Covaris E220 sonicator using peak incident power 175, duty factor 10%,
cycles per burst 200 for 240 seconds at 4 degrees Celsius. DNA was blunt ended, had an A base
added to the 3’ ends, and then had Illumina sequencing adapters ligated to the ends. Ligated
fragments were then amplified for 9 cycles using primers incorporating unique dual index tags.
Fragments were sequenced on an Illumina MiSeq using paired-end reads extending 150 bases.
4.3.5 WhatsGNU Analysis. The S. aureus database was used to produce WhatsGNU
proteomic reports for all the strains using WhatsGNU_main.py script in the ortholog
mode. Eighteen S. aureus (9 atopic dermatitis (AD) and 9 soft and skin tissue infection
(SSTI)) isolates from an ongoing project representing different clonal complexes
(CC1/5/8/22/30) were used for the comparison. The CC details for the 18 isolates are provided in
the attached excel sheet. The reports were then used to produce a heat map of the GNU scores of
GloB and FrmB using the heat map function in the WhatsGNU_plotter.py script. The heatmap
was annotated with the ortholog variant rarity index where 'r' represents a rare GNU score (in the
context of other alleles in the same protein ortholog group).
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4.3.6 Phylogenetic tree construction. Sequences of GloB, FrmB, and RpoB orthologs were
retrieved from NCBI using the BlastP function with each organism on the tree as an individual
search set. Of the returned sequences, the first complete sequence with the lowest E-value was
selected for further analysis. Organisms were selected to include a wide variety of pathogenic
and commensal microbes (32). In one instance, several of the top E. coli sequences were found
to be highly similar to S. aureus, and on further analysis we discovered that the original
sequencing samples had high levels of S. aureus reads. These contaminated sequences were
disregarded in our analysis. Sequence alignment was performed using MUSCLE, and the
unrooted phylogenetic trees were visualized using iTOL (33, 34).

4.3.7 Recombinant expression and purification of FrmB and GloB. WT FrmB and GloB
sequences from S. aureus were cloned into the BG1861 vector by GeneWiz Inc (Beijing, China)
to introduce a hexahistidine tag (35). The resultant plasmids were transformed into Stellar
chemically competent cells (Clontech Laboratories), selected with carbenicillin, and the
sequence was confirmed by Sanger sequencing. Subsequently, plasmids were transformed into
chemically competent BL21 (DE3) cells and selected with ampicillin. Overnight liquid cultures
were diluted 1:500 into LB media supplemented with ampicillin, grown shaking at 220 rpm to an
OD600 of 0.5-0.8 at 37 °C, chilled to 16 °C and induced with 0.5 mM Isopropyl β-D-1thiogalactopyranoside (IPTG) for 16-20 h. Cells were harvested by centrifugation at 6,000 x g
for 10 min at 4°C. The cell pellet was lysed by sonication in 50 mL lysis buffer containing 25
mM tris HCl (pH 7.5), 250 mM NaCl, 20 mM imidazole, 1 mM MgCl2, 10% glycerol, and 200
µM phenylmethylsulfonyl fluoride (PMSF). Insoluble proteins were removed by centrifugation
twice at 20,000 x g for 20 min. The hexahistidine-tagged proteins were affinity purified from
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soluble lysate using nickel agarose beads (Gold Biotechnology). Bound protein was washed with
50 mL lysis buffer before elution using 5 mL of elution buffer containing 25 mM tris HCl (pH
7.5), 250 mM NaCl, 300 mM imidazole, 1 mM MgCl2, 10% glycerol. Affinity purified protein
was further purified over a HiLoad 16/60 Superdex 200 gel filtration column (GE
Healthsciences) using an AKTA Explorer. FPLC buffer contained 25 mM tris HCl (pH 7.5), 250
mM NaCl, 1 mM MgCl2, and 10% glycerol. Fractions containing >90% pure protein (evaluated
by SDS-PAGE) were concentrated using an Amicon Ultra-15 centrifugal unit (EMD Millipore)
and flash frozen in liquid nitrogen before storage at -80°C.

Protein used during crystallography experiments was generated via the same FrmB and GloB
sequences, but expression was performed from vector pET28a. FrmB was cloned into the
pET28a vector by GeneWiz Inc (Beijing, China) and GloB was cloned from the BG1861 vector
using the forward primer 5’- TGCTCGAGTGCGGCCGCTTAACCGTGTAAAAATGGATTT3’
and the reverse primer 5’- CGCGCGGCAGCCATATGATGAGGATTTCAAGCTTAACTTT
-3’. The PCR product was cloned into vector pET28a digested with restriction enzymes NotI and
NdeI using InFusion HD Cloning (Takara Bio). Both cloning strategies introduce a hexahistidine
tag followed by a thrombin cleavage sequence. FrmB and GloB encoding pET28a was
transformed into chemically competent BL21 (DE3) cells. Protein expression of FrmB proceeded
as previously, except FrmB containing cells were grown in Terrific broth.

Selenomethionine labeled GloB was prepared according to Van Duyne with minor modifications
(36). Briefly, overnight cultures were grown in LB media, washed, and resuspended in M9
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minimal media (per liter: 64 g Na2HPO4, 15g KH2PO4, 2.5 g NaCl, and 5 g NH4Cl)
supplemented with 50 mg EDTA, 8 mg FeCl3, 0.5 mg ZnCl2, 0.1 mg CuCl2, 0.1 mg CoCl2, 0.1
mg H3BO3, 16 mg MnCl2, 0.1 mg Ni2SO4, 0.1 mg molybdic acid, 0.5 mg riboflavin, 0.5 mg
niacinamide, 0.5 mg pyridoxine monohydrate, and 0.5 mg thiamine per liter. Resuspended
cultures were grown overnight. The following day, cultures were back diluted 1:50 and grown to
an OD600 of 0.5-0.8 at 37 °C. Once at the appropriate OD, the following amino acids were added
to the culture media at: 100 mg/L: lysine, phenylalanine, and threonine, 50 mg/L: isoleucine,
leucine, and valine, 60 mg/L: selenomethionine. Cultures were grown for an additional 15
minutes at 37 °C before cells were chilled to 16 °C and induced with 0.5 mM IPTG for 16-20
hours.
Protein purification of FrmB and selenomethionine labeled GloB for crystallography proceeded
as previously except following affinity purification the elution was dialyzed for 16-20 h at 4°C
with 20U thrombin protease to remove the hexahistidine tag. Dialysis buffer contained 50 mM
tris pH 7.5, 50 mM NaCl, and 1 mM MgCl2. Following dialysis, uncleaved protein, the
hexahistidine tag, and thrombin were removed by flowing dialyzed protein over a benzamidine
Sepharose and nickel agarose bead column. Column flow through was further purified over a
HiLoad 16/60 Superdex 200 gel filtration column equilibrated with dialysis buffer. Protein was
concentrated to 8-10 mg/mL in an Amicon Ultra-15 centrifugal unit and frozen at -80°C.

4.3.8 Glyoxalase II activity assay. Glyoxalase II activity was assessed as previously with
minor changes (29, 37). Briefly, reactions were mixed to form a final concentration of 25 mM
Tris pH 7.5, 250 mM NaCl, 1 mM MnCl2, 10% glycerol, 200 µM 5,5’-Dithiobis(2-nitrobenzoic
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acid) (DTNB, Sigma D8130), 1 mM D-lactoylglutathione (Sigma L7140) and 0.15-0.63 µg
protein (130-550 nM GloB, 100-430 nM FrmB). Protein concentrations were varied to ensure the
reaction was linear across protein concentrations. Reactions without D-lactoylglutathione were
pre-incubated at 37 ºC for 10 minutes prior to assay initiation with the addition of substrate.
Release of glutathione from D-lactoylglutathione was quantified spectrophotometrically at 37 ºC
and 412 nm through the conversion of DTNB to TNB. Experiments were performed in triplicate
with technical duplicates.

4.3.9 4-nitrophenyl ester substrate activity assays. 4-nitrophenyl substrate specific activity
was determined in 50 µL reactions containing 25 mM Tris pH 7.5, 250 mM NaCl, 1 mM MnCl2,
10% glycerol, 1 µM protein, and 1 mM 4-nitrophenyl substrate. The tested substrates, 4nitrophenyl acetate (Sigma, N8130), 4-nitrophenyl butyrate (Sigma N9876), and 4-nitrophenyl
trimethylacetate (Sigma 135046) were resuspended in acetonitrile at 100 mM. Reactions without
4-nitrophenyl substrate were preincubated at 37 ºC for 10 minutes prior to assay initiation via
substrate addition. Conversion of 4-nitrophenyl substrates to 4-nitrophenol was tracked
photometrically at 37 ºC and 405 nm. Experiments were performed in triplicate with technical
duplicates.

4.3.10 NMR characterization of GloB and FrmB activation products. 200 or 400 µM POMHEX was incubated with 4 nmol protein (GloB, FrmB, or 4 nmol each) in 500 µL reactions.
Reactions were buffered to a final concentration of 50 mM tris pH 7.5, 50 mM NaCl, 1 mM
MgCl2. Reactions were allowed to proceed for 1 hour at 37 ˚C prior to analysis. Samples were
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prepared for NMR studies by resuspending them in water and 10% (50 µL) D2O (Deuterium
Oxide 99.9% D, contains 0.75 wt% 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid, sodium salt,
Sigma–Aldrich). NMR spectra are acquired on a Bruker Avance III HD 500 MHz spectrometer
equipped with a cryoprobe. Two-dimensional (2D) 1H-31P heteronuclear single quantum
correlation (HSQC) measurements were obtained using hsqcetgp pulse program (with duration
of 15 minutes and scan parameters of 2 scans, td=1024 and 256, gpz2 %=32.40, 31P SW= 40
ppm, O2p=20 ppm, cnst2=22.95) and analyzed using 3.1 TopSpin. The 1D projection of
columns excluding the water signal was obtained from the 2D 1H-31P HSQC spectrum by
obtaining spectra of positive projection of columns 1 to 600 and 650 to 1024 and adding them.

4.3.11 Esterase substrate specificity determination using fluorogenic SAR library. Kinetic
measurements were performed according to White et al. with minor variation (38). Lyophilized
human and mouse sera were resuspended according to manufacturer instructions in highly pure,
filtered water at protein concentrations of 85 mg/mL and 70 mg/mL respectively. 1 mL of
resuspended serum was added to a 24 mL mastermix for a final concentration of 31.25 mM tris
pH 7.5, 312.5 mM NaCl, 1.25 mM MgCl2, 12.5% glycerol, and 3.4 mg/mL or 2.8 mg/mL protein
for human and mouse serum respectively. For purified proteins, 5 mL of a 75 µg/mL stock was
added to yield a 20 mL mastermix containing 31.25 mM tris pH 7.5, 312.5 mM NaCl, 1.25 mM
MgCl2, 12.5% glycerol, and 18.75 µg/mL protein. Mastermix was stored on ice when not in use.
20 µL of mastermix was transferred to a black, 96-well half area microplate (Corning, CLS3993)
and prewarmed at 37 °C. Fluorogenic substrates were prepared as 10 mM stock solutions in
DMSO and were diluted in water to a starting concentration of 500 µM. Enzyme catalyzed
substrate hydrolysis was initiated by addition of 5 µL substrate dilution in technical duplicate to
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the prewarmed serum or protein solution. Final assay concentrations were: 25 mM tris pH 7.5,
250 mM NaCl, 1 mM MgCl2, 10% glycerol, and protein at a concentration of 2.72 mg/mL
(human serum), 2.24 mg/mL (mouse serum), or 15 µg/mL (FrmB, GloB). The resulting change
in fluorescence (λex = 485 nm, λem = 520 nm) was followed for 15 minutes at 37 °C, collecting
data every 30 seconds on a FLUOstar Omega microplate reader (BMG Labtech). Fluorescence
measurements were converted to molar concentrations using a fluorescein standard curve (2.5
nmol-0.6 pmol). The initial rates of reaction were measured three independent times with two
technical replicates per measurement and fit to a line using Graphpad Prism (GraphPad Software,
La Jolla, CA). Initial rates of reaction were plotted versus the concentration of substrate and fit to
a standard Michaelis-Menten equation, yielding estimates of Vmax and Km. Values for kcat and
kcat/Km were calculated based on amount of enzyme added when purified enzymes were used.
For substrates where saturating conditions were not met, kcat/vmax was estimated using the
following derivation of Michaelis MentenEquation (1)

When Km>>[S]
Equation (2)

Therefore
Equation (3)
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4.3.12 Microfluidics measurements on S. aureus. Overnight cultures of S. aureus were grown
in LB media, back diluted 1:500, and grown to early exponential phase (OD600 0.1-0.15), then
washed in phosphate buffered saline and loaded on a bacterial CellASIC Onix microfluidic plate.
Prior to cell loading, the microfluidics plate lines were flushed with PBS + 1% DMSO or 10 µM
fluorescent prosubstrate in PBS + 1% DMSO, and the plate was preincubated at 37 °C. The
microfluidics plate was loaded onto a Nikon Ti-E inverted microscope (Nikon Instruments, Inc)
equipped with a 100x Plan N (N.A. = 1.45) Ph3 objective, X-cite 120 LED light source (Lumen
Dynamics), and an OrcaERG CCD camera (Hammamatsu Photonics, Bridgewater, N.J), which
was used to obtain both phase contrast and fluorescent images. Filter sets were purchased from
Chroma Technology Corporation. Cells were loaded until a single field of view contained 50-150
cells or cell clusters. Following cell loading, PBS was flown through the flow cell (t = 0) and
cells were observed in both phase and fluorescent channels for 10 minutes before the flow media
was switched to PBS containing 1% DMSO and 10 µM fluorescent pro-substrate. Images were
captured every two minutes for a total of 44 minutes, and all experiments were undertaken at 37
°C. The phase contrast exposure time was kept constant at: 200 ms, and the fluorescent channel
exposure time was kept constant at 500 ms. For fluorescent images, the gain remained constant
across all experiments. Image capture and analysis was performed using Nikon Elements
Advanced Research software. Individual cells or clusters of cells were auto detected in the
fluorescent channel using the intrinsic background fluorescence of each cell. Manual curation
followed autodetection to remove debris or cells that did not stay within the field of view
throughout the experiment. Fluorescent intensity for each individual cell or cluster of cells was
measured through the duration of the experiment and normalized to the area of the identified cell
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to yield the mean fluorescent intensity. Background cell autofluorescence was corrected by
subtracting the average fluorescence across all identified objects from t = 0 through t = 10. Each
experiment was performed in duplicate, with >50 individual cells analyzed in each experiment.

4.3.13 Protein crystallography, phasing, and data refinement. Crystals of S. aureus FrmB
were grown at 16°C using vapor diffusion in 20 µL hanging drops containing a 1:1 mixture of
protein (6 mg/mL) and crystallization buffer (0.1M Tricine pH 7.7, 15% PEG6K, 2.5M NaCl,
0.125% n-Dodecyl-B-D-glucoside). Crystals were observable as early as 2 days following
mixing. Prior to data collection, crystals were stabilized in cryoprotectant (mother liquor
supplemented with 20% glycerol) before flash freezing in liquid nitrogen for data collection at
100 K. Crystals of selenomethionine labeled S. aureus GloB were grown at 16 °C using vapor
diffusion in 2 µL hanging drops containing a 1:1 mixture of protein (8 mg/mL) and
crystallization buffer (0.1 M imidazole pH 6.9, 0.2 M ammonium sulfate, 0.1 M calcium
chloride, and 21% PEG 8k). Selenomethionine labeled GloB crystals were stabilized in well
solution supplemented with 15% glycerol and flash frozen in liquid nitrogen. All diffraction
images were collected at beamline 19-ID of the Argonne National Laboratory Advanced Photon
Source at Argonne National Laboratory. HKL3000 was used to index, integrate, and scale the
data sets (39). To phase the initial dataset of FrmB, molecular replacement was performed in
PHASER using the x-ray crystal structure of a low-temperature active alkaline esterase (PDB ID:
4RGY) as a search model (40, 41). Selenomethionine labeled GloB was phased using the x-ray
crystal structure of TTHA1623 from Thermus thermophilus HB8 (PDB ID: 2ZWR) (42).
Buccaneer was used to build both initial models, and subsequent, iterative rounds of model
building and refinement used COOT and PHENIX respectively (43–45). Data collection and
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refinement statistics are summarized in Table S6. Atomic coordinates and structure factors of S.
aureus FrmB and S. aureus GloB are deposited in the RCSB Protein Data Bank.

4.3.13 Substrate Docking. GloB and FrmB structures were prepared for substrate autodocking
using AutoDock Tools 1.5.7 (46). Metals and water molecules were removed from the crystal
structure of FrmB as canonical serine hydrolases do not utilize metal in their reaction
mechanism. Solvent water in the GloB crystal structure was removed, but the active site water
and heavily coordinated zinc molecules were left in place. The three-dimensional structure of
substrate 1O was generated using ChemDraw3D, and prepared for docking using AutoDock
Tools 1.5.7. Substrate docking of FrmB and GloB was performed using AutoDock Vina (47).

4.3.14 Fresh human serum was collected from a willing volunteer in untreated BD vacutainer
tubes (BD, BD366430). Whole blood was allowed to clot at room temperature and aggregates
were separated from the remaining serum through centrifugation at 400 x g for 8 minutes. Sera
was obtained from the same volunteer on two separate occasions.

4.3.15 Serum half-life determination. Lyophilized human sera was obtained from Rockland
Inc. and resuspended in pure water. 20 µL lyophilized sera or fresh sera was prewarmed at 37 ºC
in a 96-well half area microplate (Corning, CLS3993). Following plate warming, 5 µL of the
fluorogenic substrates were added to the plate for a final concentration of 25 µM. Substrate
hydrolysis was tracked over a period of three hours at 37 ºC, with fluorescence measurements
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(λex = 485 nm, λem = 520 nm) being taken every two minutes on a FLUOstar Omega microplate
reader (BMG Labtech). The resulting fluorescence values were converted to % substrate
hydrolyzed using a fluorescein standard curve and fit to a one-phase decay model using
GraphPad Prism. Experiments were performed in technical and biological duplicate.

4.4 Results
4.4.1 Identification of microbial esterases responsible for carboxylesterase activity.
Recently, we described that in the zoonotic staphylococcal species S. schleiferi and S.
pseudintermedius, loss of the enzyme GloB, a hydroxyacylglutathione hydrolase, confers
resistance to carboxy ester prodrugs because carboxy ester prodrugs do not become deprotected
(29). However, purified GloB alone does not fully activate carboxy ester prodrugs in vitro,
indicating that at least one additional cellular enzyme is required. Based on the predicted carboxy
ester activation pathway, we predicted the missing enzyme(s) might be another carboxylesterase
or a phosphodiesterase (Figure 1B). To identify the full suite of enzymes required for carboxy
ester prodrug activation by S. aureus we made use of the Nebraska Transposon Mutant Library
(NTML), in which nearly 2,000 of the non-essential genes of S. aureus have been individually
disrupted by a stable transposon insertion (48). Using the gene ontology feature on the NTML
website (https://app1.unmc.edu/fgx/gene-ontologies.html), we identified 6 carboxylic ester
hydrolases (including GloB), 11 phosphatases, and 9 phosphoric diester hydrolases as candidate
activators of carboxy ester prodrugs (Table S1), and screened each identified transposon mutant
for resistance to the carboxy ester prodrug, POM-HEX. POM-HEX is a pivaloyloxymethyl
prodrug of the compound, HEX, which inhibits enolase (Figure 1B, Figure 2A). Of the 26
candidate esterase transposon mutants, only two strains were significantly more resistant to
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POM-HEX than the S. aureus parental strain, JE2, as determined by half maximal growth
inhibitory concentration (IC50) (Figure 2B). One of these strains had a transposon disrupting the
glyoxalase II enzyme, GloB, which we have previously found to function as a prodrug activating
enzyme, mutation in which confers resistance to POM-HEX in S. schleiferi (29). The second
strain harbored a transposon insertion in the locus encoding the predicted carboxylesterase
annotated as FrmB. FrmB has been previously identified as FphF, a serine hydrolase, and is the
primary S. aureus target of the fluorophosphonate, JCP678 (49). As S-formylglutathione
hydrolase is more likely to reflect the biological function of this protein, we will refer to this
protein as FrmB.

In parallel, we also employed an unbiased forward genetics approach to identify genetic changes
associated with POM-HEX resistance. POM-HEX-resistant staphylococci were derived by
exposing wild-type (WT) S. aureus Newman to growth inhibitory concentrations of POM-HEX.
In total, we selected and cloned 25 isolates with IC50 values ranging from 1.5-16x that of WT S.
aureus Newman (Figure 2 C, D, Supplemental Table 2).

Whole genome sequencing of POM-HEX-resistant strains revealed mutations in FrmB (n = 7)
and GloB (n = 10), with most mutations being nonsynonymous single nucleotide polymorphisms
(SNPs) (Figure 2D, Supplemental Table 2). In three instances, GloB was the only verified
genetic change in the genome. Additionally, FrmB and GloB each had one instance of a mutation
resulting in a premature stop codon truncating the protein at less than a 100 amino acid sequence.
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Overwhelmingly the observed mutations in both FrmB and GloB are predicted to have
deleterious effects on protein function (PROVEAN score below a threshold of -2.5) (Figure 2E).

To evaluate the sequence conservation of FrmB and GloB among S. aureus, we performed a
WhatsGNU analysis on all available S. aureus genomes. WhatsGNU is a bioinformatic tool that
can compress large databases and provide a readout of how many instances a specific gene has a
100% sequence and identity match within the entire database (50). This parameter, the gene
novelty unit (GNU) score, is high when a sequence is under strong selective pressure within the
population, and low when the gene is variable. GloB exhibits an exceptionally high GNU score
of 8215 (of 10350 possible) indicating that there is very strong selective pressure to maintain
GloB in S. aureus. Conversely, FrmB sequences appear to be extremely conserved within
individual S. aureus clonal complexes but varies between each complex (GNU scores of 2218 or
3370 of 10350, Figure S1). We also built a phylogenetic tree of GloB and FrmB sequences
among microbial populations. GloB orthologs are generally present, though the primary
sequence is highly variable between bacteria and does not readily cluster according to the tree of
life (Figure S2). FrmB sequences are also highly sequence divergent, though they tend to cluster
closer to the expected tree of life (Figure S2).

Ultimately, the agreement between our forward and reverse genetic screens strongly suggest that
prodrug activation is performed by two discrete predicted esterases and not a pool of redundant
cellular esterases. Additionally, the finding that mutation in either FrmB or GloB is sufficient to
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confer POM-HEX resistance suggests that the two enzymes may work in concert to bioconvert
POM-HEX into HEX.

4.4.2 FrmB and GloB are carboxylesterases with diverging substrate specificity.
GloB is predicted to be a type II glyoxalase and a member of the large metallo-β-lactamase
protein superfamily (INTERPRO IPR001279). Glyoxalase II enzymes, including the closely
related GloB ortholog from S. scheiferi, catalyze the second step in the glyoxalase pathway
which is responsible for the cellular conversion of methylglyoxal (a toxic glycolytic byproduct)
to lactic acid (29, 37, 51). Conversely, FrmB orthologs hydrolyze p-nitrophenyl esters of short
chain fatty acids (C2-C6) and are thought to mediate detoxification of cellular formaldehyde
(52).

We purified recombinant WT SaFrmB and SaGloB and proceeded to evaluate the substrate
utilization for each enzyme (Figure S3A). We first assessed glyoxalase II activity using an assay
which couples hydrolysis of the glyoxalase II substrate, S-lactoylglutathione, to a change in
absorbance (Figure S3B). SaGloB hydrolyzes S-lactoylglutathione with a specific activity
comparable to previously characterized microbial type II glyoxalases, but SaFrmB lacks
appreciable activity.

We next assessed the ability of FrmB and GloB to hydrolyze p-nitrophenyl esters of short chain
fatty acids which have a photometric change upon hydrolysis (Figure S3C). FrmB has modest
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activity against 4-nitrophenyl acetate and butyrate but no activity against 4-nitrophenyl
trimethylacetate suggesting a preference for simple short chain fatty acids (Figure S3C). This
finding is in agreement with a previous characterization of FrmB cleaving short chain
hydrophobic lipid substrates (53). GloB has no detectable activity against these substrates.
Notably, neither GloB nor FrmB has activity against 4-nitrophenyl trimethylacetate despite 4nitrophenyl trimethyl acetate bearing striking similarity to POM-HEX as a potential substrate.
This may be due to the absence of the acyloxymethyl ether moiety in 4-nitrophenyl substrates
which is found in POM-prodrugs.

We also sought to directly assess the role of GloB and FrmB in POM-HEX activation. We
incubated each enzyme, with POM-HEX, and characterized the products via 31P-1Hheteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR). We have
previously shown that GloB removes only one POM moiety, resulting in an accumulation of
mono-POM-HEX (Figure 1B) (29). Similarly, FrmB is capable of removing only one POMmoiety (Figure S4). We hypothesized that the two esterases may be stereoselective and incubated
both enzymes with POM-HEX. We find that incubation of POM-HEX with GloB and FrmB still
results in an accumulation of mono-POM-HEX, suggesting the two esterases may be unable to
cleave the charged mono-POM species (Figure S4)

4.4.3 GloB and FrmB substrate specificity.
To facilitate microbially targeted prodrug activation using these two enzymes, we next sought to
extensively characterize GloB and FrmB substrate specificity, using a 32-compound fluorescent
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ester substrate library that fluoresces upon esterase activity (Figure S5) (30). This library
systematically varies ester substrate length, branching patterns, and ether and sulfide positioning
within the substrate, thereby allowing for the precise determination of structure-activityrelationships. Kinetic measurements were performed for both FrmB and GloB over a range of
substrate concentrations for the entire library allowing for the extraction of the catalytic
specificity (kcat/Km) (Supplemental table S4, S5).

We find that FrmB and GloB tend to have the highest activity towards oxygen ethers (Figure
S6). GloB has the highest activity for short chain ethers (compounds 1-3) with some tolerance
for branching at the first carbon beyond the ester carbonyl (compounds 7-9), though extensive
branching strongly reduces activity (compound 10). Remarkably, GloB is also tolerant of the
extreme steric bulk introduced with the phenoxyacetic acid substrate if the substrate contains an
oxygen or sulfur ether (compound series 11). GloB exhibits a strong preference for oxygen at the
β-position to the carbonyl over the γ-position but is indifferent to the positioning of sulfur. While
GloB has a wider range of catalytic specificities, FrmB exhibits lower overall and narrower
range of catalytic specificity. FrmB is generally capable of hydrolyzing unbranched substrates
with little regard for chain length or the end of chain bulk (compound series 1-3, 11). Branching
at the position following the ester carbonyl (compound series 7-9, 12) is deleterious to FrmB
activity. When oxygen is included in the chain, positioning at the β-position to the carbonyl is
strongly preferred over the γ-position.
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4.4.4 Importance of substrate specificity in vivo.
While in vitro enzymatic substrate profiling is informative for how individual enzymes activate
prodrugs, it does not necessarily reflect the complex biochemical processes happening in vivo,
where additional cellular esterases may impact overall compound activation. We designed a live,
single-cell assay to measure the real-time activation of pro-fluorescent substrates. S. aureus is
loaded onto a microfluidics device and tracked on both fluorescent and phase contrast channels.
Intracellular fluorescence resulting from the rapid introduction of substrate into the chamber was
thus quantified through time.

We selected four pro-fluorescent substrates of varying catalytic specificity against FrmB and
GloB to observe in our microfluidics experiments. In vitro, substrate 1O displays high catalytic
specificity for both FrmB and GloB, 3C displays moderate catalytic specificity for FrmB and
GloB, 5O has moderate catalytic specificity against GloB but poor catalytic specificity against
FrmB, and 9C has poor catalytic specificity against both GloB and FrmB. Comparing the
activation of these substrates through time, we find that our in vitro catalytic specificity
determination correlates well with our in vivo activation rates (Figure 3, supplemental movies 14). Compound 1O, which exhibits high catalytic specificity for GloB and FrmB reaches
fluorescence saturation within the initial time point observed. Compound 3C, which has
moderate catalytic specificity for both GloB and FrmB, slowly activates over the duration of the
experiment, and 5O and 9C, which have moderate to poor catalytic specificity against both GloB
and FrmB never appreciably activate during the 30 minutes of observation (Figure 3). As
fluorescent activation is quantified per cell, we can also assess the uniformity of prodrug
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activation across the population. We observe remarkably homogenous activation of prodrugs
across all observed cells (Figure 3).

4.4.5 Three-dimensional structure of FrmB
To establish the structural basis for FrmB and GloB substrate specificity and enable future
structure guided design of protherapies, we solved the three-dimensional structures of both S.
aureus FrmB and GloB. S. aureus FrmB was solved at 1.60 Å using molecular replacement with
the low-temperature active alkaline esterase, est12 (PDB ID: 4RGY) as a search model (41).
Refinement parameters and statistics are displayed in Table S6. A single dimer of FrmB is
observable in the asymmetric unit, matching the apparent molecular weight of FrmB as we have
observed via size exclusion chromatography. The overall fold of FrmB is characteristic of the α/β
hydrolase fold. Six parallel β-strands and one anti-parallel β-strand pair form a central eight
stranded β-sheet, which is encompassed by α-helices (Figure 4A). One monomer of FrmB has
electron density for a single magnesium ion, whereas the second monomer has two magnesium
present.

A structural similarity search was performed using the DALI server to identify proteins related to
SaFrmB. The structure of SaFrmB was most similar to the molecular replacement model, Est12
from deep sea bacteria (PDB ID 4RGY, root mean squared deviation (r.m.s.d.) = 1.020 Å), but
also had similarity to the ferulic acid esterase BiFae1A from Bacteroides intestinalis (PDB ID
5VOL, r.m.s.d. = 1.137 Å) and the tributyrin esterase, estA, from Streptococcus pneumonia
(PDB ID 2UZ0, r.m.s.d. = 1.329 Å) (54, 55). All structures display strong structural conservation
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including the positioning of the prototypic serine hydrolase catalytic triad: Ser120, Asp204, and
His233 (S. aureus) (Figure S7). The most striking difference between the related structures is the
flexible cap domain, implicated in substrate specificity of estA and est12 (41). While this
manuscript was in preparation, an independent structure of FrmB was solved (53). The two
structures are nearly identical (PDB ID 6ZHD, r.m.s.d = 0.433 Å), with slightly differential
positioning of the capping domain.
We compared SaFrmB to its closest human ortholog, human esterase D (PDB ID 3fcx), finding
moderate structural similarity both in the overall fold (r.m.s.d = 4.625 Å) and in the positioning
of the catalytic triad. However, SaFrmB and human esterase D notably differ in the solventaccessible surface around the active site, suggesting the potential for distinct substrate utilization,
primarily driven by differential positioning of the cap domain (Figure 4B).

We modeled the highest catalytic specificity substrate of FrmB, 1O, onto the active site of FrmB.
Serine hydrolases classically bind the substrate carbonyl oxygen in an oxyanion hole and
substrate hydrolysis is initiated through attack of the catalytic serine on the ester carbonyl. The
docking of 1O on FrmB mimics the initial state of a serine hydrolase reaction, with the carbonyl
oxygen buried and the catalytic serine poised for attack (Figure 4C). The pocket directly next to
the oxyanion hole is relatively narrow, suggesting that steric hindrance explains FrmB’s poor
ability to hydrolyze branched substrates. The active site pocket extends and opens significantly
after passing by the oxyanion hole, supporting FrmB’s ability to hydrolyze substrates with large
steric groups far from the carbonyl carbon such as 11O.
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4.4.6 Three-dimensional structure of GloB
We also solved the structure of SaGloB 1.65 Å, using selenomethionine (SeMet)-substituted
GloB and molecular replacement using the metallo-β-lactamase, TTHA1623, from Thermus
thermophilus as a search model. Final structural refinement parameters and statistics are
presented in Table S6. Four monomers of SaGloB are observed in the asymmetric unit with each
displaying crystallographic symmetry. SaGloB exhibits the classic αβ/βα-fold that defines the
metallo-β-lactamase fold proteins, including glyoxalase II enzymes (Figure 5A).
As with SaFrmB, a DALI server search was performed to identify proteins structurally similar to
SaGloB. SaGloB displays extremely high similarity to the unusual type II glyoxalase, YcbI from
Salmonella enterica (PDB ID: 2XF4, r.m.s.d = 0.898 Å), the molecular replacement search
model TTHA1623 from Thermus thermophilus (PDB ID: 2ZWR, r.m.s.d. = 0.767), and to the
Arabidopsis thaliana glyoxalase II (PDB ID: 1XM8, r.m.s.d = 1.165 Å), with the exception that
AtGloB has a 50 amino acid C-terminal extension (Figure S8A) (42, 37, 56). Also consistent
with previously observed GloB structures, SaGloB shows clear electron density for two zinc
molecules coordinated by six histidine residues and two aspartate residues (Figure S8B). Density
for a water molecule is also visible and appears to be coordinated by the two zinc atoms, as
observed for human glyoxalase II (57).

Overlaying S. aureus GloB with Homo sapiens GloB (PDB: 1qh5) reveals that the two structures
are remarkably similar (r.m.s.d = 1.249 Å), with a few notable exceptions. HsGloB has two
extensions – one a 34 amino acid insertion, the other a 32 amino acid C-terminal extension, both
of which form helix-turn-helices that abut the active site (Figure 5B) (57). On the opposite side
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of the active site, SaGloB has a 19 amino acid flexible loop which is partially observed in the
electron density. This loop is positioned such that it may cover the active site or at the very least
sterically hinder substrate access (Figure 5B). Overall, these differences between HsGloB and
SaGloB suggest differential substrate utilization between S. aureus and humans.

We modeled the highest catalytic specificity substrate for GloB, 1O , onto our structure.
Autodock places 1O with the carbonyl oxygen directly next to the active site water (Figure 5C).
The GloB active site channel appears moderately wide, explaining why extensively branched
substrates are not tolerated. Towards the end of the active site channel, GloB appears to form a
tunnel. This is tunnel is not reached by substrate 1O, but presumably would be occupied in more
sterically bulky substrates such as 11O. One arm of this tunnel is comprised of the highly
flexible loop which is only partially visible in our electron density suggesting that during
catalysis this loop may be movable to accommodate larger substrates such as 11O.

4.4.7 Esterase specificity of human and mouse sera
We sought to evaluate whether ester promoieties could be designed for microbe-specific
activation. Using the same 32-compound fluorescent substrate library, we determine each
substrate’s serum half-life. Both reconstituted and fresh sera function comparably in their
activity and substrate preferences (Figure S9).

159

We next proceeded to perform full kinetic profiling of lyophilized human sera. As sera is a
mixture of multiple proteins instead of a single protein species, we are unable to obtain true kcat
values. Instead, we report a modified catalytic specificity, which is the Vmax/Km, normalized to
the total amount of protein added to the assay (Figure S10A). As we observed for FrmB and
GloB (Figure S10B, C), human sera has highest catalytic specificity for oxygen and sulfur ethers.
However, as opposed to FrmB and GloB, human sera is relatively uniform in its catalytic
specificity across the substrate library. Short chain substrates exhibit the highest catalytic
specificity, and though branching slightly reduces the catalytic specificity, it is not to the same
extent as with FrmB. The substrates displaying the poorest catalytic specificity are universally
the carbon series, with added branching resulting in the decreased substrate utilization.

As murine models are frequently used in the development and testing of novel pharmaceuticals,
we wanted to additionally characterize the substrate preferences of mouse sera. Notably, mice
are well known for their extremely active and broad serum esterase activity. Indeed, we find that
mouse sera exhibits on average 100-fold more catalytic specificity per mg serum protein than
human sera (Figure S10D, S11). However, this increase in catalytic specificity is not uniform
across the substrate library. Human sera underperforms on the carbon series, and does
comparatively better on the oxygen and sulfur ethers (Figure S11B). Thus, use of mouse sera
alone is likely insufficient to predict prodrug human serum stability and accurately model human
pharmacokinetics and dynamics.

160

Finally, we wanted to compare how GloB and FrmB substrate specificities could be used to drive
microbe-targeted prodrugs. As each esterase is likely to encounter multiple potential substrates in
vivo, we utilized our modified catalytic specificity (Vmax/Km) as a comparator. We performed
pairwise analysis for each combination of FrmB and GloB against human and mouse sera
(Figure 6A-D). The exact enrichment of catalytic specificity for microbial esterases compared to
serum esterases that will result in a host-resistant prodrug is difficult to estimate. Using a cutoff
of 210-fold enrichment in catalytic specificity for the microbial enzymes over the serum enzymes,
FrmB displays a preference over human sera for two compounds: 3C and 6C, whereas GloB
displays a preference for 6 compounds: 2S, 3C, 10C, 11C, 11O, and 11S (Figure 6E).
Conversely, mouse sera is able to hydrolyze all compounds within this cutoff. Lowering the
cutoff to a 25-fold enrichment in catalytic specificity over mouse sera, FrmB and GloB both are
more specific for compound 2S, and GloB additionally displays specificity for compound 11O.
4.5

Discussion

Targeted microbial delivery and activation of lipophilic ester prodrugs is a highly desirable
strategy to enable the expansion of druggable targets within bacteria while simultaneously
improving drug selectivity. Identification of microbe-specific pro-moieties is crucial to this goal.
Here, we have demonstrated that S. aureus uses two discrete esterases, FrmB and GloB, to
activate the carboxy ester prodrug, POM-HEX. FrmB and GloB both exhibit distinct ester
substrate specificities, which are supported by the structure of their active sites. Importantly,
enzymatic substrate specificity correlates with the rate of cellular ester activation. Accordingly,
simple modifications to ester prodrugs are sufficient to change their rates of activation in vivo.
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Simple ester modifications can also change the pattern of prodrug activation. For the
development of microbially targeted ester prodrugs to be feasible, compounds need to be stable
against human enzymes. Here we demonstrate that human sera has distinct ester substrate
preferences, and that both FrmB and GloB utilize substrates differentially from human sera. How
microbes beyond S. aureus activate prodrugs, as well as the substrate specificities of pathogenic
and commensal microbes remains an important, open question which will dictate how narrow
spectrum an ester prodrug will be. As microbe-specific prodrugs begin to enter clinical
development, careful attention needs to be paid to the models used to establish the
pharmacokinetic/pharmacodynamic profiles and efficacy of ester prodrugs. Our studies indicate
that mice are an inadequate model for ester prodrug activation and therapeutic efficacy in
humans. This work paves the way for structure-guided development of S. aureus-specific
prodrugs and establishes a pipeline for the identification of microbial prodrug activating
enzymes. We anticipate that these approaches will not only guide the development of novel
antimicrobials, but also aid in the development of in vivo imaging for diagnostic purposes.

162

4.6 Figures

Figure 1 Prodrug activation model and proposed mechanism. Carboxy ester promoieties highlighted in green.
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Figure 2 Forward and reverse genetics approaches identify FrmB and GloB as potential POM-prodrug
hydrolases. (a) Reverse genetics identification of potential prodrug activating enzymes. (b) POM-HEX
susceptibility of identified potential prodrug activating enzymes from (a). (c) Forward genetic screen approach. (d)
POM-HEX susceptibility of POM-HEX resistant staphylococci. (e) Mutations identified by whole-genome
sequencing in FrmB and GloB. In all experiments GloB is colored green and FrmB orange. Displayed are the means
of three independent biological experiments.
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Figure 3 Ester promoiety selection impacts in vivo activation rates. Time series of activation of various profluorescent substrates (Figure S5). Profluorescent substrates were added into the microfluidics chamber at t = 10
minutes. Displayed on the right is the quantification of individual cell or cell cluster fluorescence. Faint traces are
individual cells and darker traces represent the mean of a given experiment. Each experiment was performed in
biological duplicate. Error bars denote SD.
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Figure 4 Three-dimensional structure of FrmB. (a) overall fold, alpha helices colored in orange and β-strands
colored in purple. (b) comparison between SaFrmB (orange) and the closest human ortholog, estD (gray). Active site
residues denoted in orange spheres. (c) docking of substrate 1O (sticks) in the active site of FrmB. Left, surface
view, red indicates highly hydrophobic and white hydrophilic residues. Right, stick and cartoon view with catalytic
triad annotated.
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Figure 5 Three-dimensional structure of GloB. (a) overall fold, alpha helices colored in green and β-strands
colored in purple. (b) comparison of SaGloB (green) and Human GloB (gray). (c) docking of the substrate 1O
(sticks) in the active site of GloB. Left, partial cartoon view, Right surface view. White represents hydrophilic
residues whereas red represents hydrophobic residues. Zn ions indicated as silver spheres; water indicated as blue
sphere.
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Figure 6 Comparison between microbial esterase and serum esterase catalytic specificity. (a-d) volcano plots of
catalytic specificity. Displayed are the means of three independent experiments. P-values calculated as pairwise ttests with Holm-Sidak correction for multiple comparisons. (a) comparison between human sera and GloB, (b)
human sera and FrmB, (c) mouse sera and GloB, (d) mouse sera and FrmB). (e) structures of ester substrates with
210 enrichment in catalytic specificity for microbial esterases over human serum (left), or 25 enrichment over mouse
serum. Dashed line indicates a p-value of 0.05.
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Figure S1 Conservation of FrmB and GloB within S. aureus. (a) WhatsGNU analysis of GloB and FrmB.
Control genes, argG – argininosuccinate synthase, fba- Fructose-bisphosphate aldolase, menD – 2-succinyl-5enolpyruvyl-6-hydroxy-3-cyclohexene-1carboxylate synthase, menC- o-succinylbenzoate synthase. GNU stands for
gene novelty unit and is a count of how many sequences in the database have an exact match to the queried
sequence, with higher counts indicating sequence conservation. Strains across the x-axis are representative strains
from the 18 S. aureus colony complexes which were used to query the S. aureus database. (b, c) MAFFT alignment
of GloB (b) and FrmB (c) sequences across the S. aureus sequence database.
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Figure S2 Phylogenetic tree of FrmB and GloB. Sequences of GloB, FrmB, and RpoB were retrieved from NCBI
using BlastP against each organism. Sequence alignment performed using MUSCLE.
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Figure S3 Enzymatic characterization of GloB and FrmB. (a) SDS-PAGE gel of GloB and FrmB protein
preparations. Expected molecular weights are 23.3 kDa and 29.5 kDa respectively. (b) Glyoxalase II activity assay,
enzymatic conversion of S-lactoylglutathione releases free glutathione and reacts with DTNB resulting in increased
absorbance at 412 nm. (c) 4-nitrophenyl activation results in increased absorbance at 405 nm. Left to right, activity
when supplied 4-nitrophenyl acetate, butyrate, and trimethyl acetate. Displayed in points is the mean of two
technical replicates for individual experiments, bars indicate mean of three independent biological experiments
performed in technical duplicate. Error bars denote SD.
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Figure S4 NMR characterization of POM-HEX activation by GloB and FrmB. Two-dimensional (2D) 1H-31P
HSQC NMR spectra of products following incubation of FrmB, GloB, catalytically inactive (boiled) GloB and
FrmB, or buffer alone. Also included are the 1H-31P HSQC NMR spectra of POM-HEX and HEX. Displayed are
representative traces of three independent experiments. HEMI-POM HEX peak inferred by predicted shift.
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Figure S5 Profluorescent substrate library. Activation of substrates via esterase action results in fluorescence.
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Figure S6 Catalytic specificity of GloB and FrmB. Numbers correspond to the structures displayed in Figure S5,
compounds in the carbon series denoted in orange, oxygen series in blue, and sulfur series in green.
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Figure S7 Structural conservation of FrmB. (a) Overall structural alignment of FrmB (orange) with estA from S.
pneumonia (2UZ0), ferulic acid esterases from B. intestinalis (5VOL), and est12 from deep sea bacteria (4RGY). (b)
positioning of the serine hydrolase catalytic triad, histidine, serine, aspartate.
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Figure S8 Structural conservation of GloB. (a) Overall structural alignment of GloB (green) with YcbI from S.
enterica (2XF4), TTHA1623 from T. thermophilus (2ZWR), and A. thaliana glyoxalase II (1XM8). Zinc
coordinating residues are colored in green spheres. (b) positioning of the Zinc coordinating residues, zinc colored in
green spheres.
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Figure S9 Comparison of esterase activity between fresh and lyophilized human sera. Points represent
individual experiments; bars represent the mean of the four replicates. Error bars denote SD.
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Figure S10 Modified catalytic specificity (pmol fluorescein produced * min-1*µg-1 protein) of human sera,
GloB, FrmB, and mouse sera. X-axis corresponds to compound identities in Figure S5. Carbon containing
compounds indicated in orange, oxygen in blue, and sulfur in green. Displayed are the means of three independent
biological experiments with error bars denoting SD.
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Figure 11 Comparison of mouse and human sera. (a) Modified catalytic specificity (pmol fluorescein produced *
min-1*µg-1 protein) of human and mouse sera. Displayed is a linear regression of the fit between mouse and human
sera. (b) Volcano plot of catalytic specificity. Displayed are the means of three independent experiments. P-values
calculated as pairwise t-tests with Holm-Sidak correction for multiple comparisons. Dashed line indicates a p-value
of 0.05.
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4.7 Tables
Table S1 Half maximal inhibitory concentration (IC50) values for POM-HEX against predicted prodrug activating esterases. * p<0.05, ** p<0.01, *** p<0.005,
**** p<0.0001

SAUSA300 gene

Newman gene

Parental Strain

StrID
(NARSA)

Pan gene
symbol

JE2
NE145

SAUSA300_0742

NWMN_0727

SAUSA300_1902

NWMN_1859

SAUSA300_2173

NWMN_2121

NE223

SAUSA300_1285

NWMN_1303

NE293

SAUSA300_2515

NWMN_2477

SAUSA300_1505

NWMN_1449

SAUSA300_0142

NWMN_0084

SAUSA300_2564

NWMN_2528

SAUSA300_2473
SAUSA300_0581
SAUSA300_0299
SAUSA300_1993

NWMN_2434
NWMN_0561

SAUSA300_1752

NWMN_1700

SAUSA300_0312

NWMN_0254

NWMN_1947

0.40

Adjusted
P-value

GO term

N/A

Parental Strain

Exonuclease ABC, A
subunit

carboxylic ester
hydrolase activity,
carboxylesterase
activity
phosphoric diester
hydrolase activity

ns

0.9999

0.700

0.066

ns

0.9101

1.39

0.29

ns

0.9997

1.41

0.64

ns

0.9997

1.73

0.48

ns

0.9997

10.6

3.2

****

<0.0001

1.61

0.81

ns

0.9999

estA, frmB

6.28

2.25

****

<0.0001

fruC

1.56
1.62
1.64
1.67

0.51
0.55
0.56
0.52

ns
ns
ns
ns

>0.9999
0.9999
0.9998
0.9998

hsdM2

1.73

0.53

ns

0.9996

Hypothetical Alkaline
Phosphatase
Hypothetical protein
Hypothetical protein
PfkB family kinase
type I restrictionmodification system,
M subunit

psuG

1.73

0.51

ns

0.9997

Hypothetical protein

truA

gbaA

NE478

phnE

NE532

NE949
NE1039

Predicted function

0.17

gloB

NE621
NE812
NE937

1.54

Significantly
different from
WT (JE2)?

1.46

NE377

NE503

POM-HEX
IC50 SD
(µM)

uvrA

NE202

NE355

POM-HEX
IC50 (µM)
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Hypothetical protein
tRNA pseudouridine
synthase A
ABC transporter,
ATP-binding protein
Transcriptional
regulator, TetR
family
Hydroxyacylglutathio
ne hydrolase
Phosphonate ABC
transporter,
permease protein
Tributyrin esterase

phosphatase
phosphatase
carboxylic ester
hydrolase activity
hydroxyacylglutathion
e hydrolase
phosphoric diester
hydrolase activity
carboxylic ester
hydrolase activity
phosphatase
phosphatase activity
phosphatase activity
phosphatase
phosphoric diester
hydrolase activity
carboxylic ester
hydrolase activity

SAUSA300 gene

Newman gene

SAUSA300_0538
SAUSA300_1792

NWMN_0515
NWMN_1735

SAUSA300_0421

NWMN_0414

StrID
(NARSA)

Pan gene
symbol

POM-HEX
IC50 (µM)

POM-HEX
IC50 SD
(µM)

Significantly
different from
WT (JE2)?

Adjusted
P-value

capD

1.54
1.84

0.41
0.40

ns
ns

>0.9999
0.9994

Predicted function
NAD-dependent
epimerase/dehydrat
ase family protein
Hypothetical protein

2.15

0.48

ns

0.9938

Hypothetical protein

2.08

0.54

ns

0.9986

saeS

2.07

0.53

ns

0.9986

phoP

2.18

0.41

ns

0.9932

Hypothetical protein
Sensor histidine
kinase SaeS
Alkaline
phosphatase
synthesis
transcriptional
regulatory protein

2.20

0.54

ns

0.9927

accC

1.75
1.48

0.70
0.23

ns
ns

0.9996
>0.9999

pdhD

1.23

0.81

ns

0.9993

hlgB

1.37

0.19

ns

0.9997

NE1071
NE1173
NE1225
SAUSA300_0214

NWMN_0156

SAUSA300_0690

NWMN_0674

NE1238
NE1296
NE1486

SAUSA300_1639

NWMN_1586

SAUSA300_0840

NWMN_0808

SAUSA300_1563
SAUSA300_2508

NWMN_1507

SAUSA300_0996

NWMN_962

SAUSA300_2367

NWMN_2320

NE1505
NE1519
NE1547
NE1610
NE1682
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Hypothetical protein
Acetyl-CoA
carboxylase, biotin
carboxylase
Hypothetical protein
Dihydrolipoamide
dehydrogenase
Gamma-hemolysin
component B

GO term
phosphatase activity
phosphatase activity
carboxylic ester
hydrolase activity,
carboxylesterase
phosphoric diester
hydrolase activity
phosphatase

phosphoric diester
hydrolase activity
phosphoric diester
hydrolase activity
phosphoric diester
hydrolase activity
phosphatase activity
phosphoric diester
hydrolase activity
phosphatase

Table S2 Genotype and phenotype of POM-HEX resistant S. aureus. Displayed are the whole genome sequencing mutations that have been verified. Called
mutations that were not observed via confirmatory Sanger sequencing are excluded.
Gene
(Newman)
NWMN_1449
(gloB)
NWMN_2528
(estA, frmB)

WT_SAUR

R1

R2

R3

R5

R6
c.376G>T
p.Val126Leu

R7

R8
c.430T>A
p.Phe144Ile

R9
c.433G>A
p.Ala145Thr

c.40G>C
p.Gly14Arg
c.1472G>T
p.Arg491Met

NWMN_0144
NWMN_0240
c.23A>C
p.Asn8Thr

NWMN_0309
NWMN_0471
(tilS)
NWMN_0523
(sdrC)
NWMN_0564
NWMN_0954
NWMN_1152
NWMN_1311
(lysA)
NWMN_1425
(recN)
c.17G>A
p.Arg6His

NWMN_1655
NWMN_1735
NWMN_1754
NWMN_2040
(pdp)

c.23A>C
p.Asn8Thr

c.23A>C
p.Asn8Thr

c.17G>A
p.Arg6His

c.1412C>T
p.Ala471Val

c.1412C>T
p.Ala471Val

1.921

6.337

5.932

9.561

10.54

3.752

11.09

10.71

16.96

17.71

1.111

0.8778

0.7325

0.4846

6.261

2.594

4.974

6.602

7.264

10.65

NWMN_2253
NWMN_2388
POM-HEX
IC50 (µM)
Std.
Deviation

R4

c.1412C>T
p.Ala471Val
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Gene
(Newman)
NWMN_1449
(gloB)
NWMN_2528
(estA, frmB)
NWMN_0144

R10
c.70G>T
p.Val24Phe

R11
c.166C>T
p.His56Tyr

R12
c.326C>A
p.Pro109His

R14
c.70G>T
p.Val24Phe

R15
c.289C>T
p.Gln97*

R16

R17

c.218_219insCATATGCCATGTTAGCA
p.Met74fs

c.366G>A p.Met122Ile

c.23A>C
p.Asn8Thr

c.23A>C
p.Asn8Thr

c.23A>C
p.Asn8Thr

c.23A>C p.Asn8Thr
c.760_765dupTTTAAT
p.Phe254_Asn255dup

c.2299A>G
p.Asn767Asp
c.230_231delCT p.Ser77fs
c.359C>A
p.Pro120His

NWMN_0954
NWMN_1152
NWMN_1311
(lysA)
NWMN_1425
(recN)
NWMN_1655

c.17G>A
p.Arg6His

NWMN_1735
NWMN_1754
NWMN_2040
(pdp)

c.426G>T
p.Leu142Phe

c.17G>A
p.Arg6His
c.2754C>A
p.Phe918Leu

c.17G>A
p.Arg6His

c.17G>A
p.Arg6His

c.17G>A p.Arg6His
c.232T>A p.Leu78Ile
c.1412C>T
p.Ala471Val

NWMN_2253
c.195G>T
p.Gln65His

NWMN_2388
POM-HEX
IC50 (µM)
Std.
Deviation

R18

c.432G>T
p.Met144Ile

NWMN_0240
NWMN_0309
NWMN_0471
(tilS)
NWMN_0523
(sdrC)
NWMN_0564

R13
c.70G>T
p.Val24Phe

8.353

31.66

11.47

6.746

4.033

5.61

5.559

3.882

2.788

3.673

32.94

4.009

2.199

1.276

5.394

2.96

1.153

0.538
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Gene
(Newman)
NWMN_1449
(gloB)
NWMN_2528
(estA, frmB)
NWMN_0144
NWMN_0240
NWMN_0309
NWMN_0471
(tilS)
NWMN_0523
(sdrC)
NWMN_0564
NWMN_0954
NWMN_1152
NWMN_1311
(lysA)
NWMN_1425
(recN)
NWMN_1655
NWMN_1735

R19

R20

c.40G>C
p.Gly14Arg

R22

c.366G>A
p.Met122Ile

R23

R24
c.401C>T
p.Pro134Leu

c.356G>A
p.Gly119Asp

c.23A>C
p.Asn8Thr

R25
c.40G>C
p.Gly14Arg

c.23A>C
p.Asn8Thr

c.23A>C
p.Asn8Thr

c.1570G>T
p.Asp524Tyr
c.1145C>A
p.Ser382Tyr
c.1130T>C
p.Leu377Ser
c.17G>A
p.Arg6His

c.17G>A
p.Arg6His

c.17G>A
p.Arg6His

c.17G>A
p.Arg6His

c.17G>A
p.Arg6His

c.232T>A
p.Leu78Ile

NWMN_1754
NWMN_2040
(pdp)
NWMN_2253
NWMN_2388
POM-HEX
IC50 (µM)
Std.
Deviation

R21

5.678

3.847

3.923

4.568

3.794

8.396

3.519

2.073

1.061

1.087

4.194

0.903

1.049

0.112
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Table S3 Half maximal inhibitory concentration (IC50) values for POM-HEX against transposon mutations in genes identified by whole-genome
sequencing.

SAUSA300 gene

Newman gene

StrID
(NARSA)

Pan gene
symbol

JE2

Parental Strain

1.54

0.40

1.43

0.15

ns

0.9998

1.65

0.72

ns

0.9998

Adjusted Pvalue

Predicted function
N/A

NWMN_1723

SAUSA300_0671

NWMN_0654

SAUSA300_1505

NWMN_1449

NE377

gloB

10.6

3.2

****

<0.0001

SAUSA300_1708

NWMN_1655

NE386

rot

1.40

0.15

ns

0.9997

protoporphyrinogen oxidase
ABC transporter, ATP-binding
protein, MsbA family
hydroxyacylglutathione
hydrolase
staphylococcal accessory
regulator Rot

SAUSA300_2564

NWMN_2528

NE503

estA, frmB

6.28

2.25

****

<0.0001

tributyrin esterase

SAUSA300_1452

NWMN_1410

NE520

proC

1.47

0.75

ns

0.9999

SAUSA300_0201

NWMN_0144

1.60

0.52

ns

>0.9999

SAUSA300_1085

NWMN_1101

1.64

0.57

ns

0.9998

SAUSA300_2105

NWMN_2057

1.70

0.55

ns

0.9997

1.46

0.25

ns

0.9999

NWMN_0762

SAUSA300_1290

NWMN_1308

SAUSA300_0414

NWMN_0407

SAUSA300_0028

hemY

POM-HEX
IC50 SD (µM)

SAUSA300_1781

SAUSA300_0778

NE64

Significantly
different from
WT (JE2)?

POM-HEX
IC50 (µM)

NE364

NE541
NE874
NE929

mtlF

NE1051

pyrroline-5-carboxylate
reductase
peptide ABC transporter,
permease protein
conserved hypothetical protein
PTS system, mannitol specific
IIBC component

NE1118

dapD

1.69

0.59

ns

0.9997

hypothetical protein
tetrahydrodipicolinate
acetyltransferase

NE1127

lpl4

1.72

0.62

ns

0.9997

tandem lipoprotein

NE1283

tnp

2.10

0.36

ns

0.9986

putative transposase
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Table S4 Michaelis Menten parameters for SaGloB
Vmax (pmol*min1
*μg protein-1)
Substrate
1C
2C
3C
6C
7C
8C
9C
10C
11C
1O
2O
3O
4O
5O
6O
7O
8O
9O
10O
11O
12O
1S
2S
3S
4S
5S
6S
7S
8S
9S
11S
12S

Value
0.497
0.292

SEM
0.074
0.051

0.444

0.130

0.351

0.113

217
46.4
4.21
1.39
0.731
2.91
23.1
1.01
2.54

41.5
9.95
0.515
0.15
0.15
0.26
4.50
0.149
0.83

1.04
14.9

0.190
3.92

0.18
4.19
0.722
1.02

0.049
1.17
0.150
0.40

Km (μM)
Value
6.23
18.3
>50
48.0
>50
84.9
>50
>50
>50
73.5
42.0
8.41
18.0
21.2
12.0
20.5
15.5
55.5
>50
>50
36.9
32.5
>50
>50
>50
31.7
65.8
49.5
79.8
>50
>50
>50

SEM
3.39
9.0
29.5
47.9

25.7
19.8
3.52
5.37
11.8
3.3
10.9
6.8
36.5

15.4
20.4

21.1
34.9
21.4
56.2

Vmax/Km (pmol*min1
*mg GloB-1µM-1)
Value
79.9
15.9
10.4
9.24
6.43
4.13
0.28
0.79
0.88
2960
1103
500.
77.2
34.5
242
1130
64.9
45.7
2.96
248
28.2
457
422
31.0
126
5.60
63.7
14.6
12.8
11.1
20.5
1.86

SEM
22
5.6
1.0
4.40
0.31
2.36
0.01
0.07
0.04
1620
503
146
27.3
12.7
76.8
412
22.0
22.8
0.22
21.9
12.3
192
39.5
2.34
15.2
2.34
33.6
7.01
7.19
0.86
2.87
0.03

kcat (10-3 s-1)
Value
0.0744
0.0436

SEM
0.0111
0.0076

0.0663

0.0194

0.0524

0.0169

32.5
6.93
0.630
0.208
0.109
0.435
3.45
0.151
0.380

6.2
1.49
0.077
0.022
0.023
0.038
0.67
0.022
0.125

0.156
2.22

0.028
0.59

0.0266
0.627
0.108
0.153

0.0074
0.176
0.022
0.060

kcat/Km (M-1 s-1)
Value
11.9
2.38
1.55
1.38
0.961
0.618
0.042
0.118
0.132
442
165
74.8
11.5
5.15
36.1
168
9.71
6.84
0.442
37.1
4.21
68.4
63.1
4.63
18.8
0.840
9.53
2.18
1.92
1.66
3.07
0.278
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SEM
3.28
0.845
0.15
0.658
0.046
0.353
0.002
0.011
0.005
242
75.3
21.9
4.08
1.91
11.5
61.7
3.30
3.41
0.033
3.27
1.84
28.8
5.91
0.350
2.27
0.351
5.03
1.05
1.08
0.128
0.429
0.005

kcat/kuncat (103)
Value
21.2
17.2

SEM
16.3
7.9

12.7

33.4

79.1

26.3

38.6
19.4
4.91
8.42
17.0
5.76
23.6
6.80
14.6

15.3
11.8
1.41
5.18
24.1
1.09
21.2
1.80
16.0

1.28
11.4

0.67
13.6

4.35
12.9
7.86
9.01

2.45
7.8
3.04
7.64

((kcat/Km)/kuncat) (109 M-1)
Value
3.41
0.940
0.256
0.265
0.109
0.932
0.0244
0.0752
0.261
0.525
0.462
0.584
0.468
0.803
0.479
1.15
0.437
0.264
0.0715
0.0411
0.0348
0.351
0.0529
0.0259
0.278
0.137
0.197
0.159
0.113
0.0215
0.0662
0.0310

SEM
4.81
0.881
0.061
1.133
0.041
0.549
0.0020
0.0392
0.006
0.595
0.595
0.400
0.964
2.038
0.325
1.95
0.267
0.439
0.0346
0.0369
0.0438
0.666
0.0665
0.0088
0.057
0.116
0.224
0.142
0.136
0.0613
0.0219
0.0005

((Vmax/Km)/kuncat)
(1012pmol*mg GloB1
µM-1)
Value
380
105
28.5
29.6
12.2
104
2.72
8.38
29.1
58.6
51.5
65.0
52.1
89.5
53.4
129
48.7
29.4
7.97
4.58
3.87
39.2
5.90
2.89
30.9
15.3
21.9
17.7
12.6
2.40
7.38
3.46

SEM
536
98
6.8
126.3
4.6
61
0.22
4.37
0.7
66.5
66.4
44.6
107.5
227.2
36.3
217
29.7
48.9
3.85
4.12
4.88
74.3
7.41
0.98
6.4
12.9
25.0
15.9
15.2
6.84
2.44
0.06

Table S5 Michaelis Menten parameters for SaFrmB

Vmax (pmol*min1
*μg protein-1)
Substrate
1C
2C
3C
6C
7C
8C
9C
10C
11C
1O
2O
3O
4O
5O
6O
7O
8O
9O
10O
11O
12O
1S
2S
3S
4S
5S
6S
7S
8S
9S
11S
12S

Value
0.149
0.0637

SEM
0.059
0.0274

5.98
2.04
0.621
0.183

0.677
0.328
0.191
0.038

0.597
2.57
0.163

0.091
0.96
0.031

0.163

0.053

0.505
0.0295
0.629

0.147
0.0030
0.169

Km (μM)
Value
30.4
26.5
>50
>50
>50
>50
>50
>50
>50
30.3
13.9
9.95
30.0
>50
9.17
107
18.3
>50
74.2
>50
>50
>50
>50
>50
52.7
11.1
36.3
>50
>50
>50
>50
>50

SEM
29.5
28.9

8.33
6.76
10.06
15.2
4.66
64.8
9.66
43.6

31.3
3.61
22.3

Vmax/Km (pmol*min1
*mg FrmB-1µM-1)
Value
4.89
2.40
10.2
1.84
1.01
0.314
0.160
0.233
0.682
197
147
62.4
6.12
1.54
65.2
24.0
8.92
7.24
2.20
79.1
3.18
12.5
169
7.79
9.58
2.66
17.3
1.55
2.20
5.38
10.8
1.02

SEM
2.01
0.95
0.64
0.14
0.08
0.012
0.009
0.029
0.062
81.3
48.6
18.9
2.51
0.10
19.4
14.8
3.17
0.31
1.21
2.7
0.26
0.6
14
0.19
4.70
0.83
7.5
0.12
0.24
0.48
1.1
0.07

kcat (10-3 s-1)
Value
0.0280
0.0120

SEM
0.0112
0.0052

1.13
0.385
0.117
0.0345

0.127
0.062
0.036
0.0072

0.112
0.485
0.0307

0.017
0.180
0.0058

0.0307

0.0099

0.0950
0.00556
0.118

0.0277
0.00056
0.032
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kcat/Km (M-1 s-1)
Value
0.921
0.452
1.92
0.347
0.191
0.0591
0.0301
0.0438
0.128
37.2
27.7
11.7
1.15
0.290
12.3
4.52
1.68
1.36
0.414
14.9
0.598
2.36
31.8
1.47
1.80
0.500
3.27
0.292
0.415
1.01
2.04
0.191

SEM
0.379
0.179
0.12
0.026
0.015
0.0022
0.0018
0.0055
0.012
15.3
9.14
3.57
0.47
0.020
3.66
2.78
0.60
0.06
0.227
0.51
0.048
0.11
2.58
0.04
0.89
0.156
1.42
0.023
0.046
0.09
0.21
0.013

kcat/kuncat (103)
Value
7.99
4.74

SEM
16.5
5.38

1.34
1.08
0.911
1.40

0.31
0.49
0.656
1.70

1.49
3.31
1.38

0.48
5.69
0.47

4.97

10.26

1.40
0.910
2.44

0.70
0.187
1.42

((kcat/Km)/kuncat) (109 M1
)
Value
0.263
0.179
0.316
0.0666
0.0217
0.0892
0.0177
0.0279
0.254
0.0442
0.0777
0.0916
0.0467
0.0452
0.163
0.0309
0.0757
0.0525
0.0671
0.0165
0.00493
0.0121
0.0266
0.0082
0.0266
0.0818
0.0674
0.0213
0.0244
0.0131
0.0440
0.0213

SEM
0.557
0.186
0.050
0.0444
0.0133
0.0034
0.0019
0.0194
0.014
0.0377
0.0723
0.0653
0.1118
0.0210
0.104
0.0877
0.0482
0.0076
0.2351
0.0058
0.00115
0.0026
0.0290
0.0009
0.0223
0.0517
0.0633
0.0032
0.0058
0.0435
0.0105
0.0013

((Vmax/Km)/kuncat)
(1012 pmol*mg
FrmB-1µM-1)
Value
SEM
23.3
49.3
15.8
16.5
28.0
4.4
5.90
3.93
1.92
1.17
7.89
0.30
1.56
0.17
2.47
1.72
22.5
1.2
3.91
3.34
6.88
6.40
8.11
5.78
4.14
9.89
4.00
1.86
14.4
9.2
2.73
7.77
6.70
4.27
4.65
0.67
5.94
20.81
1.46
0.51
0.44
0.10
1.07
0.23
2.36
2.57
0.728
0.081
2.36
1.97
7.24
4.58
5.97
5.61
1.88
0.28
2.16
0.51
1.16
3.85
3.89
0.93
1.89
0.12

Table S6 Summary of crystallographic data collection and refinement statistics.

Data Collection
Space Group
Cell dimensions
Wavelength (Å)
Resolution (Å) (highest shell)
Reflections (total/unique)
Completeness (highest shell)
<I/σ> (highest shell)
Rsym (highest shell)
Refinement
Rcryst / Rfree
No. of protein atoms
No. of waters
No. of ligand atoms
R.m.s.d., bond lengths (Å)
R.m.s.d., bond angles (o)
Avg. B-factor (Å2): protein,
water, ligand
Stereochemistry: most
favored, allowed, disallowed

SaFrmB
C2
a= 128.8Å, b= 80.6Å
c=67.1Å, β=114.1o
0.979
36.8-1.60 (1.63-1.60)
145907 / 78193
96.4% (99.1%)
27.1 (4.1)
6.6% (57.3%)

SaGloB (SeMet)
P 1 21 1
a= 93.7Å, b= 44.76Å
c=105.0Å, β=96.7o
1.000
48 - 1.65 (1.71 - 1.65)
102457
96.1 % (88.8 %)

0.156 / 0.179
4164
496
3
0.009
1.34

0.225 / 0.251
6323
431
28
0.007
1.21

25.8, 37.6, 15.9
98.4, 1.6, 0 %
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39.6, 44.9, 47.5
96.2, 3.8, 0 %

Table S7 Michaelis Menten parameters for human sera
Vmax (pmol*min-1*mg
sera-1)
Substrate
1C
2C
3C
6C
7C
8C
9C
10C
11C
1O
2O
3O
4O
5O
6O
7O
8O
9O
10O
11O
12O
1S
2S
3S
4S
5S
6S
7S
8S
9S
11S
12S

Value
1.06
0.356

SEM
0.15
0.191

0.441

0.029

68.6
43.8
11.7
5.88
2.25
11.7
5.73
3.93
4.35
1.46

25.6
10.53
2.81
1.90
0.48
3.82
1.16
0.71
1.18
0.38

4.00
30.5

0.68
9.90

8.80
3.81
0.690

2.92
0.39
0.246

1.60

0.43

Vmax/Km (pmol*min1
*mg sera-1µM-1)

Km (μM)
Value
36.2
71.5
>50
>50
64.18
>50
>50
>50
>50
64.1
40.4
22.2
44.5
35.4
54.6
30.3
27.7
111.7
63.3
>50
42.2
71.8
>50
74.3
27.9
31.0
>50
30.2
>50
>50
>50
>50

SEM
11.5
70.6

8.03

45.8
21.5
14.2
30.9
17.4
35.9
14.9
12.4
48.9
31.8
15.7
43.0
45.0
7.08
26.7
19.7
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Value
0.0293
0.00498
0.00161
0.00121
0.00688
0.000791
0.000581
0.000483
0.000711
1.07
1.09
0.529
0.132
0.0635
0.215
0.189
0.142
0.0389
0.0230
0.122
0.0948
0.425
0.315
0.118
0.137
0.0222
0.0257
0.0528
0.0140
0.0247
0.0190
0.00504

SEM
0.0128
0.00271
0.00022
0.00013
0.00355
0.000062
0.000026
0.000042
0.000027
0.560
0.489
0.198
0.061
0.0274
0.107
0.078
0.057
0.0242
0.0121
0.008
0.0433
0.230
0.025
0.065
0.055
0.0092
0.0025
0.0216
0.0007
0.0021
0.0017
0.00036

((Vmax/Km)/kuncat) (1012
pmol*mg sera-1µM-1)
Value
0.139
0.0328
0.00443
0.00389
0.0130
0.0199
0.00568
0.00513
0.0234
0.0212
0.0507
0.0687
0.0894
0.165
0.0475
0.0216
0.107
0.0250
0.0621
0.00225
0.0130
0.0364
0.00440
0.0111
0.0336
0.0606
0.00886
0.0641
0.0138
0.00532
0.00682
0.00937

SEM
0.315
0.0471
0.00151
0.00381
0.0531
0.0016
0.00045
0.00251
0.0005
0.0230
0.0645
0.0604
0.2420
0.489
0.0503
0.0411
0.077
0.0519
0.2080
0.00158
0.0171
0.0890
0.00472
0.0273
0.0230
0.0510
0.00182
0.0490
0.0015
0.01651
0.00149
0.00062

Table S8 Michaelis Menten parameters for mouse sera
Vmax (pmol*min1
*mg sera-1)
Substrate
1C
2C
3C
6C
7C
8C
9C
10C
11C
1O
2O
3O
4O
5O
6O
7O
8O
9O
10O
11O
12O
1S
2S
3S
4S
5S
6S
7S
8S
9S
11S
12S

Value

SEM

17.6

9.4

3.18

0.66

437
929

135
103

Vmax/Km (pmol*min1
*mg sera-1µM-1)

Km (μM)
Value
>50
>50
>50
53.5
>50
>50
12.3
>50
>50
>50
>50
>50
>50
>50
11.5
25.9
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50
>50

SEM

58.1
8.0

8.65
7.30
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Value
4.56
1.62
0.52
0.33
2.04
1.35
0.26
0.93
0.28
14.01
15.90
57.0
6.76
20.3
38.1
35.8
15.7
6.69
2.93
3.24
11.9
14.2
5.07
9.47
24.2
1.93
12.1
11.9
5.17
1.29
1.97
5.74

SEM
0.51
0.33
0.02
0.16
0.27
0.13
0.08
0.08
0.01
0.83
1.12
43.2
0.21
12.0
15.6
14.1
0.4
0.17
0.14
0.16
0.4
1.4
0.21
0.76
2.6
0.13
0.6
1.1
0.43
0.11
0.10
0.53

((Vmax/Km)/kuncat) (1012
pmol*mg sera-1µM-1)
Value
21.7
10.7
1.43
1.05
3.86
34.0
2.53
9.87
9.34
0.28
0.74
7.41
4.57
52.6
8.42
4.08
11.8
4.30
7.91
0.06
1.64
1.22
0.07
0.88
5.96
5.27
4.16
14.4
5.07
0.28
0.71
10.7

SEM
12.4
5.7
0.13
4.65
4.04
3.3
1.46
4.74
0.18
0.03
0.15
13.17
0.82
214.7
7.39
7.40
0.5
0.36
2.36
0.03
0.15
0.54
0.04
0.32
1.08
0.71
0.41
2.6
0.91
0.89
0.09
0.9

Table S9 Primers used during this study.
NO

NAME

SEQUENCE

USE

1

NWMN_0144_F

TTTTCCTGATCCTGATTCAC

Sanger Sequencing

2

NWMN_0144_R

ATGATGCTTCCATGTTTGTT

Sanger Sequencing

3

NWMN_0306_F

AATACACCGGGTAACACAAC

Sanger Sequencing

4

NWMN_0306_R

CGTTTTGTTGAGCTAATTCC

Sanger Sequencing

5

NWMN_0309_F

ACCATGCTTAAAGGGATTTT

Sanger Sequencing

6

NWMN_0309_R

TGTCACCTAAGTCAACACCA

Sanger Sequencing

7

NWMN_0407 (lpl4nm) _F

CCGTTGGAGATAGGAAGTTA

Sanger Sequencing

8

NWMN_0407 (lpl4nm) _R

TTTGTGCTTCTTTTGAACCT

Sanger Sequencing

9

NWMN_0654_F

GAAAATGGAAGACTGATTGC

Sanger Sequencing

10

NWMN_0654_R

TAATGCATCTGACAAAGTCG

Sanger Sequencing

11

NWMN_0762_F

GGTGAAGTTTTGGACGATAA

Sanger Sequencing

12

NWMN_0762_R

TTTTCATCTGTCCGACTTTT

Sanger Sequencing

13

NWMN_1101_F

TCCACCTATTGGAATTATCG

Sanger Sequencing

14

NWMN_1101_R

AGACGTTCAATTTCAGTGCT

Sanger Sequencing

15

NWMN_1192 (pgsA) _F

TGGGACGAAGTAATTACAGTT

Sanger Sequencing

16

NWMN_1192 (pgsA) _R

ATATCCCCCTTGTATCGTTT

Sanger Sequencing

17

NWMN_1308 (dapD) _F

TCTATTCGTGGAGGTACGAT

Sanger Sequencing

18

NWMN_1308 (dapD) _R

ATCGTATGTGAGCCATTACC

Sanger Sequencing

19

NWMN_1410_F

CGATAAACCTAAACCACTCG

Sanger Sequencing

20

NWMN_1410_R

ATAAACAATGCTTGCCAAAT

Sanger Sequencing

21

NWMN_1505_F

TGAAGGTGAATTAAGCGATG

Sanger Sequencing

22

NWMN_1505_R

TGCTATTCCCAATTTGTTCA

Sanger Sequencing

23

NWMN_1655_F

GAATTGTTGCAATTTAATGGT

Sanger Sequencing

24

NWMN_1655_R

AACGTAATCATGCTCCATTC

Sanger Sequencing

25

NWMN_1679_F

CCATGGGAAAAATTAGACAA

Sanger Sequencing

26

NWMN_1679_R

AAATATCGCCTCACCTTTTT

Sanger Sequencing

27

NWMN_1723 (hemY) _F

GCCGAATACACATCCATTAT

Sanger Sequencing

28

NWMN_1723 (hemY) _R

AACCTTTGTCTCTGCTTCAA

Sanger Sequencing

29

NWMN_1851 (nadC) _F

AGCCATTTTAGCACCATAAA

Sanger Sequencing

30

NWMN_1851 (nadC)_R

TAGAATCCTGTCCTCCTGAA

Sanger Sequencing

31

NWMN_2057 (mtlF)_F

TGTACAACGGTGTTGTTTTG

Sanger Sequencing

32

NWMN_2057 (mtlF)_R

CGGTGAATAGTACGAGAGGA

Sanger Sequencing

33

NWMN_2528_F

ACTGATGCTTTACCAGAAAC

Sanger Sequencing

34

NWMN_2528_R

TCAGCGGTAGTAATAAAGGT

Sanger Sequencing
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Table S10 Accession numbers for the isolates used in WhatsGNU analysis.
Isolate

Bioproject

Biosample

WGS

SRA

AD_3_179

PRJNA512846

SAMN10689346

VYMI00000000

SRR8389007

AD_11_548

PRJNA512846

SAMN10689354

VYMN00000000

SRR8389002

AD_14_565

PRJNA512846

SAMN10689355

VYMO00000000

SRR8389003

AD_16_660

PRJNA512846

SAMN10689358

SJAX00000000

SRR8389044

AD_61_868

PRJNA512846

SAMN10689401

VYNS00000000

SRR11016776

AD_85_830

PRJNA512846

SAMN10689428

VYOK00000000

SRR8389056

AD_96_471

PRJNA512846

SAMN10689447

VYOW00000000

SRR8389016

AD_103_347

PRJNA512846

SAMN10689453

VYPC00000000

SRR8389035

AD_113_782

PRJNA512846

SAMN10689463

VYPL00000000

SRR8389099

SSTI_227_44

PRJNA563582

SAMN12642230

VUGB00000000

SRR11016228

SSTI_228_42

PRJNA563582

SAMN12642226

VUGF00000000

SRR11016232

SSTI_231_2

PRJNA563582

SAMN12642218

VUGN00000000

SRR11016241

SSTI_233_51

PRJNA563582

SAMN12642215

VUGQ00000000

SRR11016244

SSTI_235

PRJNA563582

SAMN12642210

VUGV00000000

SRR11016250

SSTI_241_9

PRJNA563582

SAMN12642203

VUHC00000000

SRR11016198

SSTI_247_75

PRJNA563582

SAMN12642193

VUHM00000000

SRR11016209

SSTI_258_57

PRJNA563582

SAMN12642177

VUIB00000000

SRR11016226

SSTI_290

PRJNA563582

SAMN12642174

VUIE00000000

SRR11016283
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Chapter 5: Conclusion
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5.1 Summary
As the prevalence of multidrug-resistant bacteria and parasites continues to grow, there is an
urgent need to develop novel antimicrobials with new targets. One underdeveloped therapeutic
strategy is targeting microbial metabolism. Metabolic inhibitors are simple to design as substrate
mimics and have multiple druggable options in each organism (1–4). Unfortunately, metabolic
based inhibitors often rely on phosphate or phosphonate residues which are cell impermeable (5–
11). In this work, we add to a growing body of literature supporting the claim that lipophilic
prodrugging strategies can increase the potency and cellular penetrability of phosphonate
antibiotics (6, Chapter 2). However, current lipophilic prodrugging strategies are readily cleaved
by host enzymes, greatly limiting the efficacy of these strategies in the clinic. For the first time,
we have described how lipophilic prodrugs are activated intracellularly by microbial cells (12,
Chapter 3). This key finding allowed us to launch a structure-activity relationship campaign on
the two staphylococcal esterases responsible for prodrug activation, FrmB and GloB (Chapter 4).
In addition to characterizing GloB (Chapter 4) and FrmB (Chapter 4, Appendix A), we also
characterize the substrate specificity of human and mouse sera, demonstrating that simple
modifications to ester prodrugs not only have an impact on rates of in vivo activation, but also
can confer specificity to the location of prodrug activation (Chapter 4). This finding is also
briefly examined for the unicellular parasite, Plasmodium falciparum (Appendix B). Together
these studies lay an important groundwork for the development of targeted prodrug therapies.
Finally, in work parallel to the primary focus of this thesis, we work to understand the origin of
P. falciparum volatile compounds such as the mosquito attractive terpene, α-pinene (Appendix C
and D).
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5.2 Lipophilic prodrug transit
We find that addition of the lipophilic promoiety, pivaloyloxymethyl (POM), to the phosphonate
residues of ERJ significantly increases potency against S. schleiferi and S. pseudintermedius (6).
POM-dependent potency increases have similarly been observed for ERJ, ERJ analogues, and
other phosphonate antibiotics against several other organisms. Presumably, the underlying
mechanism of POM-prodrug increases in potency stems from increased cellular permeability of
phosphonate antibiotics, however it is also feasible that lipophilic prodrugging increases transit
via a yet unknown transporter or siderophore. Supporting the first hypothesis, we find that while
ERJ requires the glycerol-3-phosphate transporter, GlpT, for cellular entry, POM-ERJ can
bypass GlpT mediated transport (Chapter 2). This finding has also been demonstrated in the
gram negative organism, Francisella novicida (7). The exact mechanism by which POM
prodrugs enter cells remains unknown however defining this mechanism will be crucial for
understanding the potential uses and limitations of lipophilic prodrugs.
One exciting application of lipophilic prodrugs is the targeting of drugs to specific cell types.
How lipophilic prodrugs enter cells, whether through passive permeability or through enzyme
mediated transit, remains unknown. Understanding how prodrugs enter cells will determine how
broadly lipophilic prodrugging strategies can be applied. For instance, if lipophilic prodrugs truly
passively enter cells, any lipophilic environment could harbor a prodrug. This is especially
relevant when applying lipophilic prodrugs to the clinic and would impact the dosing strategies
depending on the lipid content of each individual patient. Simple experiments utilizing massspectrometry to track prodrug localization in whole liposomes as opposed to washed and lysed
liposomes would serve to address this question. Similarly, development of liposome transit
assays will allow an understanding of how lipid composition impacts prodrug transit.
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5.3 The (lack of) efficacy of lipophilic prodrugs on gramnegative bacteria
Consistently we and others have observed that POM-ERJ is ineffective against E. coli and other
gram-negative organisms (K. pneumoniae, S. typhimurium, S. sonnei, S. marcescens, and B.
tahilandensis) (6). Notably, the compound POM-ERJ is ineffective against E. coli despite the
activated compound, ERJ, displaying potent activity both against whole-cell E. coli and ERJ’s
target, EcDXR (6) (Chapter 2). POM-HEX is similarly ineffective against whole cell E. coli,
though whether HEX has activity against EcENO remains unknown. Three hypotheses exist
which explain this lack of activity (Figure 1). First, gram negative organisms may not maintain
the enzymes responsible for prodrug activation resulting in no accumulation of activated drug in
vivo. Second, POM-prodrugs may not effectively transit the double membrane of gram-negative
bacteria. The final hypothesis is that POM-prodrugs are activated by gram-negative bacteria but
are not activated in the correct cellular location to achieve target inhibition. In the following
section we will discuss the cases for and against each of these hypotheses. Defining why POMprodrugs do not have efficacy on gram-negative organisms will ultimately determine how
efficacious targeted lipophilic prodrugging strategies will be as antimicrobials.

Hypothesis 1) POM-prodrugs are not activated in vivo by gram-negative organisms. We
have shown that in the gram-positive organism, S. aureus, two carboxylesterases, FrmB and
GloB, catalyze the removal of the first POM-moiety in di-POM prodrugs (Chapter 4). At least
one additional enzyme is required for the final conversion from the mono-POM-prodrug to the
fully deprotected version of this compound, though the identity of this protein is unknown. GloB
and FrmB both have orthologs in E. coli, suggesting that at least the first step in prodrug
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activation may be possible in E. coli. Low conservation of FrmB and GloB between E. coli and
S. aureus raises the possibility that the substrate specificities of these two enzymes vary
disallowing prodrug activation in E. coli (Chapter 4). We have expressed each SaFrmB and
SaGloB individually in E. coli using classical IPTG inducible promoters and protein expression
vectors and find that E. coli remains insensitive to POM-ERJ. It remains possible that the final
enzyme(s) in POM-prodrug activation are not present in E. coli.

Hypothesis 2) POM-prodrugs do not diffuse through the periplasm. POM-prodrugs are
hypothesized to bypass active transit mechanisms and diffuse freely into cells. In part, this
hypothesis is founded on the GlpT independent transit of POM-prodrugged fosmidomycin and
fosmidomycin analogues (6, 7). This hypothesis is also grounded in chemistry, as POM-prodrugs
of small metabolites often have cLogP values > 1.5, reflective of the lipophilic nature of POMprodrugs. As a result, one would imagine that in single membrane cellular environments, the
POM-promoiety has a rate of transition between the being exposed extracellularly and
intracellularly, while similarly transitioning between the aqueous environment and the lipophilic
environment. Rapid hydrolysis of intracellular POM-prodrugs would thus result in an
accumulation of activated drug inside the cell.
In gram-negative organisms which have two membranes separated by periplasmic space, pure
diffusion of lipophilic compounds may result in no activation (Figure 1). An extracellular
lipophilic prodrug entering a cell must first enter the extracellular membrane, subsequently
diffuse into and across the periplasm before imbedding into the intracellular membrane, flipping
from the periplasmic side of the intracellular membrane to the intracellular side of the
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membrane, and finally dissociate into the cytoplasm for cleavage. For extremely lipophilic
groups, the equilibrium between the extracellular membrane and periplasmic space would
heavily favor the compound staying imbedded in the membrane. Any compound reaching the
intracellular membrane would also heavily favor staying in that membrane. Given an infinite
time, eventually the concentrations of POM-prodrug in each membrane would equilibrate,
however this equilibration may not occur on a biologically relevant timescale.
Perhaps the strongest evidence against this hypothesis is the potent anti-E. coli activity of a
lipophilic prodrug of FR900098 (13). The designed FR900098 prodrug is similarly lipophilic to
POM-ERJ (cLogP 2.14 and 1.44 respectively), however the promoieties are highly divergent.
This suggests that compound lipophobicity alone does not prevent drug penetrance across the
gram-negative double membrane.
Hypothesis 3) POM-prodrugs are activated in periplasmic space and cannot cross the inner
membrane. Several enzymes localize to the gram-negative periplasm, including at least three
hydrolases (14). This raises the possibility that these hydrolases can activate, either fully or
partially, POM-compounds. As even partially deprotected phosphonate molecules are membrane
impermeable, any compound partially activated would be stuck in the periplasmic space (Figure
1) (15). Perhaps the strongest evidence against this hypothesis is that in E. coli the glycerol-3phosphate transporter (GlpT) is localized to the inner membrane of E. coli (16, 17). This would
suggest that in the case of POM-ERJ, conversion to ERJ in the periplasm would still result in
inhibition of E. coli. One potential explanation remedying this disagreement is that partial
conversion of POM-ERJ, for example to hemi-POM-ERJ, would likely be sufficient to prevent
GlpT mediated transport while simultaneously leaving the molecule membrane impermeable.
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With all three hypotheses addressed, POM-prodrug activation by two additional organisms needs
to be considered. Mycobacterium tuberculosis, a gram intermediate, and Francisella novicida, a
lightly stained gram-negative, are both killed by POM-prodrugs (7, 18). The cell wall of M.
tuberculosis most closely resembles that of gram-positive organisms. However, the
peptidoglycan layer of M. tuberculosis often accumulates a layer of lipids forming a
pseudoperiplasm (19). This lipid layer is sufficient to retain gram-stain, though whether this
layer recapitulates the typical gram-negative outer membrane for POM-prodrugs is not clear.
Defining why POM-prodrugs do not inhibit gram-negative organisms will ultimately inform how
widely lipophilic microbe specific prodrug targeting can be applied. If POM-prodrugs fail
because they cannot cross the periplasm lipophilic prodrugging strategies targeting cytoplasmic
esterases will never work for gram-negative organisms. If substrate specificity is the limiting
factor then alternative promoieties, cleavable by gram-negative organisms, can be designed.
Several experiments can be quickly performed to identify which of the above hypotheses is
correct. Quantifying POM-prodrug activation in intact and lysed E. coli will directly answer
whether E. coli has the capacity to activate POM-promoieties. Similarly, these experiments could
be performed with pro-fluorescent substrates as in Chapter 4. Alternatively, the activity of POMprodrugs could be assayed in the presence of outer membrane pore formers such as polymyxin B
as a means of decoupling prodrug transit and activity.

5.4 The Cellular Roles of FrmB and GloB
We have shown that carboxy ester prodrug activation in Staphylococcus spp. hijacks two
esterases which are conserved throughout the tree of life, FrmB and GloB. Both enzymes have
high GNU scores indicating they are well conserved within S. aureus and suggesting that their
native function is important for cell survival and fitness. Somewhat surprisingly, deletion of
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either FrmB or GloB results in no observable fitness defects in rich axenic culture. The native
role(s) and physiological function(s) for FrmB and GloB remain unclear.
GloB is annotated as a hydroxyacylglutathione hydrolase and is the second enzymatic step of the
two-step glyoxalase pathway (comprised of GloA and GloB). This pathway is canonically
viewed as a means of cellular protection from the toxic cellular metabolite, methylglyoxal.
Methylglyoxal is spontaneously generated via nonenzymatic decomposition of glyceraldehyde-3phosphate (GAP) and dihydroxyacetone phosphate (DHAP) and is highly reactive impacting
both protein function and glycating nucleic acids (20–22). Spontaneous coupling of
methylglyoxal to glutathione, isomerization to D-lactoylglutathione, and subsequent hydrolysis
to lactate and glutathione are catalyzed by GloA and GloB respectively. Despite endogenous
methylglyoxal detoxification, addition of exogenous methylglyoxal kills S. schleiferi with a halfmaximal inhibitory concentration (IC50) in the low mM. Surprisingly, mutations in GloB do not
impact S. schleiferi sensitivity to methylglyoxal, despite GloB having traditional GloB activity
(Chapters 3 and 4). Two hypotheses potentially explain these findings. First, Staphylococcus spp.
have multiple means of detoxifying methylglyoxal. S. aureus has 6 enzymes with predicted
GloA activity and 3 enzymes with predicted GloB activity (including the GloB characterized
here). In addition to the genetic redundancy within the glyoxalase pathway, S. aureus has
recently been described to have a glutathione independent methylglyoxal detoxification
mechanism (23). Beyond these two pathways, it is feasible that alternative oxidoreductases may
play a role in methylglyoxal detoxification (24–26). Secondly, it is possible that while GloB
mutations are tolerated in the short term, long term mutations in GloB become lethal. Protein
glycation has only been demonstrated to slightly reduce the activity of glycolytic proteins
suggesting some glycation may be tolerable (20). DNA glycation, conversely, is likely to be fatal
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as it results in strand breaks and interstrand cross-linking, though these errors may be slow to
accumulate (21).
Similar to GloB, FrmB is also annotated as a detoxification enzyme. Rather than detoxifying
methylglyoxal, FrmB is reported as a formylglutathione hydrolase, responsible for protecting
against free cellular formaldehyde. Formaldehyde detoxification mirrors the glyoxalase pathway.
Free formaldehyde is coupled to glutathione, oxidized via a formaldehyde dehydrogenase, before
subsequent hydrolysis to formate and glutathione by FrmB. FrmB and FrmB orthologs have been
characterized in several eukaryotes and prokaryotes, however the conditions where FrmB is
required remains unclear (27–32). In Paracoccus denitrificans, FrmB is required for growth on
methanol, methylamine, and choline suggesting that the pathway is essential for growth on
methylotrophic growth in some organisms. In humans, mutation of the analogous esterase,
esterase D, have been linked to Wilson’s disease and retinoblastoma (33).
Several intriguing questions remain regarding the native roles of FrmB and GloB. Are their
conditions where these two genes are essential? How redundant are the two pathways that FrmB
and GloB comprise respectively? Growing FrmB or GloB mutant strains in a variety of nutrient
conditions and stressors may reveal growth phenotypes which can be traced to a native function.
Performing these experiments in competition with WT S. aureus may improve the sensitivity of
these assays. Additionally, generating reporter strains that fluoresce upon FrmB or GloB
transcription should be a relatively easy process that stands to improve assay sensitivity enabling
a secondary means of evaluating when the cell requires FrmB or GloB (34). The impact of GloB
or FrmB loss on survival and virulence in in vivo settings remains another interesting avenue.
Ultimately, understanding how essential GloB and FrmB are for S. aureus growth and virulence
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is an important consideration given how quickly POM-prodrug resistance can arise due to
mutations in these genes.

5.5 Alternative resistance mechanisms to POM-prodrugs
We have described here three independent screens of Staphylococcus spp. resulting in resistance
to POM-prodrugs. Multiple SNPs were identified in two esterases, FrmB and GloB. We have
demonstrated that mutations in FrmB and GloB disrupt protein functionality and lead to a lack of
prodrug activation in these mutant cells. However, several strains (S. aureus 8/25, S. schleiferi
9/16, S. pseudintermedius 4/18) have no identified mutations in FrmB or GloB. The genetic
cause of prodrug resistance in these staphylococci remains unclear. In several of the S. aureus
strains, there are no candidate SNPs following Sanger sequencing. Further, of the strains with
SNPs remaining, none of the impacted genes have an obvious mechanism of resistance.
To explore the possibility of SNPs that were missed by Whole Genome Sequencing, we
performed Sanger Sequencing on GloB and FrmB for each unexplained mutant of S. aureus. In
addition to sequencing the coding region, we also sequenced the 500 bp upstream of the FrmB
start codon to find any potential promoter disruptions. No mutations were identified in the
coding region of either gene, nor were SNPs discovered in the promoter region of FrmB. The
promoter region of GloB was not sequenced as there is no clear 5’ promoter region as GloB may
be a member of an operon. Barring promoter disruptions in GloB and sequencing errors that
obfuscate any existing SNPs one possible means of resistance in these strains is silencing of
RNA encoding either GloB, FrmB, or yet unknown prodrug activating enzymes. The evolution
of RNAi to change gene expression in response to drug selection has been observed in the fungal
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pathogen Mucor circinelloides (35). S. aureus maintains several sRNAs indicating that the basal
machinery to produce sRNAs (36–38). Further, addition of exogenous siRNA to S. aureus has
been demonstrated to decrease gene expression (39). While siRNA mediated drug resistance has
not yet been observed in bacteria, it appears all the requisite tools are in place. Investigation into
how our remaining staphylococci have become POM-prodrug resistance will either result in
identification of a new resistance mechanism for bacteria or more information about POMprodrug activation.

5.6 Barriers to metabolic prodrug resistance
The work presented here focuses on the development of two anti-metabolites, POM-HEX and
POM-ERJ. In the organisms where these inhibitors have been studied, very rarely does resistance
arise due to mutations in the target of the inhibitor. In E. coli, resistance to the ERJ analogue,
fosmidomycin, through mutation of the target, DXR, only occurs upon PCR-mediated generation
of resistance (13, 40). Similarly, after repeated fosmidomycin selections in P. falciparum, only
one mutation in DXR has been observed (data not shown). Instead of mutating metabolic
enzymes, resistance tends to arise via other mechanisms for metabolic inhibitors. In S. schleiferi
and F. novicida, fosmidomycin resistance arises by disrupting the transporter which allows
fosmidomycin into the cell (6, 41). In P. falciparum, fosmidomycin resistance arises through
manipulation of the metabolic flux through the isoprenoid biosynthetic pathway (42). In part, this
is to be expected. The enzymes targeted by anti-metabolites are essential. Most anti-metabolites
are competitive active site inhibitors. Most mutations that would prevent active site inhibitor
binding also disrupt binding of the native substrate. While resistance can arise via other
mechanisms, metabolic rerouting only confers a partial resistance to fosmidomycin in P.
falciparum and results in decreased fitness in the absence of fosmidomycin (43). Fosmidomycin
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resistance in S. schleiferi and F. novicida can be acquired through disruption of active transit
mechanisms, but lipophilic prodrugging strategies circumvent this resistance mechanism.
Providing microbially targeted lipophilic promoieties can be developed, metabolism as an
antibiotic target appears to be a ripe and underdeveloped area. Inhibitors can be readily designed
as substrate mimics, and mutations in target proteins appear difficult to acquire. Quantifying the
barrier to resistance for metabolic inhibitors and their prodrugged forms, as well as the
development of animal models to study resistance generation are useful avenues for
understanding the clinical efficacy of metabolic prodrugs. It is feasible that in clinical settings
pathogens will simultaneously face both the prodrugged and active form of metabolic inhibitors.
For POM-ERJ, it seems unlikely that S. schleiferi would simultaneously mutate both GlpT and
either FrmB or GloB. Quantifying the likelihood of resistance in dual treatment would be more
reflective of a clinical setting. Further, understanding the causes of this resistance may reveal
mechanisms of metabolic regulation. Finally, combination therapy approaches to prodrug
administration- using independent esterases for prodrug activation- may be an interesting avenue
to pursue.

5.7 The Complete Prodrug Activation Pathway
We have demonstrated that mutations in the carboxylesterases GloB or FrmB confer resistance
to di-POM-prodrugs. NMR characterization of the products of GloB and FrmB with di-POM
prodrugs suggests that both enzymes remove the first POM moiety but are unable to remove the
second and fully deprotect the compound (Figure 2). This is not altogether unsurprising when
considering the reaction mechanisms for each FrmB and GloB. GloB is hypothesized to
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deprotonate a water molecule and utilize the hydroxide ion to initiate attack on carbonyl
substrates (44). A negatively charged, mono-POM compound may be repelled from the
hydroxide, thereby preventing further hydrolysis. Similarly, FrmB is hypothesized to undergo
several charge rearrangements during substrate hydrolysis. These charge transfers presumably
become unfavorable for a charged mono-POM molecule. How mono-POM phosphonates are
converted to the fully deprotected compound remains unknown. Understanding how prodrugs are
fully activated affords an additional layer of specificity that can be engineered into prodrug
activation. This approach may be especially useful in attempting to develop anti-metabolites
which are otherwise host toxic.
One hypothesis is that a phosphodiesterase is required to terminate prodrug activation. We have
performed three forward genetic and one reverse genetic screen in efforts to identify prodrug
activating enzymes. Our reverse genetic screen purposefully included every non-essential
phosphodiesterase of S. aureus. Unfortunately, we were unable to identify enzymes beyond
GloB and FrmB that contribute to prodrug activation. Two hypotheses are likely to explain this
finding. First, the final enzyme is required to S. aureus growth. Secondly, the final enzymatic
step could be performed by multiple enzymes with each enzyme being supplied in excess. If this
is the case, deletion of just one enzyme would have no impact on POM-prodrug survival as other
cellular enzymes would compensate for the lost activity. Our screens are unable to differentiate
between these two hypotheses. To identify the final enzyme(s) in the prodrug activation
pathway, the most straightforward approach is likely to perform an activity-based-proteomics for
enzymes hydrolyzing mono-POM substrates (45–48).
Targeting multiple microbial esterases simultaneously for prodrug activation may be an optimal
strategy. While POM-prodrugs have no activity against enzymes, single mutations in either GloB
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or FrmB do not fully protect S. aureus from POM-HEX. Presumably, this is because both GloB
and FrmB can partially activate POM-HEX. Along this reasoning, creation of a S. aureus strain
with mutations in both FrmB and GloB would likely result in high levels of resistance to POMHEX. As the development of microbe targeted promoieties continues, promoieties that have
redundant activation pathways in bacteria may be preferred. Promoieties taking advantage of
multiple esterases increases the number of mutations required for full resistance to arise. Likely,
redundant targeting of esterases also increases the rate of prodrug activation in vivo, thereby
contributing to higher intracellular levels of active drug.

5.8 Prodrug activation in P. falciparum
In Appendix B we discuss prodrug activation by one of the malarial parasites, Plasmodium
falciparum. Since 2000, rates of malaria cases and deaths have fallen, yet P. falciparum still
causes an enormous disease burden annually. The increasing prevalence of artemisinin resistance
threatens the progress made to date. New antimalarial inhibitors which are safe and effective,
especially those capable of killing all parasites after administration as a single dose, are urgently
needed. Prodrug targeted therapies, whether activated by the erythrocyte or by the parasite,
present an intriguing opportunity to both increase antimalarial potency while simultaneously
improving pharmacokinetic properties. Identification and characterization of erythrocyte and
parasite esterases remains a high priority for the development of these inhibitors.
We developed a unique screening approach to identify the malarial esterase responsible for
activation of POM-ERJ. In using parasites with mutations in HAD1 as a parental strain, we
removed one mechanism of resistance to the activated compound, ERJ. Regrettably, we were not
able to generate stable mutants resistant to POM-ERJ, and thus unable to identify the
209

Plasmodium esterase responsible for POM-ERJ activation. While this is promising for POMERJ, more attempts at raising resistance should be made before classifying POM-ERJ as
“irresistible”. One attractive explanation for the lack of resistance to POM-ERJ is that
erythrocyte esterases activate POM-ERJ and release ERJ for normal uptake. As the parasites
already have mutations in HAD1, resistance to ERJ may be more difficult for parasites to
achieve. While it should be noted that increased resistance to fosmidomycin, an analogue of ERJ,
has already been observed in HAD1 backgrounds (data not shown), POM-prodrugs being
activated by erythrocyte esterases is not unheard of. Acyclic immucillin phosphonates (AIPs) are
potent inhibitors of hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRT) in
vitro, yet are ineffective at killing whole-cell parasites despite the enzyme being essential (49).
POM-prodrugging of AIPs resulted in compounds that were membrane permeable, but still
ineffective against P. falciparum due to cleavage in the erythrocyte (49). Similarly, POM-HEX,
a potent inhibitor of enolase, potently inhibits erythrocyte enolase, ultimately causing hemolysis
(15).
While on the surface, erythrocyte targeted prodrugs may appear to be undesirable, targeting
erythrocytes for prodrug activation may be extremely beneficial. P. falciparum demonstrates a
remarkable ability to become resistant to antimalarials, including prodrugs (50). Targeting
erythrocytes for prodrug activation eliminates one potential resistance strategy for the parasite.
Further, this targeting strategy has enormous pharmacokinetic potential. Inhibitors that are
trapped inside erythrocytes (due to the exposed charge on phosphonate residues, for example)
will not be subject to the same metabolic processing that free serum compounds would.
Likewise, drugged erythrocytes are not generally cleared by the liver or kidney, thereby reducing
the amount of drug eliminated from the system. Depending on the length of time drug-loaded
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erythrocytes circulate, these compounds could be highly effective prophylactics and may enable
a drug-based malaria elimination campaign. While the major benefit conferred by lipophilic
prodrugging of phosphonates appears to be membrane permeability, some inhibitors, such as
fosmidomycin, appear to be readily taken up by P. falciparum. Likely uptake of fosmidomycin
requires an active transport mechanism, however resistance to fosmidomycin via transporter
mutations has not been observed yet as it has in bacterial systems. Potentially other nutrients
required for P. falciparum growth also transit through this channel.
While erythrocyte targeted prodrug activation is okay for some compounds, others, such as the
AIPs, require parasite specific targeting. We have demonstrated that medium chain lipophilic
ester promoieties are already targeted for parasite specific activation. These promoieties are
removed at rates fast enough to observe significant fluorescence accumulation (Appendix B).
More work defining the relevant esterases for P. falciparum and human erythrocytes is needed.
Promoieties that are preferentially activated by either the P. falciparum esterase(s) or the
erythrocyte esterase(s), and not serum esterases, have enormous potential to both increase the
druggable space for antimalarials as well as improve dosing regimens and patient efficacy.

5.9 Clinical opportunities for microbially targeted prodrugs
Some microbial infections are difficult to treat as the pathogen becomes sequestered in locations
that receive poor drug penetrance. For example, antituberculosis treatment courses exceeding 6
months are routinely prescribed to eliminate drug tolerant Mycobacterium tuberculosis (Mtb)
(51). One of the hallmarks of Mtb infection is the formation of large aggregates of immune cells
around replicating Mtb. These lesions are termed granulomas and serve to limit the spread and
success of Mtb. Unfortunately, the formation of these lesions also restricts delivery of antibiotics
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to replicating bacteria (52–55). Similarly, bacterial infections that result in biofilms, or infections
that localize to the bone such as S. aureus osteomyelitis, can be recalcitrant to treatment due in
part to poor drug penetrance (56–60). Development of lipophilic prodrugs targeting microbes
may increase drug penetrance thereby facilitating the development of new antimicrobial agents
while simultaneously improving treatment efficacy.
Selectively targeting prodrugs for microbial activation as opposed to host activation is likely
feasible. How broadly prodrugs are activated amongst the microbial populations, however,
remains an open and intriguing question. It is feasible that prodrug therapies will be broadly
hydrolysable by all microbial populations. In this case, microbially targeted protherapies serve to
help all microbial infections as broad-spectrum antibiotics. However, it is likewise possible that
targeted protherapies will result in narrow-spectrum antibiotics, possibly even at the level of
genus or species. On first glance, narrow-spectrum antibiotics may seem less useful as clinicians
need to identify the cause of infection prior to treatment. However, narrow-spectrum antibiotics
are less likely to acquire resistance mechanisms from microbial community members thereby
prolonging their clinical efficacy (61). Additionally, treatment with narrow, as opposed to broadspectrum, antibiotics is less likely to result in microbiome depletion and mitigates the risk of
Clostridium difficile infection (62, 63).
If pro-therapies are indeed narrow-spectrum, promoieties can also be utilized to develop novel
diagnostic imaging techniques. One can imagine in vivo imaging agents similar to the fluorescent
pro-substrates that are inactive prior to activation. Once activated, these pro-substrates would
subsequently yield high signal in the imaging channel. This diagnostic technique would be
especially useful in diagnosing microbial infections in body sites where samples are difficult to
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acquire, or where the diagnostic itself is slow or unreliable. For example, culture based Mtb
diagnostics are limited by the growth rate of Mtb, and diagnosis of S. aureus osteomyelitis often
requires invasive bone biopsies (64, 65).

5.10 Transitioning microbially targeted prodrugs to the
clinic
In chapter 4 we demonstrate that the microbial esterases FrmB and GloB from S. aureus exhibit
catalytic specificity differences for simple ester substrates. Further, the catalytic specificities of
FrmB and GloB are discriminatory from human and mouse serum esterases suggesting that ester
promoieties may be tuned to activation by staphylococcal esterases. This finding has many
potential clinical implications. Microbially targeted prodrugs open significant druggable space
for development. Additionally, selective prodrug activation will increase the therapeutic index of
many antimicrobials. Before these compounds can move into clinical development, several
questions need to be addressed.
In chapter 4 our analysis focuses on the catalytic specificity of microbial esterases and serum
esterases using a fluorogenic reporter library. This analysis is likely an oversimplification of the
true biological situation. We directly compare the activity of purified microbial esterases to the
total protein in unpurified human sera. Additionally, when prodrugs are dosed in a clinical
setting they circulate in the serum for an undefined period before eventually entering the target
cells. We are unable to account for variable incubation time in our assays. Finally, the rate of
prodrug activation required for each antimicrobial has the potential to vary. Some compounds
will be exceptionally potent inhibitors only requiring a few molecules of inhibitor per cell,
whereas others will require more. A slow rate of intracellular prodrug activation is tolerable for
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exceptionally potent but will not suffice if large amounts of activated drug are required. While
the fluorogenic substrate library facilitates high-throughput analysis, it is not capable of
answering the question “how fast is fast enough?”. Several prodrugs should be synthesized using
the same active compound but selecting varying promoieties. These varying promoieties should
subsequently be evaluated for their ability to survive hydrolysis in sera and their ability to kill the
target organism. In doing this, direct comparisons back to the rates of prodrug activation
identified via the fluorogenic screen can be used to benchmark relevant rates of microbial
prodrug activation, and meaningful stability in human sera. This strategy also allows for the
expansion of the fluorogenic substrate library, enabling promoiety screening independent of the
warhead.
In addition to defining the relevance of prodrug activation rates, an important consideration prior
to clinical deployment of these compounds is the toxicity of prodrug byproducts. POM-prodrug
activation likely results in the release of formaldehyde and pivalic acid, however more chemical
analysis of prodrug activation products is required (10). Both pivalic acid and formaldehyde raise
concern for their release into humans. Long term exposure to pivalic acid in humans has
associated with reduced levels of carnitine (66). For a full microbially targeted prodrug, toxic
prodrug byproducts would be expected to remain microbially contained if the cell remained
intact. Further research in understanding how prodrugs are activated, and what happens to
prodrug byproducts following microbial activation, is necessary.
Perhaps the final challenge for the development of microbially targeted prodrugs will be
assessing the pharmacokinetics and dynamics (PK/PD) profiles and efficacy of these prodrugs.
PK/PD studies are necessary to understand how a developing drug performs in a more complex
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system such as host. These studies directly inform the dosing of novel drugs and serve as
preliminary proof that the developing drug is safe. Typically, PK/PD models are first tested in a
murine model and subsequently performed in additional animal models that more closely
replicate humans. In chapter 4, we demonstrate a longstanding understanding that the esterases in
mouse sera are different than those in human sera. The benefits of targeted prodrugs stem from
the prodrug being delivered intact at the site of infection. Thus, if prodrug PK/PD models do not
accurately reflect prodrug cleavage, the efficacy and dosing requirements of prodrugs will be
incorrect. Several tools exist already to combat this barrier. First, esterase inhibitors have been
developed in effort to reduce esterase activity in mice (67). Second, esterase 1 knockout mice
have been developed in an effort to recapitulate human sera in mice (68). Finally, alternative
animals which more closely mimic human sera exist as model systems including guinea pigs,
rabbits, and rats. Unfortunately, each organism has discrete differences in carboxylesterase
activity (69–78). Carboxy ester stability will likely need to be evaluated in a serum model for
each animal to find activity profiles matching those of humans before efficacy and PK/PD
studies can be performed.

5.11 Closing thoughts
Rising rates of antimicrobial resistance are an important concern for global health and we
urgently need to develop new therapeutic strategies and incentivize antimicrobial research. The
development of microbially targeted prodrugs not only increases the druggable space for
antimicrobials but also serves to de-risk antimicrobial development by increasing drug
specificity. In this work, we have described the benefits of lipophilic prodrugging strategies.
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Additionally, we have uncovered the partial activation mechanism for these prodrugs in
staphylococci. Finally, we have highlighted how knowledge of the activation pathway for
lipophilic prodrugs can guide targeted prodrug design. We expect that these studies will enable
the development of microbe-specific prodrugs and novel imaging based diagnostic mechanisms
for microbial infections.
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5.12 Figures

Figure 1 Models for lack of POM-prodrug activity on gram negative organisms.
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Figure 2 Proposed POM-HEX activation mechanism. GloB and FrmB accumulate mono-POM-HEX (circled in gray) when incubated
individually or in combination with POM-HEX. Promoieties highlighted in green.
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Appendix A: FrmB mutational studies
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A.1 Introduction
S. aureus is a highly successful human pathogen responsible for a wide variety of invasive and
life-threatening infections. Widespread methicillin resistance in S. aureus (MRSA) is especially
concerning and has been labeled a “serious threat” by the Centers for Disease Control and
Prevention (CDC) (1). New antimicrobials are urgently needed to address this pressing threat.

Recently, advancements in the understanding of prodrug activation in S. aureus have led to the
possibility of S. aureus targeted prodrugs (Chapter 4). One of the identified proteins, FrmB, was
found to have several mutations which resulted in resistance to pivaloyloxymethyl (POM)
prodrugs. FrmB is a carboxylesterase with a suggested biological function of detoxifying
formaldehyde (2). We previously hypothesized that mutations in FrmB prevent catalytic activity
thereby conferring resistance to POM prodrugs. The structural rationale for FrmB mutations
conferring POM-prodrug resistance, was not explored. Here, we examine how each of the
previously identified mutations in FrmB impact catalytic activity. Further, we explore how FrmB
dimerization impacts catalytic activity as well as the impact of mutations in the flexible capping
domain.

xxv

A.2 Methods
A.2.1 Cloning of mutant FrmB
FrmB mutations (Table 1) were generated using QuikChange PCR mutagenesis (Agilent) using
the previously cloned WT FrmB from S. aureus as a template and the primers listed in Table 2.
Mutant FrmB constructs were cloned into the E. coli expression vector, pET28a, to introduce a
hexa-histidine tag, and plasmids were maintained in TOP10 chemically competent E. coli
(Thermofisher). All plasmids and mutations were verified using Sanger sequencing.

A.2.2 Mutant FrmB purification
FrmB mutant plasmids were introduced into chemically competent BL21 (DE3) E. coli cells
(Thermofisher) and selected for using 50 μg/mL kanamycin. A single colony was used to
inoculate a 5 mL overnight culture in LB media supplemented with 50 μg/mLkanamycin. The
following day, 2 mL of the overnight culture was back diluted into 1 L terrific broth (24 g Yeast
Extract, 12 g Tryptone, 9.4 g K2HPO4, 2.2 g KH2PO4, 0.04% glucose per liter) supplemented
with 50 μg/mL kanamycin. Cultures were grown at 37 ºC until reaching an OD600 of 0.4-0.7 at
which point the cultures were chilled to 16 ºC and protein expression was induced with 0.5 mM
isopropyl β-D-1-thiogalactopyranoside. Following 16 hours of induction, cell cultures were
harvested via centrifugation at 6000 x g for 15 min at 4 ºC. Cell pellets were resuspended in 45
mL lysis buffer (25 mM Tris pH 7.5, 250 mM NaCl, 1 mM MgCl2, 10% glycerol, 1 mM PMSF,
and 20 mM imidazole). Pellets were lysed via sonication and insoluble cell fractions were
removed via centrifugation at 12,000 x g for 45 minutes at 4 ºC. Hexa-histidine tagged FrmB
mutants were purified via nickle agarose beads. Bound protein was washed with 50 mL lysis
buffer, and washed protein was eluted with lysis buffer supplemented with 300 mM imidazole.
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Eluted proteins were dialyzed in dialysis buffer containing 25 mM Tris pH 7.5, 100 mM NaCl,
and 20% glycerol. Protein concentrations were determined using the Bradford assay.

A.2.3 FrmB activity assay
FrmB activity against the substrate 4-nitrophenyl acetate was determined in 100 μL assays in 96
well clear flat bottom plates. Assays were performed in buffer consisting of 25 mM tris pH 7.5,
250 mM NaCl, 1 mM MgCl2, 10% glycerol, and 5 μg purified protein. 4-nitrophenyl acetate
concentrations were varied from 1 mM to 0.5 μM in 2-fold dilutions. Reactions were initiated
through the addition of substrate and the formation of 4-nitrophenol was monitored
spectrophotometrically at 405 nm using a Tecan platereader. Prior to assay initiation, assay
plates were pre-warmed to a temperature of 37 ºC. Assays preformed without the addition of
enzyme were used as a negative control for background substrate hydrolysis. Reactions were
performed in triplicate with technical duplicates. The initial velocity for each reaction was fit to a
line using Graphpad Prism. Initial rates of reaction were plotted versus the concentration of
substrate to a standard Michaelis-Menten equation using Graphpad Prism to obtain estimates of
the Vmax and Km for each mutant. For proteins where saturating conditions were not met, kcat/Km
was estimated using the following derivation of Michaelis MentenEquation (1)

When Km>>[S]
Equation (2)
xxvii

Therefore
Equation (3)
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A.3 Results
A.3.1 SNPs near FrmB active site disrupt catalytic activity
Mutations in the formylglutathione hydrolase, FrmB, confer resistance to the carboxy ester
prodrug POM-HEX in S. aureus. POM-HEX requires hydrolysis to inhibit the target enzyme,
enolase. As, WT FrmB hydrolyzes POM-HEX, a natural conclusion of these two pieces of
evidence is that mutations in FrmB disrupt catalytic activity, thereby conferring protection to
POM-HEX. Three of the four observed mutations in FrmB rationally should disrupt protein
function. M74X truncates a majority of FrmB including the active site. Two additional
mutations, G119D and M122I, are located within the active site and conceivably disrupt protein
function (Figure 1A).

To test the hypothesis that FrmB mutations disrupt catalytic activity we substituted G119 and
M122 with alanine mutations (Table 1). We utilized the chromogenic esterase substrate, 4nitrophenyl acetate, which results in a change of absorbance upon hydrolysis. Mutation of G119
to alanine or M122 to alanine results in protein with no detectable activity (Figure 1B).

A.3.2 SaFrmB dimerization may be critical to FrmB function
The last observed mutation conferring resistance to POM-HEX, G14R, is puzzling as the G14 is
located on a loop far from the active site (Figure 2A). Size exclusion chromatography indicates
that FrmB is a dimer in solution, and the crystal structure of FrmB has two monomers in the
asymmetric unit (Figure 2A). Thus, a natural hypothesis is that FrmB is only catalytically active
as a dimer and disruption of the dimerization interface results in attenuated catalytic activity.
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We next created a FrmB mutation with residue G14 mutated to an arginine. In addition to G14R,
we generated two additional mutations in a different portion of the dimerization interface: S32A
and V36L (Figure 2B). The resulting mutant proteins exhibit markedly reduced catalytic activity
(Figure 2C, Table 3). Each of these mutations exhibits a >6-fold reduction in catalytic specificity
which appears to be driven by a lack of enzyme turnover. Taken together, this structural and
enzymatic data suggests that FrmB dimerization is important for substrate catalysis, but not
substrate binding. Future studies should more rigorously assess the dimeric state of FrmB
mutants as well as the binding affinity of FrmB mutants.

A.3.3 The flexible capping domain of FrmB is essential for protein function.
Previous studies on structurally similar esterases have suggested that the flexible cap domain of
FrmB may be responsible for substrate specificity (Figure 3A) (3–5). Additionally, mutations in
this region may impact the thermostability of the esterase (5). Unfortunately, the flexible cap
domain is not entirely resolved in the crystal structure of SaFrmB due to poor electron density.
We generated mutations in several residues of the flexible cap domain including I167P, L170D,
and G175A (Figure 3A). Surprisingly, each of these mutations completely ablated catalytic
activity (Figure 3B, Table 3). I167P likely severely reduces the flexibility of this loop. Likewise,
G175A introduces steric hindrance and presumably reduces the flexibility of the capping
domain. While L170D adds some steric bulk, likely the more problematic change is the addition
of a charge which may alter normal loop movement. In summation, these data suggest that the
flexibility of the cap domain is essential for FrmB function. How these mutations impact
xxx

substrate utilization and temperature sensitivity, as well as the affect of less drastic substitutions,
remains unknown.
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A.4 Discussion
FrmB has been identified as an activator of POM-prodrugs in S. aureus. Preliminary structureactivity relationships have identified several substrates that are well-cleaved by FrmB but poorly
cleaved by human sera, suggesting these substrates may be used to target FrmB for S. aureusspecific prodrugs. Here we characterize several domains of FrmB using targeted mutagenesis.
We find that mutations in the active site, dimerization interface, and the capping domain all
severely attenuate FrmB activity. Notably, mutations to the dimeric interface appear to reduce
substrate turnover irrespective of substrate binding. This suggests that dimerization is critical for
the catalytic competency of FrmB.

Previous studies have demonstrated esterases requiring dimerization for catalysis (6, 7). Other
studies have demonstrated that mutation of the catalytic serine and histidine from other α/β
hydrolases results in decreased substrate turnover and binding affinity. Conversely, mutagenesis
of the catalytic aspartate only impacts substrate turnover (8). As a result, the prevailing model in
the field suggests that esterase dimerization leads to movement of the catalytic aspartate into a
catalytically competent orientation.

Further analysis, especially regarding the ability of FrmB to change substrate specificities, are
warranted to understand the possibility of FrmB mediated prodrug resistance. Beyond FrmB as a
potential prodrug activator, esterases also play an important role in industrial conversion and
production of chemicals. Utilizing FrmB as a scaffold for specific esterase activity may be
possible.
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A.5 Figures

Figure 1 SNPs near the FrmB catalytic triad disrupt FrmB activity. (A) Crystal structure of SaFrmB. Indicated in gray is the catalytic triad,
indicated in orange are the mutations observed to confer POM-HEX resistance. (B) Catalytic activity of WT and mutant FrmB. Values are the
means of three independent experiments performed in technical duplicate. Error bars denote SD.
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Figure 2 Mutations at the dimerization interface disrupt FrmB activity. (A) Locations of SNP G14R (orange sticks) in relation to catalytic
triad (gray spheres). FrmB monomer A in green, monomer B in blue. (B) Location of mutations made at the dimerization interface. (C) Activity
of mutant FrmB proteins. Displayed are the means of three independent experiments with technical duplicates. Error bars denote SD.
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Figure 3. Mutations in the flexible cap of FrmB ablate catalytic activity. A) Locations of mutations made at in the flexible capping domain.
Residues 168-175 are not observable in the electron density due to flexibility. Catalytic triad represented in gray spheres. (B) Activity of mutant
FrmB proteins. Displayed are the means of three independent experiments with technical duplicates. Error bars denote SD.
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A.6 Tables
Table 1. FrmB mutants generated and verified by Biol 4522.
Natural Amino

Kinetics

Position

Acid

Substitutions Made

Tested

14

Gly

Arg

Arg

32

Ser

Ala

Ala

36

Val

Ala, Leu

Leu

71

Ala

Asp, Trp

Trp

119

Gly

Ala, Cys

Ala

122

Met

Ala, Ser

Ala

167

Ile

Pro

Pro

170

Leu

Ala, Asp

Asp

175

Gly

Ala

Ala

221

Ile

Ala, Glu

Glu

245

Arg

Leu
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Table 2. Primers used during this study
Primer Name

Sequence

S32A Forward

CCGGAAGATCAAAGCTTCTTTAATGCGGATACAACTG

S32A Reverse

CAGTTGTATCCGCATTAAAGAAGCTTTGATCTTCGCG

S32R Forward

CCGGAAGATCAAAGCTTCTTTAATCGGGATACAACTG

S32R Reverse

CAGTTGTATCCCCATTAAAGAAGCTTTGATCTTCGCG

V36A Forward

ACGGATACAACTGCTAAACCATTAAAAACT

V36A Reverse

AGTTTTTAATGGTTTAGCAGTTGTATCGCT

V36L Forward

ACGGATACAACTCTTAAACCATTAAAAACT

V36L Reverse

AGTTTTTAATGGTTTAAGAGTTGTATCGCT

A71D Forward

GCGAATGAACACAAATTAGATGTGATTATGCCCAATGTGG

A71D Reverse

CCACATTGGGCATAATCACATCTAATTTGTGTTCATTCGC

A71W Forward

GCGAATGAACACAAATTATGGGTGATTATGCCCAATGTGG

A71W Reverse

CCACATTGGGCATAATCACCCATAATTTGTGTTCATTCGC

G119C Forward

GACAATTTTATAGCATGTCACTCTATGGGAGGATATGGC

G119C Reverse

GCCATATCCTCCCATAGAGTGACATGCTATAAAATTGTC

G119A Froward

GACAATTTTATAGCAGCTCACTCTATGGGAGGATATGGC

G119A Reverse

GCCATATCCTCCCATAGAGTGAGCTGCTATAAAATTGTC

M122A Forward

CAGGTCACTCTGCGGGAGGATATGGCAC

M122A Reverse

GTGCCATATCCTCCCGCAGAGTGACCTG

M122S Forward

GCAGGTCACTCTTCGGGAGGATATGGCAC

M122S Reverse

GTGCCATATCCTCCCGAAGAGTGACCTGC

I167A Forward

TCAAAAGAGGCCATAGCTGGCAATCTTTCAAGT

I167A Reverse

ACTTGAAAGATTGCCAGCTATGGCCTCTTTTGA

I167P Forward

TCAAAAGAGGCCATACCTGGCAATCTTTCAAGTG

I167P Reverse

CACTTGAAAGATTGCCAGGTATGGCCTCTTTTGA

L170D Forward

GAGGCCATAATTGGCAATGATTCAAGTGTTAAAGGAAC

L170D Reverse

GTTCCTTTAACACTTGAATCATTGCCAATTATGGCCTC

L170P Forward

GACGCCATAATTGGCAATGCTTCAAGTGTTAAAGGA

L170P Reverse

TCCTTTAACACTTGAAGCATTGCCAATTATGGCCTC

G175A Forward

GGCAATCTTTCAAGTGTTAAAGCTACTGAACATGATCCG

G175A Reverse

CGGATCATGTTCAGTAGCTTTAACACTTGAAAGATTGCC

G175H Forward

GGCAATCTTTCAAGTGTTAAACACACTGAACATGATCCG

G175H Reverse

CGGATCATGTTCAGTGTGTTTAACACTTGAAAGATTGCC

I221A Forward

ATTTATCACGCGCAAATGTTCCTTATCAATTTGAAGATGGACC

I221A Reverse

GGTCCATCTTCAAATTGATAAGGAACATTTGCGCGTGATAAAT

I221E Forward

ATTTATCACGCGAAAATGTTCCTTATCAATTTGAAGATGGACC

I221E Reverse

GGTCCATCTTCAAATTGATAAGGAACATTTTCGCGTGATAAAT
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Table 3. Michaelis-Menten parameters for mutant FrmB. All values are the results of three independent experiments performed in technical
duplicate. N/A indicates that no appreciable activity was detected using 5 μg protein.
Mutant

Kcat/Km (min-1μM-1)
Mean

Kcat/Km*kuncat (μM-1)

SE

Mean

SD

WT

8.31E+02

2.4E+01

4.04E+09

2.50E+09

G14R

1.22E+02

7E+00

5.91E+08

6.70E+08

S32A

1.34E+02

9.7E+00

6.54E+08

9.97E+08

V36L

7.16E+01

A71W

N/A

6.3E+00
N/A

3.48E+08
N/A

6.5E+08
N/A

G119A

N/A

N/A

N/A

N/A

M122A

N/A

N/A

N/A

N/A

I167P

N/A

N/A

N/A

N/A

L170D

N/A

N/A

N/A

N/A

G175A

N/A

N/A

N/A

N/A

1.40E+08

4.61E+08

I221E

2.88E+01

4.5E+00

kuncat (1/min)

2.06E-07

9.7E-09
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Appendix B: Carboxy ester prodrug
activation by Plasmodium falciparum
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B.1 Introduction
Antimalarial drug resistance threatens an already fraught global health issue of enormous scale.
In 2018, over 210 million individuals suffered a malaria infection (1). Further, resistance to the
current frontline therapy, artemisinin, has become increasingly common and is detected at a
significant prevalence (>5%) in south-east Asia, Guyana, Papua New Guinea, and Rwanda (2).
New antimalarials are urgently needed to combat this looming crisis.

One approach to drug development which has attracted recent attention is prodrugging. A
prodrug is a compound which has been chemically modified to be inactive until converted
(chemically or enzymatically) back into the active compound. Prodrugging affords chemists a
means of altering the drug-like properties of a drug (e.g. solubility, oral absorption), without
modifying the underlying active drug. This is especially attractive when the goal is to develop
inhibitors, such as phosphonates, which are otherwise cellularly impermeable as lipophilic
promoieties may be attached to confer increased cellular penetrance.

We have previously deployed the lipophilic promoiety, pivaloyloxymethyl (POM) to improve
the potency of the isoprenoid biosynthesis inhibitor, fosmidomycin, and several structural
analogues (3). Unfortunately, the POM-promoiety is rapidly cleaved by serum esterases
returning the less potent phosphonate warhead in any treatment setting (3). Identification of the
POM-prodrug activating enzyme(s) of P. falciparum will allow for the structure-guided
development of promoieties which are specifically activated by P. falciparum.

xlii

One P. falciparum esterase, PfPARE, has recently garnered attention as a prodrug activatior for
unbranched or minimally branched C6 esters (4–6). We have previously found that PfPARE
mutations do not confer resistance to our prodrugged analogue of fosmidomycin, POM-ERJ
(Figure 1). This finding suggests that additional esterases, either parasite or erythrocyte resident,
must be responsible for POM-ERJ activation. Here, we attempt to identify the esterase
responsible for POM-prodrug activation in P. falciparum. We also demonstrate the localization
of simple ester prosubstrates in P. falciparum, laying the groundwork for future exploration in P.
falciparum targeted prodrug development.
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B.2 Methods
B.2.1 P. falciparum maintenance and culturing
The P. falciparum strain used for POM-ERJ selection was the had-1 strain, AM1-G3 (7). For
imaging experiments, the P. falciparum strain used was 3D7 (8). Strains were cultured at 37 °C
in a suspension of 2% human erythrocytes in RPMI-1640 medium (Sigma-Aldrich, SKU R4130)
supplemented with 27 mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium
pyruvate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 μg ml-1 gentamycin, and 0.5%
albumax (Life Technologies) under an atmosphere of 5% O2/ 5%CO2 / 90% N2 as previously
described (9). Culture growth was monitored by microscopic analysis of Giemsa-stained blood
smears.

B.2.2 Selection of POM-ERJ resistant P. falciparum
The had-1 strain, AM1-G3 was used as the parental strain for resistant mutant selection. The
parental strain was seeded at 0.5 % parasitemia in 4 mL cultures at the initiation of POM-ERJ
selection. Parasites were cultured in media containing 60, 120, or 300 nM POM-ERJ (1, 2, and
5x the 3-day half maximal growth inhibitory concentration), and continuously maintained at or
below a parasitemia of 4 %. In some cases, drug was removed from the media once parasites
were no longer visible in culture wells.

B.2.3 Quantification of POM-ERJ resistance
Asynchronous P. falciparum cultures were counted microscopically via Giemsa-stained blood
smears and diluted to a parasitemia of 0.5%, prior to being cultured in POM-ERJ concentrations
ranging from 3 μM to 5.9 nM. After 3 days, parasite growth was quantified by measuring DNA
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content using PicoGreen (Life Technologies) on a FLUOstar Omega platereader (BMG Labtech)
at 485 excitation and 528 emission (10). The half maximal inhibitory concentration (IC50) was
calculated by nonlinear regression in GraphPad Prism.

B.2.4 P. falciparum microscopic analysis of prodrug activation
Asynchronous cultures of P. falciparum 3D7 were enriched for infected erythrocytes using a
magnetic cell fractionation system (MACS, Mitenyi Biotec). Parasite cultures were loaded onto a
MACS column pre-equilibrated with culture medium and placed within a magnetic field.
Parasites were subsequently washed with culture medium until unbound erythrocytes no longer
eluted from the column, at which point the column was removed from the magnetic field and
infected erythrocytes were recovered in culture media. Immediately prior to cell loading, P.
falciparum cultures were diluted to a concentration of 5x106 cells/mL and transferred into sterile
filtered Dulbecco’s phosphate-buffered saline (DPBS) supplemented with 20 mM glucose. Cells
were immediately loaded on a bacterial CellASIC Onix microfluidic plate (Millipore Sigma
B04A-03) prewarmed to 37 °C and pre-equilibrated with DPBS + 20 mM glucose. Prior to plate
loading, CellASIC Onix microfluidic lines were flushed with DPBS + 20 mM glucose or 10 µM
fluorescent prosubstrate in DPBS + 1% DMSO + 20 mM glucose.

The microfluidics plate was loaded onto a Nikon Ti-E inverted microscope (Nikon Instruments,
Inc) equipped with a 100x Plan N (N.A. = 1.45) Ph3 objective, X-cite 120 LED light source
(Lumen Dynamics), and an OrcaERG CCD camera (Hammamatsu Photonics, Bridgewater, N.J),
which was used to obtain both phase contrast and fluorescent images. Filter sets were purchased
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from Chroma Technology Corporation. Cells were loaded until a single field of view contained
20-50 cells. Following cell loading, PBS was flown through the flow cell (t = 0) and cells were
observed in both phase and fluorescent channels for 10 minutes before the flow media was
switched to PBS containing 1% DMSO and 10 µM fluorescent pro-substrate. Images were
captured every two minutes for a total of 44 minutes, and all experiments were undertaken at 37
°C. The phase contrast exposure time was kept constant at: 200 ms, and the fluorescent channel
exposure time was kept constant at 500 ms. For fluorescent images, the gain remained constant
across all experiments. Image capture and analysis was performed using Nikon Elements
Advanced Research software.
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B.3 Results
B.3.1 Generation of POM-ERJ resistant P. falciparum
We attempted to generate POM-ERJ resistant P. falciparum by culturing the had1 strain, AM1G3 in the presence of 1x, 2x, or 5x the half maximal inhibitory concentration (IC50) of POMERJ. We selected AM1-G3 as the parental strain as we were interested in identifying the prodrug
activating enzymes responsible for POM-ERJ activation, and HAD1 loss appears to be a rapid
and easy means of generating resistance to isoprenoid biosynthesis inhibitors. Within 3-5 days of
drug application no parasites were visibly replicating in the 2x and 5x IC50 conditions. Parasites
were cultured continuously in the presence of POM-ERJ, and following 3 weeks of culturing, the
1xIC50 condition had robust levels of parasites present. The IC50 of these strains against POMERJ was determined and found to be insignificantly different than the wild-type parental strain
(Figure 2A).

We next attempted an alternative selection method wherein drug is kept in the culture media
until parasites are no longer visible and then is removed to allow an expansion of any surviving
parasite populations. 2x or 5x the IC50 of POM-ERJ was applied to AM1-G3 until parasites were
no longer visible via thick smear. Once parasites had recovered, the IC50 of these strains against
POM-ERJ was again determined and found to be insignificantly different than the parental strain
(Figure 2B).
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B.3.2 P. falciparum carboxyester activation
We next sought to understand where whole-cell P. falciparum activates prodrugs. We enriched
for late-stage parasites (trophozoites and schizonts) via magnetic bead sorting and transferred
parasites into a microfluidics device placed under a fluorescence microscope. This microfluidics
device allows for individual cells to be held in place while the surrounding media is rapidly
exchanged. We acquired a 32-compound pro-fluorescent carboxy ester substrate library which
fluoresces upon ester cleavage (11). We selected 2 compounds, 3C and 1O, which display
moderate and high catalytic specificity respectively, for the Staphylococcus aureus esterases,
FrmB and GloB, and tracked pro-substrate activation by P. falciparum (Figure 3A).

As observed for wild-type S. aureus, compound 1O is rapidly activated and the fluorescent signal
reaches saturation within the first frame of the experiment. Conversely, pro-substrate 3C is
slowly activated and the fluorescent signal increases steadily through the course of the
experiment (Figure 3B). As observed in our experiments with S. aureus, compound 1O has a
significant amount of background fluorescence, suggesting that the probe has slowly activated
ahead of introduction to the microfluidics device.

One attractive advantage of prodrugs is targeted activation to specific tissues or cellular
compartments. P. falciparum has several compartments where prodrug activation could be
targeted, including the parasite cytoplasm, food vacuole, and the surrounding erythrocyte
cytoplasm. Again, using our microfluidics setup we use compound 3C to visualize where the
substrate is activated in P. falciparum. Fluorescence predominantly accumulates in the parasite
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cytoplasm and appears to be excluded from the parasite food vacuole and the erythrocyte
cytoplasm (Figure 4).

While our imaging field was dominated by trophozoites, we were fortunately able to capture
some cells infected with early stage schizonts, and one instance of schizonts egressing. We find
that trophozoites and early schizonts activate compound 3C to similar levels (Figure 4 middle,
bottom). While egressed schizonts still accumulate fluorescence, it is attenuated in comparison to
intact schizonts (Figure 4 bottom).
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B.4 Discussion
Targeted prodrug delivery to P. falciparum is an exciting possibility with potential to
fundamentally change drug design for antimalarials. Identifying the malarial enzymes
responsible for prodrug activation will allow a structure-guided approach to prodrug
development. While one esterase, PfPARE, is responsible for the activation of hexylester
prodrugs, it is not responsible for the activation of POM-ERJ (4). This finding is unsurprising as
PfPARE does not act on the tertiary carbamate, MMV030666, whose prodrug motif is highly
similar to the POM moiety. Unfortunately, the activation mechanism for POM- prodrug motifs
by P. falciparum remains an intriguing question. Here, we have attempted to identify the P.
falciparum esterase responsible for POM-prodrug activation, by raising resistance to the prodrug,
POM-ERJ.

Unfortunately, we were unsuccessful in generating long-lasting resistance to POM-ERJ.
Parasites grew in the presence of inhibitory concentrations of POM-ERJ but were not shown to
be resistant to POM-ERJ via a 3-day IC50. Additional studies in this area remain a valuable
endeavor and future studies should employ a varied approach in resistance generation, such as
the step-up approach where parasites are cultured in low levels of drug and the concentration of
drug is slowly increased in response to parasite tolerance. Alternatively, multiple rounds of drugpulsing may be an appropriate route forward. It is interesting to hypothesize that POM-ERJ may
be an “irresistible” drug, however multiple rounds of attempted resistance selection with large
pools of parasites being screened before this claim is made. All resistance attempts in this
manuscript were carried out using the had1 null strain, AM1-G3, to reduce the potential number
of non-esterase mutations acquired. Resistance should still be achievable in these strains,
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however, as P. falciparum can become more resistant to the POM-ERJ non-prodrugged analog,
fosmidomycin, through loss of HAD2 among other genes (12).

Erythrocyte esterases are a second candidate for antimalarial prodrug activation. While
erythrocyte esterase mediated activation does not protect host cells from potential antimalarial
toxicity, it still has several appealing benefits. Resistance to hexyl ester prodrugs is rapidly
achieved by P. falciparum through mutation of PfPARE, however, parasite modification of host
esterases would be a substantial feat and is unlikely to occur. Additionally, erythrocyte targeted
prodrugs may have an extensive lifetime within the host as the converted drug would be
sequestered inside erythrocytes and thus safe from host metabolism and excretion. One major
potential drawback to erythrocyte targeted prodrugs is that activated drugs may not transit from
the erythrocyte cytoplasm to the parasite cytoplasm. This appears to be the case with the POMprodrug of the hypoxanthine-guanine-xanthine-phosphoribosyltransferase (HGXPRT) inhibitor,
Immucillin-H 5’phosphate (ImmHP) (13). While ImmHP is a potent inhibitor of HGXPRT in
vitro, it has no activity against whole cell P. falciparum. Further investigation has revealed that
the POM-prodrug of ImmHP effectively enters the erythrocyte but is rapidly converted back to
ImmHP and is unable to enter the parasite cytoplasm to exert its activity.

Ultimately, the localization and timing of prodrug activation across P. falciparum lifecycles is an
important consideration in antimalarial prodrug development. Here, we have shown that simple
lipophilic esters 1O and 3C are activated primarily in the cytoplasm of P. falciparum though at
different speeds. Expanding the understanding of how prodrugs are activated in P. falciparum,
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specifically how different ester promoieties act, is an important next step for P. falciparum
prodrug development. Finally, how fast a prodrug needs to activate in vivo remains an open
question which will dictate prodrug efficacy.
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B.5 Figures

Figure 1 ERJ and POM-ERJ sensitivity of WT and PfPARE mutant P. falciparum. Black- wild-type P. falciparum, red- PfPARE mutant parasites.
IC50 determined by Rachel Edwards, points represent the mean of a single biological replicate in technical duplicate (A) ERJ (B) POM-ERJ.

Figure 1 ERJ and POM-ERJ sensitivity of WT and PfPARE mutant P. falciparum. Black- wild-type P. falciparum, red- PfPARE mutant parasites.
IC50 determined by Rachel Edwards, points represent the mean of a single biological replicate in technical duplicate (A) ERJ (B) POM-ERJ.
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Figure 2 Quantification of POM-ERJ resistance for parasites growing in media containing POM-ERJ. Black- parental strain,
AM1-G3, red- parasites grown in POM-ERJ. (A) Parasites grown for 3 weeks in media containing 1xIC50 POM-ERJ. (B) Parasites
pulsed with POM-ERJ until parasites were no longer visible by microscopy. Points represent the mean of a single experiment in
technical duplicate.
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Figure 3 Time-dependent pro-substrate activation by P. falciparum. (A) Activation mechanism and structure of pro-fluorescent substrates tested. (B)
Time-lapse imaging of single cell P. falciparum. Pro-fluorescent substrate was rapidly added to media 10 minutes into the experiment. Images
representative of experiments performed in technical duplicate.
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Figure 4 Pro-fluorescent substrate 3C activation by P. falciparum. Parasites were incubated with pro-fluorescent substrate for 30
minutes and subsequently imaged. Images representative of experiments performed in technical duplicate.
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Abstract
Plasmodium falciparum, the primary cause of deadly human malaria, remains a critical global
health concern, particularly for young infants and children who are uniquely susceptible to
severe disease and death. Unfortunately, the most widespread rapid diagnostics tests for malaria
have high false positive rates and are increasingly at risk due to the spread of parasite strains that
avoid detection. There is an urgent need for new malaria diagnostics, and the World Health
Organization has declared this a key global health priority. Multiple studies indicate that
Plasmodium-infected hosts are more attractive to Anopheles mosquitoes than uninfected and
gametocyte negative controls. This altered behavioral preference is likely due to changes in the
infected host’s odor profile, as reflected in the skin and breath. In this chapter, we examine the
changes that Plasmodium spp. infection imparts on host odors and the resulting influences on
vector behavior. We also review recent studies on human malaria, which have investigated the
malaria-induced changes in skin and breath odors in asymptomatic and symptomatic malaria
patients.
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C.1 Overview of malaria
In 2017, an estimated 219 million cases of malaria occurred worldwide, resulting in an estimated
435,000 deaths. Aggressive global efforts to control malaria over the last fifteen years have been
highly successful, with 20 million fewer cases in 2017 than in 2010. However, progress has
stalled alarmingly over the last several years 1. Among the more pressing current challenges to
malaria control is the need for additional effective diagnostic tools to detect both symptomatic
and asymptomatic infections.
Malaria is caused by infection by protozoan parasites in the genus Plasmodium. While several
Plasmodium spp. infect humans, the majority of severe and life-threatening malaria is due to P.
falciparum infection. Transmitted person-to-person by Anopheles mosquitoes, symptomatic P.
falciparum malaria is characterized by repeated cycles of asexual replication within mature
human erythrocytes. A small proportion of asexual bloodstream parasites undergo sexual
differentiation. Ongoing malaria transmission requires consumption of these sexual-stage
parasites, termed gametocytes, during blood meals by female Anopheles. Malaria diagnostics
used for point-of-care clinical diagnostic testing of symptomatic individuals in malaria-endemic
areas must be highly sensitive to the presence of asexual bloodstream Plasmodium infection. In
contrast, a diagnostic test that reflects gametocytemia would impact public health strategies to
identify individuals at risk of malaria transmission.
For more than a century, microscopic evaluation of capillary blood samples has been used to
identify bloodstream malaria parasites 2. Highly sensitive and specific nucleic acid-based tests
have been also developed 3, 4, but are not readily available in low- and middle-income countries
(LMIC) where malaria is endemic. Conversely, lateral-flow-based rapid diagnostic tests (RDTs)
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are sensitive and require little training, making them overwhelmingly the method of choice to
evaluate for point-of-care diagnosis in malaria-endemic areas. In 2017, 276 million RDTs were
sold, and an estimated 75% of diagnostic testing in sub-Saharan Africa was performed by RDT1.
The current generation of RDTs largely relies on detection of a distinct P. falciparum-specific
protein, HRP2. Unfortunately, HRP2-based RDTs possess critical weaknesses. False positive
RDTs are common as HRP2 can be detected up to one month after malaria clearance, making it
impossible to distinguish acute from recent infections 5. More importantly, HRP2-based RDTs
are at risk due to the recent emergence and spread of P. falciparum strains that lack HRP2. Hrp2
null parasites were first reported in 2010 in South America 6, but deletions have subsequently
been found in several locations in Africa 7-10. In a recent study in Eritrea, up to 80% of all
patients were infected with hrp2- parasites 7. Computational modeling projects a dramatic rise in
RDT-undetectable parasites, as widespread use of RDTs has maintained ongoing selective
pressure against parasites that still express HRP2 11.
Other challenges in the diagnosis of malaria include addressing the large asymptomatic reservoir,
as nearly 75% of individuals infected with Plasmodium spp. are asymptomatic. Asymptomatic
individuals constitute a major source of ongoing transmission, because they are more likely to be
bitten by mosquitoes than parasite-free individuals, they do not present for care (and are
therefore not diagnosed or treated), and are often mobile, increasing their potential for malaria
transmission and geographic spread 12.
Growing evidence suggests that vector mosquito species can differentiate between malariainfected and uninfected individuals based on odor. This finding has inspired recent work to
address the possibility of diagnosing malaria via volatile biomarkers emitted by breath and/or
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skin. In this chapter, we examine the changes that Plasmodium spp. infection imparts on host
odors and the resulting impacts on vector behavior. We also review recent studies on human
malaria that have evaluated volatiles from the skin and breath of Plasmodium-infected
individuals.

C.2 Mosquito attraction to malaria-infected hosts
Female Anopheles mosquitoes require mammalian blood meals to mature eggs; however,
mosquito biting behavior is highly complex and context-dependent. Mosquitoes detect human
hosts using a combination of cues, with olfactory cues being undoubtedly the most important
group of external stimuli affecting mosquito behavior 13. From a distance, female mosquitoes
sense CO2 and preferentially migrate to areas of higher CO2. As they move closer to the target
blood meal, they sense host heat, skin odors, and potentially the breath volatiles of the target host
14

. Increasing evidence, reviewed below, indicates that host volatiles—and, as a result, mosquito

behavior—are exploited by mammalian Plasmodium spp. parasites, including P. falciparum, to
increase likelihood of transmission (Figure 1).
Humans infected with P. falciparum may be more mosquito-attractive than uninfected humans.
For example, investigators evaluated the attraction of Anopheles gambiae to 5-12 year old
Kenyan children of variable infection status and their uninfected classmates, using a dual-choice
olfactometer (a setup which allows testing preference of one odor against another) 15.
Plasmodium-infected children were treated with antimalarials and, following parasite clearance,
the attraction of mosquitoes to these children was reassessed. Investigators found that A.
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gambiae mosquitoes were nearly twice as attracted to children carrying high burdens of
gametocytes (microscopically visible) than parasite-free individuals, individuals infected with
only asexual stages, or individuals carrying sub-microscopic levels of gametocytes 15. As
expected, treatment with antimalarials reduced asexual and sexual-stage parasite levels below the
limits of molecular detection. Importantly, following antimalarial treatment, Plasmodiuminfected children were no longer preferentially attractive to A. gambiae mosquitoes. This is in
agreement with a previous study by Lacroix et al 16 in which mosquito attractiveness was seen to
be approximately double in gametocyte-positive children, relative to uninfected children or those
with asexual-stage parasitemia.
While there is increasing evidence that P. falciparum infection alters A. gambiae host-seeking
behavior, it is not clear which volatile compounds may be responsible. To address this question,
Robinson et al 17 assessed the behavioral response of A. gambiae to the foot odors of 5-12 year
old Kenyan school children, before and after antimalarial treatment. Foot odors of asymptomatic
P. falciparum-infected and -uninfected children were collected on socks over 20 h and extracted
for mass-spectrometry analysis. For infected individuals, odors were collected after
administration of the first dose of treatment with the antimalarial. Following confirmed parasite
clearance (21 days later), odor samples were collected in the same manner from the same
children. A. gambiae mosquitoes were offered the choice of either Day 1 or Day 21 odor samples
from the same child, in a dual-choice cage assay. Investigators found that mosquitoes did not
differentiate between Day 1 and Day 21 odor samples from uninfected children but were more
attracted to the Day 1 samples from children harboring asexual or gametocyte-stage Plasmodium
parasites. Somewhat unexpectedly, researchers did not observe the gametocyte-specific effect
that was previously described 15, 16. The authors suggest that imperfect detection of low densities
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of gametocytes could play a role in this discrepancy. Alternatively, gametocyte-specific
attraction may be communicated through a distinct mechanism.
Non-human animal studies also provide evidence for increased mosquito attractiveness of
Plasmodium-infected individuals. For example, De Moraes et al 18 evaluated whole-body
volatiles from healthy and P. chabaudi-infected mice throughout the course of infection.
Investigators found that A. stephensi were preferentially attracted to infected mice, relative to
control mice, during the time period in which mice harbored relatively high levels of
gametocytes. The investigators also observed increased attraction to gametocyte-positive vs.
gametocyte-negative individuals during this period. Alongside these behavioral studies, the
investigators observed distinct body odor profiles between healthy and Plasmodium-infected
individuals, during both acute and chronic stages of infection. The characteristic components of
Plasmodium-infected odor profiles were identified by mass spectrometry and subsequently
confirmed to increase mosquito attraction individually, when added to the odor of healthy mice.
Specifically, hexanoic acid, 2- and 3-methyl butanoic acid, and tridecane were increased in
abundance in the odor profiles of malaria-infected animals and displayed a direct relationship
with mosquito attractiveness. Conversely, benzothiazole, present in reduced amounts in
chronically infected mice, was inversely related with mosquito attraction.
While several studies have focused on identifying the changes in odor profiles resulting from
Plasmodium infection, fewer studies have focused on the origin of these changes. Three
hypotheses currently exist for the basis of Plasmodium-dependent odor changes: 1) Plasmodium
infection leads to changes in the skin microbiome that indirectly change the host odor profile; 2)
Plasmodium infection stimulates endogenous host changes that alter the host odor profile; and 3)
Plasmodium spp. directly generate and release malaria-associated volatile compounds.
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The direct production of Plasmodium-volatile compounds by Plasmodium garnered early
attention as Kelly et al 19 identified the plant-like terpenes α-pinene and limonene as arising from
cultured P. falciparum-erythrocytes. Apicomplexan parasites, including Plasmodium species,
contain an apicoplast, an organelle with a similar endosymbiotic evolutionary origin to plant
chloroplasts, which synthesizes isoprenoids (such as α-pinene and limonene) via the
methylerythritol phosphate (MEP) pathway. This pathway is not present in animals, though a
parallel metabolic route, the mevalonate pathway, does exist. Kelly et al 19 hypothesized that P.
falciparum parasites might utilize the MEP pathway to produce terpenes and indeed saw that
inhibition of the pathway via the MEP-pathway specific inhibitor (fosmidomycin) ablated
accumulation of α-pinene and limonene. Interestingly, Emami et al20 found that, even in the
absence of P. falciparum parasites, introduction of the isoprenoid precursor (E)-4-hydroxy-3methyl-but-2-enyl pyrophosphate (HMBPP) altered erythrocyte headspace volatile profiles and
increased mosquito attractiveness. Specifically, HMBPP-treated erythrocytes produced higher
headspace levels of aldehydes (octanal, nonanal, and decanal) and monoterpenes (α-pinene, ßpinene, and limonene). This result remains surprising, as there is no clear biosynthetic route to
monoterpenes in human erythrocytes and the metabolic origin of these compounds in
erythrocytes is enigmatic. There is some overlap in the types of compounds (terpenes and
aldehydes) found in P. falciparum-infected and HMBPP-treated erythrocytes. Indeed, as noted
below, several of these compounds have been also detected in the odor profiles of malariainfected human subjects 21-24.
Given the important role of host odor profiles on Anopheles spp. mosquito attraction, the finding
that Plasmodium spp. infection consistently alters mosquito attraction provides an important
proof-of-concept that malaria parasites reproducibly alter host volatile profiles. Below we review
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the current literature on breath and skin odor changes during asymptomatic and symptomatic
Plasmodium spp. infection in humans.

C.3 Breath odor profiles in asymptomatic malaria
While acute, uncomplicated P. falciparum infection in children is most often characterized by
fever, a large proportion of P. falciparum infections in semi-immune individuals in highly
endemic regions will be asymptomatic. As individuals with asymptomatic infections do not
present for care, asymptomatic infections are an important public health concern as they
represent a hidden reservoir that contributes to persistent malaria transmission. Detecting submicroscopic infections requires sensitive molecular diagnostic methods, such as polymerase
chain reaction (PCR) or loop-attenuated isothermal amplification (LAMP). These molecular
diagnostic tests have shown that even in regions of low endemicity, asymptomatic Plasmodium
spp. infection is common, representing up to 75% of positive individuals in community surveys
25

.

To identify biomarkers of asymptomatic malaria, odor profiles of breath and skin have been
characterized both under natural field conditions in malaria-endemic regions and during
controlled human malaria infection (CHMI). During CHMI, volunteers receive a direct
intravenous inoculation of Plasmodium-infected erythrocytes, followed by close monitoring and
treatment. CHMI trials are increasingly being used to aid vaccine and drug development.
The first study on breath biomarkers of P. falciparum CHMI volunteers was published by Berna
et al 26. One liter of breath was collected from each volunteer as malaria infection progressed and
additional samples were taken following antimalarial administration. Exhaled breath was
collected using sampling bags, and volatiles were then transferred from the bags to sorbent tubes
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(Tenax/ Unicarb) via a pump. The authors identified nine compounds whose concentrations
varied significantly over the course of malaria infection: carbon dioxide, isoprene, acetone,
benzene, cyclohexanone, and 4 thioethers (allyl methyl sulfide, 1-methylthio-propane, (Z)-1methylthio-1-propene, and (E)-1-methylthio-1-propene) (Table 26.1). The malaria-associated
thioethers were of particular interest as a potential disease biomarker, because they have not
previously been associated with any pathological condition, and because their concentrations
changed during infection for all individuals. Machine learning methods were further applied,
which accurately classified all samples into “active infection” and baseline/post-P. falciparum
clearance on the basis of thioester levels. Of note, due to the nature of CHMI, parasite counts
were quite low and gametocytes, which take approximately two weeks to develop, were never
detected. Berna et al 26 attempted to detect thioethers in in vitro cultures of P. falciparum, but did
not find any appreciable levels. While the metabolic origin of breath thioethers found during
CHMI is not known, these results suggest that interplay between host and parasite metabolic
pathways may be required. In a follow-up study, these same researchers 21 found that thioether
concentrations in breath exhibit a diurnal cyclical pattern and, in general, thioether levels are
significantly higher in P. falciparum CHMI volunteers compared to healthy control individuals.
Moreover, the authors demonstrated that breath volatiles have a time-of-day variation that
impacts the ability to predict P. falciparum infection using the thioethers. Additionally, this study
found that terpenes (α-terpinene, m-cymene, limonene, and terpinolene) were elevated in the
breath of P. falciparum-infected individuals. Of these terpenes, limonene had been previously
reported to be associated with cultured asexual P. falciparum19. The top two compounds with the
highest classification accuracies (healthy vs P. facliparum) were terpinolene (87.7% correct
classification), followed by m-cymene (92.7% correct classification).
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Malaria-associated volatile biomarkers have also been investigated in skin samples. De Boer et al
23

collected skin odor samples from two cohorts of P. falciparum CHMI volunteers. Skin odors

were collected by placing one foot of the volunteer into a clean bag, and volatiles from the bag
were then pumped into Tenax filter and Porapak filters. Skin odor samples were collected two
days prior to parasite challenge, during Plasmodium infection, and post-treatment. Foot odor
profiles were distinct in P. falciparum-challenged individuals. In Table 26.1, we report those volatile compounds that showed significant differences “before treatment” versus “during malaria
infection” (qPCR-positive for P. falciparum). Several compounds (e.g., sesquiterpene, 1dodecene, 2-methyl butanal, and dodecanal) increased significantly upon infection. Aldehydes
have been previously found in mammalian skin odors and are well recognized as host attractants
for hematophagous insects. The authors hypothesize that the increased aldehyde levels found in
malarious samples originate from lipid peroxidation, caused by oxidative stress induced by P.
falciparum. Alternatively, the authors postulate that the aldehydes might be produced directly by
Plasmodium parasites, as aldehydes are emitted by HMBPP-treated erythrocyte cultures 20. In
parallel with compound identification, researchers performed dual-choice olfactometer
experiments to determine whether changes in body odor during P. falciparum infection affect
mosquito behavior. Unexpectedly, they found reduced attractiveness of parasite positive
participants in one cohort and no significant effect of P. falciparum infection in a second group.
They attributed this discrepancy to the use of different parasite strains in both cohorts. Mature
gametocytes were not detected in any of the participants during any portion of this study.
A more recent study also aimed to identify malaria-associated skin odor biomarkers, through
evaluation of more than 400 primary school children (aged ≤12 y) in western Kenya 24. In this
study, investigators profiled arm and foot volatiles from each individual, using a portable volatile
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collection system. Collection from both sites occurred in parallel, prior to treatment of malariapositive individuals, and odors were stored on HayeSep adsorbant polymer prior to gas
chromatography-mass spectrometry (GC-MS). Machine learning was employed to identify
volatile patterns that predicted malaria infection (Table 26.1). Of these, only 2-ethylhexan-1-ol
and ethylbenzene were found in both foot and arm samples. Critically, predictive models
successfully identified asymptomatic infections with 100% sensitivity in foot samples and 75%
sensitivity in arm samples. The majority of the identified foot volatiles increased in concentration
during infection, whereas the direction of the change was not specified for the majority of skin
volatiles. The authors indicate that all identified compounds have either previously been reported
from human volatile collections or have known mechanisms of natural production from humans
or potentially human-associated microbes. Interestingly, none of the volatiles reported in this
study were also reported from skin volatile profiling from asymptomatic CHMI volunteers 23.
To explore the molecular basis of odor manipulation by malaria, Robinson et al 17 both
quantitatively and qualitatively compared the volatile compounds emitted from the feet of
asymptomatic infected children in Western Kenya. This work was done in parallel with the
mosquito attraction work mentioned earlier in this chapter. Of note is that the study site was the
same as De Moraes 24 and Busula 15. For each child, one foot was placed in a plastic bag, and
volatiles were collected in Porapak filters (similar to De Boer et al. 23) and sampled for 100 min
(at 500 mL/min). Detailed infection status (uninfected, infected with low parasitemia, high
parasitemia, or infected with gametocytes) was collected using an 18S-based qPCR for P.
falciparum asexual stages and QT-NASBA qPCR for quantifying gametocytes. (E)-2-decenal
was the only compound that showed significant differences if individuals were categorized
simply as Plasmodium-positive or parasite-free (Table 26.1). The analysis also revealed higher
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abundance in the levels of the aldehydes heptanal, octanal, nonanal, (E)-2-octenal, and (E)-2decenal by infected asymptomatic individuals compared to control (solvent) or empty bag. A
positive trend on the levels of these VOCs was also observed when associated to the parasite
densities (low and high). Additionally, the ketone 2-octanone was found to be associated with the
presence of microscopic gametocytes. Although similar VOC collection technique was used by
De Boer et al 23 (from the same research group), none of the compounds identified by De Boer et
al were reported in this work. Inconsistencies could be due to the low parasitemia present in De
Boer et al 23 as well as the absence of gametocytes.
Taken together, the results from this collection of recent studies on volatiles emitted from skin
and breath clearly establish that malaria infection is associated with changes in volatile profiles.
Of the malaria-associated VOCs reported (Table 26.1), only nonanal was detected in two
independent studies of individuals with asymptomatic parasitemia. However, the two studies
problematically disagree about the direction of change with infection: in one study, nonanal
levels increase with malaria infection 17; in the other, nonanal levels decrease24. A possible
source of this discrepancy may be the variability in volatile collection methods, absorbent
materials, and/or analytical techniques employed. While diet is thought to influence breath and
skin volatile profiles, both studies in question recruited from the same locality in western Kenya.
More broadly, the use of malaria-naïve individuals (as in CHMI) versus naturally infected
individuals (in endemic areas) also presents challenges for comparison purposes, as study
participants in field studies are likely to have had previous malaria exposure.
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C.4 Breath odor profiles of symptomatic Plasmodium
infection
The first report of candidate diagnostic biomarkers in the breath of symptomatic P. falciparum–
infected children from a typical malaria-endemic clinical setting was published recently by
Schaber et al. 22 Samples were collected in Malawi from children 3–15 years old presenting for
care for fever. In the study, 1 L of exhaled breath was collected in a sample bag and transferred
to stainless-steel sorbent tube (Tenax/Carbograph/Carboxen). Investigators found global
differences in breath VOC composition based on infection status. In addition, six breath volatiles
were highly correlated with infection status, and together yielded a classification accuracy of
83%: methyl undecane, dimethyl decane, trimethyl hexane, nonanal, isoprene, and tridecane
(Table 26.2). Of these six VOCs, methyl undecane and dimethyl decane levels increased with
malaria infection. The only compound that had previously been associated with Plasmodium
infection was nonanal. Plasmodium-infected individuals have decreased levels of skin-emitted
nonanal, when arm volatiles were sampled 24. In contrast, skin-emitted nonanal from the feet of
Plasmodium-infected individuals was elevated compared to controls 17.
Schaber et al. 22 also found significantly increased breath levels of two terpenes, α-pinene (p =
0.04, with 20% higher mean) and 3-carene (p = 0.01, with a 28% higher mean). α-Pinene has
been observed reproducibly to arise during P. falciparum asexual infection of erythrocytes in
culture 19. In addition, this terpene is a direct, potent, and specific activator of A. gambiae
odorant receptors 19. Both α-pinene and the related 3-carene are among the volatiles produced by
mosquito-preferred nectar-providing plant species 27. The investigators postulate that because
malaria-induced volatiles are chemically identical to those produced by mosquito-preferred
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plants, parasites might produce or induce production of these volatiles in order to hijack
mosquito behavior and increase transmission.
Of note, the results of this research group were somewhat distinct from the previous breath
metabolite findings reported by Berna et al 26, from a population of naïve healthy adults
undergoing CHMI P. falciparum infection. Thioethers were not detected, suggesting that parasite
densities, parasite stage, or age of host might induce a range of physiological changes in the
human body that manifest in the breath and body odor. Alternatively, P. falciparum may produce
volatiles in a density- or stage-specific manner. Prior parasite exposure may also be required for
host-generated volatiles produced during P. falciparum infection. The different sorbent material
and storage conditions used in both studies, may also contribute to an absence of thioethers in the
work of Schaber et al. 22
De Moraes et al 24 also examined symptomatic Plasmodium-infected children at a primary school
located in western Kenya. In this work, researchers collected foot and arm volatiles and
employed machine learning algorithms to develop predictive models for infection status. The
following volatiles were found to be key predictors of malaria: 4-hydroxy-4-methylpentan-2-one,
toluene, ethylcyclohexane, and ethylbenzene (Table 26.2). Toluene is notable in that it has
previously been reported to be produced by P. falciparum in vitro 19 and has also been found to
be associated with human skin. De Moraes et al 24 suggest that toluene could be produced by
Clostridium spp. residing in the human microbiome 28. Most of the volatiles found by De Moraes
et al 24 in arm and foot samples were in lower abundance in Plasmodium-infected individuals.
Importantly seven of the volatiles reported in symptomatic malaria cases were also detected in
samples from asymptomatic Plasmodium-infected individuals (VOCs in boldface text - Tables
26.1 and 26.2). Predictive models using foot volatiles exhibited greater sensitivity (91%) than
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using arm volatiles (89%). It is important to note that these sensitivities were achieved using
samples that were collected over 3 years across 41 schools in western Kenya. Additionally, some
subjects were co-infected with multiple Plasmodium species, and, in some cases, were coinfected with other organisms including HIV and intestinal helminths.
No volatiles were found in common among studies with symptomatic patients, possibly due to
variations in collection methods and/or materials.

C.5 Summary
Despite substantial global investment, malaria remains a serious global health problem. Young
infants and children are particularly at risk, with more than 400,000 deaths each year. Over the
past decade, rapid diagnostic tests (RDTs) have transformed malaria diagnosis and have been
instrumental to malaria control efforts. However, there is an urgent need to develop new malaria
diagnostics. Because parasite proteins can persist in the bloodstream long after treatment, “false
positive” tests are common in children who do not have malaria, meaning that non-malaria
infections can be missed and untreated. Even more ominously, variant parasite strains have
emerged, such that in some parts of the world, 80% of parasites are no longer detected by current
tests. There is a pressing need for highly sensitive and specific malaria diagnostics that are also
simple and affordable. For public health campaigns, noninvasive testing would also represent a
major advance, since all current malaria tests require blood samples.
There is mounting evidence that malaria parasites affect the behavior of Anopheles mosquito
vectors and hosts in ways that increase the contacts between them to favor parasite transmission.
Such changes in attractiveness have been demonstrated in both animal and human malaria
systems, as well as in other vector-borne disease systems. Body odor, comprising the volatile
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compounds emitted from the skin and breath of vertebrates, is the most important cue used by
Anopheles for host location. While increased attractiveness of Plasmodium-infected individuals
has been demonstrated in a malaria-endemic setting, remarkably, very few studies have
investigated the chemical ecology underlying this phenomenon. Volatiles emitted from human
skin, breath, and from cultured human red blood cells are all altered in the presence of
Plasmodium spp. infection. Of note, the identified volatile biomarkers have been highly variable
from study-to-study. These differences may reflect variability in volatile collection methods,
absorbent materials, and/or analytical techniques employed. In addition, study populations were
distinct with respect to prior exposure to malaria and duration of infection, which may influence
the volatile profiles due to presence/absence of gametocytes and parasite densities. However, the
reproducible finding that malaria induces volatile changes provides compelling hope for a future
malaria diagnostic that identifies both asexual parasitemia and the presence of gametocytes.
Future work should include research in different geographical regions using collection methods
and analytical techniques similar to those used in previous studies. In addition, a compelling
question is how diet, age of host, genetic, and environmental factors affect the volatile
fingerprint of malaria-infected individuals. The biological origin of those volatile compounds
induced by malaria are yet unknown, and remains an outstanding question of importance in
understanding the specificity of these volatiles as biomarkers to be used in a noninvasive
diagnostic for malaria.

lxxv

C.6 Figures

Figure 1 Life cycle of P. falciparum and volatile attraction schematic. (A) Life cycle of Plasmodium
falciparum. (B) Human body odor is altered upon malaria infection and attracts Anopheles spp.
mosquitoes.
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C.7 Tables
Table 1 Summary of studies on individuals with asymptomatic Plasmodium spp. Infection.
Sample
type

Compounds

Study population

Ref

Breath

(E)-1-methylthio-1-propene
(Z)-1-methylthio-1-propene
1-methylthio-propane
allyl methyl sulfide
α-terpinene
m-cymene
limonene
terpinolene
sesquiterpene
1-dodecene
2-methyl butanal
dodecanal
Foot
nonanal
2-ethylhexan-1-ol
benzaldehyde
1-ethyl-3-methylbenzene
toluene
4-hydroxy-4-methylpentan-2one
ethylbenzene
hexanal
Arm
2-ethylhexan-1-ol
ethylbenzene
toluene
dodecane
octanal
octane
2,4-dimethylhept-1-ene
(E)-2-decenal

Controlled human malaria
infection (malaria-naïve
adults)

Berna et al 21,

Controlled human malaria
infection (malaria-naïve
adults); foot odors

De Boer

Naturally infected schoolchildren; foot/arm odors

De Moraes et
al 24

Naturally infected schoolchildren; foot/arm odors

*Robinson et
al 17

Skin

26

et al 23

In bold, volatiles were also found in subjects with symptomatic Plasmodium infection (Table 26.2). In
blue, levels of volatile increased with infection. In coral, volatile levels decreased with infection. In black,
direction of change was not provided. *Volatiles reported in this table are based on comparisons relative
to parasite-free individuals vs. all individuals with detectable Plasmodium spp. parasitemia.
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Table 2 Summary of studies on individuals with symptomatic Plasmodium spp. infection.
Sample Compounds
type
Breath

dimethyl decane
isoprene
methyl undecane
nonanal
tridecane
trimethyl hexane
3-carene
α-pinene

Patients/volunteers Ref
Naturally infected
children (age 3-15)

Schaber et al 22

Foot
Naturally infected
De Moraes et al 24
school-aged
hexanal
4-hydroxy-4-methylpentan-2-one children; foot/arm
toluene
odors
ethylcyclohexane
ethylbenzene
1-ethyl-3-methylbenzene
Arm
octanal
2-ethylhexan-1-ol
m-xylene (or p-xylene)
4-hydroxy-4-methylpentan-2-one
toluene
ethylcyclohexane
ethylbenzene
2,4-dimethylhept-1-ene
In boldface, volatiles were also found in subjects with asymptomatic Plasmodium infection
(Table 26.1). In blue, levels of volatile increased with infection. In coral, volatile levels decreased
with infection. In black, direction of change was not provided.

Skin
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Appendix D: The malaria metabolite
HMBPP does not trigger erythrocyte terpene
release
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D.1 Abstract
Infection with malarial parasites renders hosts more mosquito attractive than their uninfected,
healthy, counterparts. One volatile organic compound, α-pinene, is associated with Plasmodium
spp. infection in multiple studies and is a known mosquito attractant. However, how malarial
infection results in elevated levels of host-associated α-pinene remains unclear. One study
suggests that erythrocyte exposure to the malarial metabolite, (E)-4-hydroxy-3-methyl-but-2enyl pyrophosphate (HMBPP), results in increased levels of α-pinene. Here, we establish that
endogenous levels of α-pinene are present in human erythrocytes, that these levels vary widely
by erythrocyte donor, and that α-pinene levels are not altered by HMBPP treatment.
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D.2 Introduction
Plasmodium falciparum, the primary causative agent of lethal malaria infections, has a two-host
life cycle between humans and mosquitoes. Transit between the two hosts is a critical
requirement for the parasite lifecycle and represents a substantial population bottleneck(1).
Mosquitoes are more attracted to humans(2–5), mice(6), and birds(7) infected with malaria
parasites in comparison to uninfected, healthy hosts. This observation has led to the hypothesis
that Plasmodium species actively manipulate host odor profiles to coordinate transmission to the
mosquito. Indeed, changes in the composition of host odor profiles have been observed in
humans(8–13) and mice(6) infected with malaria; however the molecular basis for infectioninduced changes in volatile organic compound (VOC) production or release remains unknown.

Of particular interest has been the mosquito semiochemical, α-pinene, which is found in higher
concentrations in the breath of humans with symptomatic Plasmodium infection(8) vs healthy
controls. Additionally, α-pinene has been identified in the headspace above Plasmodium
falciparum infected erythrocytes(14). The VOC α-pinene is a member of the large and bioactive
class of molecules termed terpenes. Terpenes are biosynthesized by a variety of plants, soil and
environmental organisms, mammalian commensal and pathogenic microbes, and some
insects(15–22). α-pinene is a known component of plant-derived odorant blends that are
attractive to the Anopheles spp. mosquitoes that transmit malaria(23, 24). As for other terpenes,
biosynthesis of α-pinene begins with the 5-carbon isoprenoid precursor, isopentyl pyrophosphate
(IPP), which is enzymatically condensed with a second molecule of IPP by geranyl
pyrophosphate synthase (GPPS) to form the 10-carbon metabolite, geranyl pyrophosphate (GPP).
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Subsequent rearrangement and cyclization are catalyzed by a monoterpene synthase (pinene
synthase) to yield α-pinene (Figure 1A).

Recently, it was reported that incubation of the microbial metabolite (E)-4-hydroxy-3-methylbut-2-enyl pyrophosphate (HMBPP) with uninfected human erythrocytes results in increased
attraction and feeding behavior of anopheline mosquitoes. Concordantly, an increase in the
headspace concentration of α-pinene above HMBPP-treated erythrocytes was also reported(25).
HMBPP is a late intermediate in the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway for
synthesis of IPP and downstream isoprenoids (Figure 1A). While eubacteria and apicomplexan
parasites, such as Plasmodium spp., utilize the MEP pathway for isoprenoid biosynthesis(26),
humans utilize a distinct and evolutionarily divergent biosynthetic pathway (mevalonate
pathway) to synthesize IPP(27).

The mechanism by which HMBPP exposure of erythrocytes may lead to α-pinene production or
release is unclear, but two possibilities may explain these findings. First, HMBPP may serve as
an exogenous signal that triggers erythrocytes to release stores of α-pinene which may have
accumulated via metabolic, environmental, or dietary routes. A potent activator of human
Vγ9Vδ2-T cells(28), HMBPP is recognized as a pathogen-associated molecular pattern (PAMP)
through its interaction with butyrophilin receptors(29), suggesting that HMBPP may serve a
signaling role to mediate erythrocyte α-pinene release. Alternatively, because HMBPP is itself a
precursor to isoprenoids and terpenes in bacteria and plants, this metabolite may be directly
incorporated into α-pinene in erythrocytes via the pathway illustrated in Figure 1A, or via an aslxxxv

yet-undescribed alternative enzymatic route. However, human erythrocytes do not express the
known biosynthetic machinery for synthesis of α-pinene from HMBPP; mammals lack the MEP
pathway and specifically do not express the final enzyme in the pathway, IspH, which converts
HMBPP to the immediate α-pinene precursor, IPP. Finally, no erythrocyte monoterpene
synthases, nor any proteins with the terpene synthase fold, have yet been described that might
mediate the final biocatalysis of GPP to α-pinene. In contrast, humans do express other prenyl
diphosphate synthase orthologs, and these enzymes have been reported to moonlight as terpene
synthases(20–22). For this reason, we sought to interrogate the possibility of HMBPP-triggered,
erythrocyte-produced α-pinene.
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D.3 Methods
D.3.1 Materials and reagents
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate, HMBPP, was purchased from both Sigma
Aldrich and Echelon Biosciences Incorporated (Salt Lake City, Utah, USA), resuspended at 4
mM in highly purified water, and stored at -80 ºC. Human erythrocytes (types A, B, and O,
leukocyte reduced and irradiated) were obtained from the St. Louis Children’s Hospital Blood
Bank (St. Louis, Missouri, USA).

D.3.2 Volatile collection and GC-MS analysis
Erythrocytes were washed 3 times with an equal volume of RPMI-1640 media (Sigma-Aldrich,
SKU R4130) supplemented with: 27 mM sodium bicarbonate, 11 mM glucose, 5 mM HEPES, 1
mM sodium pyruvate, 0.37 mM hypoxanthine, 0.01 mM thymidine, 10 µg/mL gentamycin, and
0.5% albumax (Thermo Fisher Scientific, 11020039) and stored at 50% hematocrit at 4 ºC. When
testing responses of erythrocytes to HMBPP and water, erythrocytes were stored as 1.4 mL
aliquots in individual 1.5 mL microfuge tubes (Thermo Fisher Scientific, 05-408-129), wrapped
in parafilm (Sigma-Aldrick, SKU P7793) and stored at 4 ºC. Prior to sampling, 1 mL 50%
erythrocytes were transferred to 4 mL glass autosampler tubes (Thermo Fisher Scientific, 03391-19), closed with screw caps with septa (Thermo Fisher Scientific 03-391-21), and
equilibrated at 38 ºC for 15 minutes. Following equilibration, 2.5 µL of 4 mM HMBPP (final
concentration 10 µM) or purified water were added to the erythrocytes, caps were closed, and
parafilm was used to seal the vial. Volatiles were immediately collected from the headspace
using solid phase micro-extraction (n=5, randomized order for each sample). Directly before
sampling, the Divinylbenzene/Caboxen/Polydimethylsiloxane fiber (Sigma-Aldrich, SKU
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57348) was conditioned for 30 minutes at 225 ºC in the inlet of an Agilent 7890A gas
chromatographer. Headspace sampling occurred over 30 minutes with temperatures maintained
at 38 ºC. Following sampling, the collected volatiles were desorbed onto the injector of the
Agilent 7890A gas chromatographer with an Agilent HP-5MS column (30m, 0.25-mm inner
diameter, 0.25-µm film thickness) and interfaced with an Agilent 5975C mass spectrometer.
Throughout the run, the inlet temperature was held constant at 225 ºC. Injection was performed
in the splitless mode for one minute before split vent opening. The oven program followed a
linear temperature gradient, with an initial temperature of 60 ºC (held for 2 minutes), a ramp of
10 ºC/min until 225 ºC, and a final hold for 5 minutes at 225 ºC. Helium was used as the carrier
gas with a constant flow of 1 mL/min (25.6 cm/sec). The transfer line temperature was held
constant at 300 ºC. Ionization was performed using electron ionization, with an ion source
temperature, electron energy, and emission current set at 230 ºC, 70 eV, and 300 µA respectively.
Mass spectra were acquired in scan mode between 40.0 and 170.0 m/z. α-pinene was identified
based on retention time of an analytical standard (Sigma-Aldrich, SKU 80605), and abundance
was quantified using the area under the curve of extracted ion 93. Integration was performed in
Agilent MassHunter (Version B.05.00 Build 5.0.519.0) using the Agile integrator. To measure
the background contamination of HMBPP with α-pinene 2.5 µL of 4 mM HMBPP (final
concentration 10 µM) was added to 1 mL of erythrocyte storage media.
An α-pinene standard curve was generated through the addition of 2.5 µL of commercial αpinene diluted in hexanes to autosampler tubes containing 1 mL pure water and sampled as with
erythrocyte treatments. Tested concentrations of α-pinene were 500 ng, 250 ng, 100 ng, 75 ng,
50 ng, 25 ng, 10 ng, and 0 ng (hexanes spiked into water). Standard curve generated by
measuring samples in three independent experiments. The limit of detection was defined as 3
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times the area under the curve (ion 93) at the retention time for commercial α-pinene in negative
controls containing only water and sampled as with erythrocytes.

D.3.3 Measuring α-pinene time-dependent concentration
To measure α-pinene loss over time, 14 mL of washed erythrocytes were placed in a 15 mL
conical (Sigma-Aldrich, SKU CLS430791) and stored at 4oC. For some experiments, analytical
α-pinene, diluted in water, was added to a final concentration of 10 ng/mL in erythrocytes at the
time of aliquoting. During the experiment, erythrocytes were stored, capped, on ice and
iteratively sampled from. Volatile collection and GC-MS analysis proceeded as above.
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D.4 Results
D.4.1 Erythrocytes do not release α-pinene upon HMBPP exposure
We established a working method for sampling the volatile organic compounds associated with
cultured erythrocytes. Similar to Emami et al., we sealed donated human erythrocytes within a
closed, airtight chromatography vial, prewarmed to 38 ºC, and performed headspace sampling
using solid phase microextraction (SPME) (Figure 1B) (25). Headspace composition was
determined using gas chromatography-mass spectrometry. Using a pure commercial α-pinene
standard, we established the sensitivity and dynamic range of this assay (Figure 1C), yielding a
signal-to-noise ratio of 3 and a limit-of-detection of 0.3 ng α-pinene (area under the curve for ion
93, 2.36 x 103) . Accommodating volumes up to 1 mL of blood, we can detect α-pinene blood
concentrations as low as 2.2 nmol/L. We next sought to determine whether α-pinene was present
in the headspace above untreated erythrocytes. Indeed, we confirmed that α-pinene can be
detected in the headspace from donor erythrocytes, and both the retention time and mass spectra
match that of the pure α-pinene standard (Figure 1D,E).

A previous study had indicated that treatment of human erythrocytes with the microbial
metabolite HMBPP leads to substantial release of α-pinene. To control for batch-to-batch
variability in low-level contaminants present in purified HMBPP, we acquired HMBPP from two
independent chemical suppliers. Headspace sampling from both pure preparations of HMBPP
confirmed that neither had contaminating levels of α-pinene above our limit-of-detection (Figure
2A). We next treated erythrocytes with either HMBPP or water (vehicle control) and quantified
headspace α-pinene. Because monoterpenes such as α-pinene can diffuse into the ambient air, we
pre-aliquoted all blood samples into sealed individual-use aliquots. Treatment of erythrocytes
xc

with HMBPP did not result in increased levels of α-pinene (Figure 2B), and this finding was not
donor-dependent. A previous study also indicated that levels of other monoterpenes (β-pinene
and limonene), as well as several aldehydes (octanal, nonanal, and decanal), were increased in
response to HMBPP treatment. While we searched for the presence of these additional VOCs
they were not detected in our assay. Our studies thus indicate that if erythrocytes can sense
HMBPP, this signal is not accompanied by a substantial release of α-pinene within the thirty
minutes our experiment proceeded. Alternatively, if erythrocytes do incorporate HMBPP for the
direct de novo synthesis of α-pinene, it does not occur during the thirty minutes our experiment
proceeded.

D.4.2 Erythrocyte α-pinene levels are donor-dependent
In the course of the above experiments, we noted substantial donor-to-donor variability in the
endogenous levels of α-pinene present in a given erythrocyte culture. We therefore secured
erythrocytes from an additional 3 independent, unrelated donors and quantified α-pinene levels
as before. We find that α-pinene levels are strongly dependent on donor identity and range
widely among our 6 donors (Figure 3). We find that blood α-pinene concentrations range from
0.37 ng/mL - 2.57 ng/mL (mean and standard deviation, 0.91 +/- 0.84 ng/mL). While
biosynthesis of α-pinene has not been documented in humans, α-pinene is a volatile component
of several common dietary plants, suggesting that one explanation for the variability in α-pinene
levels is due to the variability in diet of individual donors. Alternatively, α-pinene may be
synthesized by members of the human microbiome that may contribute to endogenous α-pinene
levels. Unfortunately, blood samples were provided anonymously with no dietary recall or
additional sampling available, prohibiting additional analysis.
xci

D.4.3 α-pinene levels deplete with repeated sampling
To reconcile our findings with previous studies that had reported HMBPP-induced α-pinene
release we hypothesized that loss of volatile α-pinene through diffusion, following repeated
sampling of the same sample over time, may be a possible explanation for the results observed
by the previous study. To test this hypothesis, we filled a single air-tight sample tube with
erythrocytes from a single donor. At t=0, we removed 1 mL of erythrocytes from the conical tube
and measured the headspace concentration of α-pinene according to our previous assay. We left
the remainder of the sample sealed (Figure 4A). We repeated this process for a total of 10
iterations, allowing the tube of erythrocytes to reequilibrate for one hour between sampling. We
find that α-pinene levels decrease by 25-60% (100 * first run / final run) as a result of repeated
sampling (Figure 4B). As expected given its vapor pressure (4.75 mm Hg at 25 °C), α-pinene is
in a vapor-liquid equilibrium(30). Each time our pooled erythrocytes are uncapped and sampled,
vaporous α-pinene diffuses away, and a new vapor-liquid equilibrium is established. The total
concentration of liquid α-pinene is thus depleted over time, thereby resulting in a reduced pool of
α-pinene in each subsequent sampling. To confirm that this is not unique to α-pinene naturally
absorbed within erythrocytes, we supplemented erythrocytes with 10 ng/mL (73.4 nM) α-pinene
and found that α-pinene levels drop by 66-80% over the course of repeated sampling (Figure
4C).
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D.5 Discussion
While run-to-run variability and the run-order effect is a commonly observed problem for mass
spectrometry, our results highlight an additional precaution that needs to be taken when sampling
biologically generated volatiles. All samples should be aliquoted and sealed in an air-tight
container prior to the start of the experiment, as repeated sampling from the same container will
result in artificially decreased volatile concentration over time. Investigators should continue to
control for run-order effects by randomizing the order in which samples are run.

While mounting evidence suggests that Plasmodium infection alters host odor profiles and
results in increased mosquito attraction, the mechanism by which this occurs remains unclear.
One class of molecules, terpenes, notably α-pinene, has been repeatedly highlighted for being
both mosquito attractive and enriched during Plasmodium infection. The metabolic origin of
terpenes during Plasmodium infection remains unclear as mammals do not express orthologs of
the terpene synthases required for terpene production. Here, we establish that endogenous levels
of α-pinene are present in human erythrocytes. While α-pinene levels from erythrocytes from a
single donor sample are highly reproducible, α-pinene levels vary widely by erythrocyte donor.
While the source of erythrocyte α-pinene remains enigmatic, it is possible that α-pinene may be
dietary in origin, explaining the donor-to-donor variability that we observe.

While HMBPP-mediated α-pinene release has been previously reported(25), we do not find
evidence that the headspace of HMBPP-treated erythrocytes contains increased levels of αxciii

pinene. HMBPP-treated erythrocytes also appear more mosquito attractive than untreated
erythrocytes(25). Human erythrocytes bind several chemokines(31, 32) and human Vγ9Vδ2-T
cells actively respond to HMBPP(28), raising the possibility that HMBPP exposure of
erythrocytes may result in other properties that increase mosquito attraction, independent of αpinene release. CO2 emission from erythrocytes has also been reported to be elevated upon
HMBPP exposure. As CO2 is also a mosquito semiochemical(33, 34), elevated CO2 levels could
be responsible for mosquito attraction to HMBPP-treated erythrocytes. However,
supplementation of 5 ppm CO2 to untreated erythrocytes was not sufficient to sway mosquitoes
from HMBPP-treated erythrocytes.

Subsequent experiments are needed to identify the origin of Plasmodium infection-associated
volatiles. Infection of germ-free animal models may be valuable in discerning volatiles that arise
from microbiome vs. host or Plasmodium parasite metabolism. Identification of either human or
malarial terpene synthases or metabolic labeling studies are required to understand the origin of
Plasmodium infection-associated terpenes. Carefully controlled dietary recall studies are
necessary to understand whether erythrocyte endogenous α-pinene is biosynthesized by humans
or human microbiome members.
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D.6 Figures

Figure 1. α-pinene biosynthesis and detection. (A) Metabolic pathways leading to α-pinene. Enzymes highlighted with salmon boxes.
HMBPP- E-4-hydroxy-3-methyl-but-2-enyl pyrophosphate, MPP- mevalonate pyrophosphate, IPP- isopentenyl pyrophosphate, GPP- geranyl
pyrophosphate. (B) Schematic of α-pinene detection assay. (C) α-pinene standard curve generated using commercial α-pinene over a range of
500 ng/mL to 0 ng/mL. Displayed are the means of standards measured in triplicate, error bars denote SD. (D) gas chromatography-mass
spectroscopy trace of commercial α-pinene (bottom) and erythrocyte headspace (top) for α-pinene parent ion, 93. (E) Mass spectra from
retention time 4.77 min, the elution time for commercial α-pinene, for erythrocyte headspace (top) and commercial α-pinene (bottom).
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Figure 2. Erythrocytes do not release α-pinene following HMBPP exposure. (A) α-pinene abundance in HMBPP from Echelon
Biosciences, Sigma Aldrich, or vehicle control (water). (B) Erythrocyte α-pinene abundance following treatment with HMBPP or vehicle
control (water). Values are not significantly different by Mann-Whitney U test (Donor 1: p = 0.841, Donor 2: p = 0.548, Donor 3: p = 0.420).
All assays performed with n = 5. Line indicates the mean of each sample, with error bars indicating standard error of the mean.
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Figure 3 α-pinene abundance in the headspace of untreated human erythrocytes, n = 5.
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Figure 4. α-pinene levels decrease with repeated sampling. (A) Schematic of repeated sampling mechanism. Time between each sampling
is one hour. At each sampling, one mL erythrocytes are removed and the headspace composition of the removed cells is assessed. (B, C)
Headspace concentration of α-pinene over untreated human erythrocytes (B) or erythrocytes (C) supplemented with 10 ng/mL commercial αpinene as a function of GC-MS run (and accordingly number of tube openings). Displayed are the values of experiments performed in
duplicate, with connecting lines indicating an individual replicate.
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